



Oral Immunotherapy and Viaskin® Peanut for Peanut Allergy: Effectiveness and Value

Final Evidence Report

July 10, 2019

Prepared for



None of the above authors disclosed any conflicts of interest.

DATE OF PUBLICATION: July 10, 2019

Jeffrey A. Tice served as the lead author for the report, led the systematic review and authorship of the comparative clinical effectiveness section, and wrote the background, other benefits, and contextual considerations sections of the report. Greg Guzauskas and Ryan Hansen developed the cost-effectiveness model and authored the corresponding sections of the report. Rick Chapman and Remziye Zaim were responsible for oversight of the cost-effectiveness analyses and developed the budget impact model. Emily Tsiao authored the section on coverage policies and clinical guidelines. David Rind and Steve Pearson provided methodologic guidance on the clinical and economic evaluations. Celia Segel managed the timeline and public process, and performed quality controls. We would also like to thank Laura Cianciolo and Noemi Fluetsch for their contributions to this report.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at <https://icer-review.org/>.

The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Laura and John Arnold Foundation. No funding for this work comes from health insurers, pharmacy benefit managers, or life science companies. ICER receives approximately 19% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. There are no life science companies relevant to this review who participate in this program. For a complete list of funders and for more information on ICER's support, please visit <https://icer-review.org/about/support/>.

About CTAF

The California Technology Assessment Forum (CTAF) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. CTAF seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The CTAF Panel is an independent committee of medical evidence experts from across California, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about CTAF is available at <https://icer-review.org/programs/ctaf/>.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

Expert Review

In the development of this report, ICER's researchers consulted with several clinical experts, patients, manufacturers, and other stakeholders. The following experts provided input that helped guide the ICER team as we shaped our scope and draft report. None of these individuals is responsible for the final contents of this report or should be assumed to support any part of this report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of stakeholders from whom we requested input, please visit:

<https://icer-review.org/material/peanut-allergy-stakeholder-list/>.

Expert Reviewers

Ruchi S. Gupta, MD, MPH

Professor of Pediatrics & Medicine

Ann & Lurie Children's Hospital of Chicago

Northwestern Feinberg School of Medicine

Disclosure: *Dr. Ruchi Gupta has received grants from Aimmune Therapeutics and has served as a medical consultant for DBV Technologies and Aimmune Therapeutics.*

Nurry Hong

Chief of Strategy and Innovation

Food Allergy Research & Education (FARE)

Disclosure: *Nurry Hong is a cofounder of a start-up biotech company that is in its research stages of development. The company is in the pre-financing stage of formation and Nurry Hong does not receive any salary or compensation from the company at this time.*

FARE is a 501(c)(3) public charity and receives financial support from multiple sources, including individuals, other charitable entities, and for-profit companies. Currently or in the past, FARE has received general support grants or corporate sponsorship from each of DBV Technologies and Aimmune Therapeutics. These general support grants/sponsorships are charitable in nature and do not require FARE to perform any service for or on behalf of either DBV or Aimmune. At one time FARE was a shareholder of Aimmune, but those shares were sold in their entirety in 2016.

Table of Contents

Executive Summary	ES1
1. Introduction	1
1.1 Background	1
1.2 Scope of the Assessment	2
1.3 Definitions	5
1.4 Insights Gained from Discussions with Patients and Patient Groups	6
1.5. Potential Cost-Saving Measures in Peanut Allergy	9
2. Summary of Coverage Policies and Clinical Guidelines	10
2.1 Coverage Policies	10
2.2 Clinical Guidelines	10
3. Comparative Clinical Effectiveness	13
3.1 Overview	13
3.2 Methods	13
3.3 Results	15
3.4 Summary and Comment	26
4. Long-Term Cost Effectiveness	28
4.1 Overview	28
4.2 Methods	28
4.3 Results	42
4.4 Summary and Comment	50
5. Potential Other Benefits and Contextual Considerations	52
5.1 Potential Other Benefits	53
5.2 Contextual Considerations	54
6. Value-Based Price Benchmarks	55
7. Potential Budget Impact	56
7.1 Overview	56
7.2 Methods	56
7.3 Results	57

7.4 Access and Affordability Alert.....	59
8. Summary of the Votes and Considerations for Policy	60
8.1 About the CTAF Process.....	60
8.2 Voting Results	62
8.3 Roundtable Discussion and Key Policy Implications	67
References	75
Appendix A. Search Strategies and Results.....	81
Appendix B. Previous Systematic Reviews and Technology Assessments	86
Appendix C. Ongoing Studies.....	88
Appendix D. Comparative Clinical Effectiveness Supplemental Information.....	94
Appendix E. Comparative Value Supplemental Information.....	117
Appendix F. Public Comments	128
Appendix G. Conflict of Interest Disclosures	135

List of Acronyms Used in this Report

AAAAI	American Academy of Allergy, Asthma & Immunology
AHRQ	Agency for Healthcare Research and Quality
AE	Adverse event
AHRQ	Agency for Healthcare Research and Quality
BSACI	British Society for Allergy and Clinical Immunology
BSCA	Blue Shield of California
CADTH	Canadian Agency for Drugs and Technologies in Health
CC	Complications and comorbidities
CDC	Center for Disease Control
CI	Confidence interval
CMS	Centers for Medicare and Medicaid Services
DBPCFC	Double blind placebo-controlled food challenge
DHCF	California Department of Health Care Services
DRG	Diagnosis Related Group
EAACI	European Academy of Allergy and Clinical Immunology
EFC	Exit food challenge
EoE	Eosinophilic esophagitis
ER	Emergency room
FDA	Food and Drug Administration
GDP	Gross domestic product
GMFM	Gross Motor Function Measure
IgE	Immunoglobulin G
LCD	Local Coverage Determination
LEAP	Learning Early about Peanut Allergy
LY	Life year
MCC	Major complications and comorbidities
NCD	National Coverage Determination
NIAID	National Institute of Allergy and Infectious Diseases
NICE	National Institute for Health and Care Excellence
NR	Not reported
OFC	Oral food challenge
OIT	Oral immunotherapy
PSA	Probabilistic sensitivity analysis
PICOTS	Population, Interventions, Comparisons, Outcomes, Timing, Setting, and Study Design
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QALY	Quality-adjusted life year
RCT	Randomized controlled trial
SAE	Serious adverse event
UHC	United Healthcare
US	United States
USPSTF	United States Preventive Services Task Force
WAC	Wholesale acquisition cost
WHO	World Health Organization
WTP	Willingness-to-pay

Executive Summary

Background

Peanut is a common childhood allergen in the United States (US). According to recent estimates approximately 1.4-4.5% of children in the US suffer from peanut allergy.¹⁻³ In addition, peanut allergy is the leading cause of death from anaphylaxis due to food, particularly in teenagers, though the rate is low.⁴ The national food allergy death registry reports fewer than four deaths per year over the past 10 years in the US.⁵ The economic cost of food allergies in the US is estimated at \$24.8 billion per year, of which only \$4.3 billion was direct medical costs.⁶ Non-medical costs accounted for \$20.5 billion and included out-of-pocket medical costs, the costs of special foods, and lost caregiver productivity.

The primary approach to managing food allergies is to avoid the trigger. Epinephrine is used first line for anaphylaxis, often administered by the patient or family using an autoinjector. Research has focused on desensitizing patients by exposing them to increasing amounts of the food, but no therapies are FDA approved. Desensitization means that patients are less likely to react to an accidental exposure to peanut protein with ongoing treatment, but does not imply tolerance – the ability to eat any amount of food containing peanuts without risk of a serious reaction.

This evidence review examines the effectiveness and value of two technologies to desensitize patients with peanut allergy that are expected to be approved by the FDA—AR101 and Viaskin® Peanut—as well as non-commercialized oral immunotherapy (OIT) for peanut allergy.⁷

AR101 (Aimmune Therapeutics) is peanut flour produced using Good Manufacturing Practices. The peanut flour is mixed into pudding, applesauce, or other foods. The dose is gradually increased every two weeks to a goal dose of 300 mg daily. The initial dose escalation and each subsequent increase in dose must be observed by a health care professional (minimum of 12 total visits). Given the current state of knowledge, therapy must be continued daily to maintain desensitization.

Viaskin Peanut (DBV Technologies) is a patch applied daily to the upper back (rotating the location) that delivers 250 mcg of peanut antigen for desensitization treatment. The first patch is placed under the supervision of a medical professional, but subsequent patches can be applied at home. The patch is worn six hours a day for one week, then 12 hours a day for another week, and then 24 hours a day from then on. The dose escalation phase may be extended if patients have significant skin reactions. Given the current state of knowledge, therapy must be continued daily to maintain desensitization.

Insights Gained from Discussions with Patients and Patient Groups

Several themes emerged from speaking with patients and patient representatives. First was the burden of day-to-day living with peanut allergy. Patients and their caregivers experience tremendous anxiety, stress, and report poor quality of life. Caregivers frequently miss time from work or even leave the workplace to help manage the safety of the places that their loved ones visit. Patients with peanut allergy may feel they are restricted in where they live: some will not travel beyond a short distance from their specialist or tertiary care center. Some children do not go on field trips or to birthday parties or restaurants out of fear of exposure; patients and families may choose not to travel via airplane or travel abroad. Patients and their caregivers often lead a lifestyle heavily impacted by fear and anxiety. An important goal for patients is to be able to live and eat more freely.

Many within the patient community are excited to have FDA approved products with standardized treatment protocols. Unregulated OIT that is practiced now may not always be reimbursed by insurance since it can be viewed as experimental and the majority of Allergists do not offer it. Out of pocket expenses are a major issue for patients, both with regard to medications and food, and can have potential impact on managing disease and adherence to new treatments.


Asthma and Allergy Foundation of America (AAFA) Survey⁸

AAFA surveyed 853 caregivers of children with peanut allergies in April 2019. Roughly 77% of peanut allergy respondents were caregivers of children with peanut allergy between the ages of 5-17; 69% of respondents were white, 12% Latino, 5% Asian, and 4% black/African American. Nearly all respondents (93%) had children with multiple food allergies, with the most prominent comorbid allergies including tree nut, egg, and milk.

According to the survey data, 86% of caregivers indicated that their child's peanut allergy was always on their mind, and over half of respondents said they were always fearful of accidental exposure to an allergen. Caregivers highlighted both anxiety and post-traumatic stress disorder (PTSD) in family members as a direct consequence of the peanut allergy.

Figure ES1. AAFA Survey: Caregiver Beliefs About Their Child's Food Allergy

In thinking about your child's food allergy, which of the following do you believe?



Caregivers also reported on the financial burden of their child's peanut allergy on their families. On a scale of 1-5, over 40% of respondents reported a moderate to major financial burden for their families. The most common comments were about lost income because caregivers gave up or limited their jobs: "I had to quit my job to care for my daughter" and similar comments were repeated many times. The second most common series of comments focused on the costs of special foods: "I can definitely say 'safe' foods are 4x the cost."

Potential Cost-Saving Measures in Peanut Allergy

As described in its Final Value Assessment Framework for 2017-2019, ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create additional resources in health care budgets for higher-value innovative services (for more information, see <https://icer-review.org/material/final-vaf-2017-2019/>). To date we have received the following recommendations, which follow the AAAAI Choosing Wisely recommendations:

- *Don't perform unproven diagnostic tests, such as immunoglobulin G (IgG) testing or an indiscriminate battery of immunoglobulin E (IgE) tests, in the evaluation of allergy.*
- *Don't perform food IgE testing without a history consistent with potential IgE-mediated food allergy.*

Comparative Clinical Effectiveness

We abstracted evidence from RCTs of individuals ages four to 17 years with peanut allergy comparing desensitization therapy to strict peanut avoidance. Age is an important effect modifier for the efficacy of desensitization therapy. Early trial results led to a focus on children ages four to 11 years in the Phase 3 trial of Viaskin Peanut and ages four to 17 in the Phase 3 trial of AR101. Our review focused on clinical benefits (reduction in allergic reactions, epinephrine use, ER visits, hospitalizations, and quality of life) as well as potential harms (systemic allergic reactions due to the therapies, serious adverse events, and adverse events leading to discontinuation of therapy).

The two randomized trials of AR101 and the three randomized trials of Viaskin Peanut were all of good quality/low risk of bias, though all of the trials were at risk for partial unblinding due to adverse events. For the OIT trials other than AR101, the two RCTs were of poor quality and the two other studies were uncontrolled case-series. We also summarized a recent systematic review of randomized trials of OIT for peanut allergy that included a broader patient population.

Clinical Benefits

Because of changes in study design in the Phase 3 trials compared with earlier trials, the clinical benefits and harms of AR101 and Viaskin Peanut are primarily driven by the results of the Phase 3 trials, PALISADE and PEPITES. Table ES1 summarizes the key elements of both trials.

Table ES1. Comparison of the Phase 3 PALISADE and PEPITES Trials

	AR101	Viaskin Peanut
Key Study	PALISADE	PEPITES
Ages	4 – 17 years	4 – 11 years
Peanut Sensitivity	ED ≤100 mg	ED ≤300 mg
Median Baseline ED	10 mg	30 mg
Primary Outcome in DBPCFC	Tolerate 600 mg peanut protein	ED 300 mg if baseline ED ≤10 mg ED 1000 mg if baseline ED ≥30 mg
Dose Escalation*	3 mg to 300 mg daily with increases every 2 weeks for 24 weeks	250 mcg patch worn for 3 hours day 1, 6 hours week 1; 12 hours week 2; and 24 hours thereafter
Maintenance Dose	300 mg orally every day	250 mcg by patch every day
Clinic Visits	Every dose escalation for at least 90 minutes	Day 1 only
Met Primary Outcome, Active vs. Placebo	67.2% vs. 4.0%	35.3% vs. 13.6%
Overall Withdrawal Rate, Active vs. Placebo	21.0% vs. 7.3%	10.5% vs. 9.3%

DBPCFC: double-blind, placebo-controlled food challenge, ED: eliciting dose

*This dose escalation is the ideal if no complications, but may be slowed for adverse events and adherence issues.

Several important differences should be highlighted. First, the PALISADE trial of AR101 included older patients (ages 12 to 17 years) who are less likely to respond to desensitization therapy. The PALISADE trial also enrolled participants with a lower eliciting dose (≤ 100 mg rather than 300 mg). Finally, the primary outcome in the PALISADE trial required a tolerated dose of 600 mg or higher compared with 100 mg for the low-eliciting dose group in the PEPITES trial of Viaskin Peanut or 300 mg for the high-eliciting dose in PEPITES. Thus, the PALISADE trial enrolled participants who were sensitive to lower doses of peanut protein and had a primary outcome that was more difficult to achieve.

The primary benefit documented in both trials was desensitization. In the PALISADE trial, a greater percentage of participants randomized to AR101 met the definition of desensitization compared with those randomized to placebo (67.2% vs. 4.0%, $p < 0.001$). In the PEPITES trial, a greater percentage of participants randomized to Viaskin Peanut met the definition of desensitization compared with those randomized to placebo (35.3% vs. 13.6%, $p < 0.001$), but the primary outcome of the trial was not met: the lower bound of the 95% confidence interval for the difference between the two groups was less than 15% (21.7%, 95% CI 12.4% to 29.8%).

Neither trial documented improvements in quality of life for the treated group compared with the placebo group and neither trial documented a reduction in reactions from accidental exposures to peanut protein.

The studies of OIT used a variety of doses and sources of peanut protein, different target doses for the maintenance phase and different definitions for desensitization. In the randomized trials, successful desensitization was reached in 21% to 49% of the OIT participants and none of the controls. In two retrospective case series 81% and 85% of participants respectively were able to reach the target maintenance dose. The systematic review of 12 randomized trials, including the AR101 trials, reported that a higher proportion of patients were desensitized using a variety of definitions based on an OFC (OR 12.4, 95% CI 6.8-22.6). There were no significant differences in quality of life between the OIT and placebo groups.

Harms

The most common adverse events for AR101 were gastrointestinal (52% abdominal pain, nausea, vomiting) and though the incidence declined in the dose maintenance phase compared with the dose escalation phase, they remained high. Withdrawal rates overall (21.0%) and withdrawals due to adverse events (11.6%) were substantially higher than those observed in the placebo group. Systemic allergic reactions (14.2% vs. 3.2% placebo) and the use of epinephrine (14.0% vs. 6.5% placebo) were more common in the AR101-treated group.

The most common adverse events for Viaskin Peanut were skin reactions at the site of the patches including itching (34.5%) and redness (28.2%). Most of these adverse events were mild to

moderate. Systemic allergic reactions related to the patch were uncommon (3.8%), though epinephrine use was more frequent (9.2% vs. 3.4% placebo). Withdrawal due to adverse events was uncommon in the active treatment group (1.7%), but more than 10% withdrew from the study during one year of follow-up.

The harms in the OIT studies mirrored those of AR101. The primary adverse events leading to discontinuation were GI, including abdominal pain, nausea, and vomiting. In studies with very high maintenance doses, food aversion also played an important role. No new adverse events were identified. The systematic review reported increases in the risk for anaphylaxis (OR 3.1, 95% CI 1.8-5.6), epinephrine use (OR 2.2, 95% CI 1.3-3.8), and serious adverse events (OR 1.9, 95% CI 1.0-3.7).

Controversies and Uncertainties

The primary benefit of desensitization to peanuts in patients with peanut allergy is likely to be the improvements in quality of life for both the patient and caregivers. However, the quality of life outcomes for the Phase 3 trials have not yet been published. It is challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.

The lack of an accepted standard definition for desensitization presents a major challenge. The primary outcome differed across all of the trials. A consensus definition for clinically meaningful desensitization is urgently needed. Furthermore, desensitization is a surrogate outcome for the clinically meaningful outcomes of a decrease in reactions to accidental exposure to peanuts, a reduction in use of epinephrine, and an improvement in quality of life. Studies have not yet demonstrated that desensitization to peanut protein improves these outcomes.

Finally, there is considerable uncertainty about the long-term outcomes for both AR101 and Viaskin Peanut. There is hope that a subset of patients may develop sustained unresponsiveness, but for now the assumption is that patients will remain on these therapies indefinitely. This raises issues about long-term adherence to therapy, particularly during adolescence and young adulthood. If patients are not continuously adherent, they may no longer be desensitized and could have a serious allergic reaction to the therapy itself. With oral immunotherapy, food aversion can be an issue in a subset of patients and eosinophilic esophagitis may become more common

Summary and Comment

AR101

The substantial increase in patients treated with AR101 who are able to tolerate 600 mg of peanut protein during an OFC compared with those treated with placebo (67.2% vs. 4.0%) is balanced by a significant increase in gastrointestinal symptoms, systemic allergic reactions, and epinephrine use. The net health benefits of AR101 will be driven by changes in quality of life and reductions in

reactions to accidental exposure to peanuts, neither of which has been demonstrated. Thus, there is only moderate certainty of a comparable, small, or substantial net health benefit and a small (but non-zero) likelihood of a negative net health benefit for AR101 compared with strict avoidance and rapid use of epinephrine (PI, promising, but inconclusive). Given the need for frequent visits to doctors during the dose escalation phase and the frequent adverse events, it will be important to ensure that patients receive adequate informed consent and that their preferences are carefully elicited prior to initiating desensitization therapy with AR101.

Viaskin Peanut

The small increase in patients able to tolerate 100 to 300 mg of peanut protein compare with those treated with placebo (35.3% vs. 13.6%) is balanced by relatively few adverse events, but significant increases in systemic allergic reactions, and epinephrine use. As with AR101, the net health benefits are likely to be driven by changes in quality of life and reductions in reactions to accidental exposure to peanuts, neither of which has been demonstrated. Thus, there is only moderate certainty of a comparable, small, or substantial net health benefit and a small (but non-zero) likelihood of a negative net health benefit for Viaskin Peanut compared with strict avoidance and rapid use of epinephrine (PI, promising, but inconclusive).

Oral Immunotherapy (OIT)

The studies of OIT, other than AR101, were relatively small, unblinded poor quality studies that used peanut protein not subject to Good Manufacturing Practices. There were differences in the dose escalation phase and in the maintenance dose as well as differences in the outcomes used to define desensitization. Finally, there were significant increases in adverse events, anaphylaxis, and epinephrine use associated with OIT and no clear net improvements in quality of life. Thus, the level of certainty in the evidence for OIT is low (I, insufficient).

Comparisons Among Therapies

There are no head to head trial between these agents, and the patient populations and primary outcomes differed sufficiently to preclude indirect comparisons. Based on surrogate outcomes (oral food challenges), AR101 appears more efficacious than Viaskin Peanut, but appears to have more adverse effects. However, the level of certainty in the comparative evidence is low (I, insufficient).

Long-Term Cost Effectiveness

The primary aim of this analysis was to estimate the lifetime cost-effectiveness of the two peanut allergy immunotherapies from a US health care sector perspective. The cost-effectiveness model included two comparisons: 1) AR101 oral immunotherapy plus avoidance compared to avoidance

alone, and 2) Viaskin Peanut plus avoidance compared to avoidance alone. These two immunotherapies were modeled independently; i.e., all incremental values, including incremental cost-effectiveness ratios (ICERs), solely reflect comparisons to the placebo control from the respective trials. Participant survival, quality-adjusted survival, serious adverse events (anaphylaxis), and health care costs were summarized over a lifetime time horizon for each treatment option. All costs and outcomes were discounted at 3% per year. We modeled a variety of scenarios beyond the base case, including a modified societal perspective to capture the quality of life and economic impacts of peanut allergy on parents and/or caregivers.

The first year of the model was created using the clinical trial data separately for AR101 and Viaskin Peanut. In that year, the placebo patients from each trial experienced the events and the food challenges that were recorded in the trials, with these events being used to estimate the avoidance alone patient's experience. After the first year, all placebo patients who were not successful in completing the exit food challenge moved to the untreated with peanut sensitivity health state.

Participant survival was modeled using United States Centers for Disease Control (CDC) life tables⁹ for age-based background mortality, and we also applied a small (5.77×10^{-7}) annual probability of death from an allergic reaction to the peanut sensitivity and desensitized health states (but not the peanut tolerant health state) in years 2+ of the model; both estimates were converted to and applied as a weekly probability for year one.¹⁰

Spontaneous Peanut Tolerance

The rate of spontaneous tolerance to peanuts (resolution of the allergy) was applied to both the untreated with peanut sensitivity and peanut desensitized health states in years 2+. The same transition probability of 1.1% per year was applied to each state.¹¹

Discontinuation of Immunotherapy

The rate of immunotherapy discontinuation in the first year reflects the trial-reported number of participants who did not complete the trial. In the case of AR101 versus avoidance alone, we utilized available discontinuation data stratified by dose escalation phase from the PALISADE trial.¹² For Viaskin Peanut, discontinuation rates were based on the reported discontinuation rates at year one in the PEPITES trial.¹³ The rates of discontinuation for each time period were converted to weekly transition probabilities that were used to transition participants from the treatment or avoidance alone with peanut sensitivity health state to the untreated with peanut sensitivity health state during modeled year one.

Utilities

Participants in peanut sensitivity health states received the utility value of food allergy participants, and peanut tolerant participants received the non-food allergic utility value from Protudjer et al. We also assumed that participants in the peanut desensitized health state had an improvement in utility that was 60% of the difference between utilities for the untreated with peanut sensitivity and peanut tolerant health states. This is a conservative assumption based on the available data and with the expectation that while desensitization reduces risk, there is still an underlying potential risk of reaction to exposure and the need to avoid exposure to peanuts and to carry epinephrine

Immunotherapy Cost Inputs

The costs of immunotherapy with AR101 and Viaskin Peanut are currently unknown as they have not been made commercially available. However, analyst estimates have recently forecasted an expected cost for AR101 of \$5,000 to \$10,000 for the first six months of use, and \$300 to \$400 per month after. Analysts also predict that Viaskin Peanut will cost more than \$6,000 for a year's supply.¹⁴ Based on these estimates, we assumed AR101 placeholder costs of \$350 per month (\$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter).¹⁴ For Viaskin Peanut, we assumed a placeholder cost of \$6,500 per year.¹⁴ We also present the model-calculated, value-based prices necessary to meet the willingness-to-pay thresholds of \$50,000, \$100,000, and \$150,000 per QALY for each of the two comparisons.

Base-Case Results

Immunotherapy with AR101 resulted in increased QALYs due to the utility benefit of more patients having peanut desensitization, with 0.75 incremental QALYs versus avoidance alone (Table ES2). We did not model a difference in mortality among comparators, therefore both AR101 and avoidance alone resulted in 28.69 life years gained and there was no gain in overall survival for AR101. Using the available placeholder price, the total lifetime cost was \$72,000 for AR101 versus \$6,000 for avoidance alone, and the incremental cost-effectiveness ratio was \$88,000.

Table ES2. Discounted Base-Case Results: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$72,000	27.19	28.69	\$88,000
Avoidance Alone	\$0	\$6,000	26.44	28.69	
Incremental	\$65,000	\$66,000	0.75	0.00	

Immunotherapy with Viaskin Peanut resulted in increased QALYs due to the utility benefit of

increased peanut desensitization, with 0.26 incremental QALYs versus avoidance alone (Table ES3). As noted above, there was no difference in overall survival, therefore both Viaskin Peanut and avoidance alone resulted in 28.69 life years gained. Using the available placeholder price, the total cost was \$62,000 for Viaskin Peanut versus \$6,000 for avoidance alone, and the incremental cost-effectiveness ratio was \$216,000.


Table ES3. Discounted Base-Case Results: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$62,000	26.81	28.69	
Avoidance Alone	\$0	\$6,000	26.55	28.69	
Incremental	\$56,000	\$56,000	0.26	0.00	\$216,000

Sensitivity Analyses

We performed one-way sensitivity analysis to evaluate the impact of single parameter uncertainty on the incremental cost-effectiveness ratios for immunotherapy versus avoidance alone (Figure ES2). For the comparison of AR101 versus avoidance alone, the parameters with the greatest impacts on the ICER were utilities associated with peanut sensitivity and peanut desensitization, the cost of immunotherapy, and results of the exit food challenge. For the comparison of Viaskin Peanut versus avoidance alone, the parameters with the greatest impacts on the ICER were very similar to those driving the AR101 comparison. We performed probabilistic sensitivity analyses to evaluate the impacts of joint parameter uncertainty over 5,000 model simulations; detailed results of the probabilistic sensitivity analysis can be found in the Appendix, Tables E6 and E7.

Figure ES2. One-Way Sensitivity Analyses for Immunotherapy versus Avoidance Alone Using Placeholder Prices



Societal Perspective

For this analysis, we included the annual societal costs listed in the main report in Table 4.12. The addition of societal costs notably decreased the incremental cost-effectiveness ratios at each value-based price anchor point, as seen in Tables ES4 and ES5.

Table ES4. Societal Perspective: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$99,000	27.19	28.69	\$27,000
Avoidance Alone	\$0	\$79,000	26.43	28.69	
Incremental	\$65,000	\$20,000	0.75	0.00	

Table ES5. Societal Perspective: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$112,000	26.81	28.69	\$155,000
Avoidance Alone	\$0	\$72,000	26.55	28.69	
Incremental	\$56,000	\$40,000	0.26	0.00	

Threshold Analysis Results

The annual cost at which the immunotherapies would reach cost-effectiveness thresholds ranging from \$50,000 to \$150,000 per QALY gained are presented in Table ES6 below.

Table ES6. Threshold Analysis Results

	Annual Cost to Achieve \$50,000 per QALY	Annual Cost to Achieve \$100,000 per QALY	Annual Cost to Achieve \$150,000 per QALY
AR101	\$2,369	\$4,808	\$7,248
Viaskin Peanut	\$1,508	\$3,010	\$4,513

Model Validation

Model validation followed standard practices in the field. We tested all mathematical functions in the model to ensure they were consistent with the report (and supplemental Appendix materials). We also conducted sensitivity analyses with null input values to ensure the model was producing findings consistent with expectations. Further, independent modelers tested the mathematical functions in the model as well as the specific inputs and corresponding outputs.

Model validation was also conducted in terms of comparisons to other model findings. We searched the literature to identify models that were similar to our analysis, with comparable populations, settings, perspective, and treatments.

Summary and Comment

Our analysis indicates that the long-term cost-effectiveness of AR101 or Viaskin Peanut is dependent on the prices at which these technologies come to market. The analysis estimated that treatment with AR101 resulted in 0.75 incremental QALYs compared to no immunotherapy treatment over a lifetime time horizon. The analysis of Viaskin Peanut estimated that it resulted in 0.26 incremental QALYs compared to no immunotherapy treatment over a lifetime time horizon. The results of both analyses were most sensitive to the health state utility values and the proportion of patients who passed the exit food challenge at the end of the first year.

Using placeholder prices of \$350 per month (\$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter) for AR101 and \$6,500 per year for Viaskin Peanut, we estimated the total cost of AR101 to be \$66,000 over a lifetime, and an incremental cost-effectiveness ratio of \$88,000. The estimated lifetime cost for Viaskin Peanut was \$56,000, and its incremental cost-effectiveness ratio to be \$216,000.

Our scenario analyses indicate that the proportion of patients who are assumed to have responded (choice of threshold for desensitization) and continue treatment is an important parameter, as this predicts the size of the treated population. Furthermore, the background rate of spontaneous tolerance among patients with peanut allergy may be a key driver in the estimation of incremental value for new immunotherapies.

Potential Other Benefits and Contextual Considerations

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. These elements are listed in Table 5.1 in the main report.

Potential Other Benefits

Both AR101 and Viaskin Peanut have the potential to reduce the economic disparities that lead to higher emergency department visits and hospitalization in patients from low income households if they are given access to these therapies. In addition, the prevalence of peanut allergy is greater in non-Hispanic Blacks, and Hispanics than in non-Hispanic whites and in low-income families. These disparities have the potential to be reduced with FDA approval of these therapies.

Viaskin Peanut uses a novel mechanism of action by delivering immunotherapy transcutaneously. Prior immunotherapy approaches have been oral, sublingual, or subcutaneous.

There are inadequate data to assess whether these therapies will reduce caregiver psychosocial burden, physical burden, and anxiety, as well as improve quality of life and productivity, though both therapies have the potential to do so.

Contextual Considerations

Both AR101 and Viaskin Peanut will be the first therapies approved by the FDA to treat peanut allergy. The current method to manage peanut allergy is avoidance, which is not treatment and can result in potentially life-threatening accidental exposure to peanut allergens.

Peanut allergy has a significant, lifelong impact on patients', families, and caregivers' quality of life. These therapies have the potential to improve their quality of life.

There is significant uncertainty about the long-term risks and benefits for both therapies as the placebo-controlled comparisons are only one year in length and the data from the extension trials are sparse.

Value-Based Benchmark Prices

Our value-based benchmark annual prices for AR101 and Viaskin Peanut are presented in Table ES7. As noted in the initial ICER methods document <http://icer-review.org/wpcontent/uploads/2016/02/Value-Assessment-Framework-slides-for-July-29-webinar-FINALcorrected-8-22-1.pdf>, the value-based benchmark price for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between \$100,000 and \$150,000 per QALY gained.

Table ES7. Value-Based Benchmark Prices for AR101 and Viaskin Peanut for the Treatment of Peanut Allergy*

	Annual Cost to Achieve \$100,000 per QALY	Annual Cost to Achieve \$150,000 per QALY
AR101	\$4,808	\$7,248
Viaskin Peanut	\$3,010	\$4,513

*No wholesale acquisition costs are currently available for either product. Therefore, no estimates of price discounts are provided.


Potential Budget Impact

We used the cost-effectiveness model to estimate the potential total budgetary impact of AR101 and Viaskin Peanut in children with peanut allergy, ages four to 17 years and ages four to 11 years, respectively. We calculated the budget impact using the placeholder prices and those estimated to achieve willingness-to-pay (WTP) thresholds between \$50,000 to \$150,000 per QALY gained. As in the cost-effectiveness analysis, we also used placeholder prices from publicly available analysts' estimates. We assumed a placeholder price of \$350 per month for AR101 (i.e., \$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter).¹⁴ For Viaskin Peanut, we assumed a placeholder price of \$6,500 per year.¹⁴ Note that these placeholder prices for both AR101 and Viaskin Peanut may not reflect the actual prices at launch, and therefore the actual budget impact of these technologies may differ from our estimates.

As shown in Figure ES3, approximately 41% of eligible patients could be treated in a given year with AR101 without crossing the ICER budget impact threshold of \$991 million at the placeholder price

(\$4,200/year). Approximately 25%, 37%, and 67% of patients could be treated in a given year without crossing the budget impact threshold at the \$150,000, \$100,000, and \$50,000 per QALY threshold prices (at \$7,248, \$4,808, and \$2,369 per year, respectively).

Figure ES3. Budget Impact of AR101 at Placeholder* and Threshold Prices



*Placeholder price is used until list or net prices become available.

At the placeholder price (\$6,500/year) for Viaskin Peanut, approximately 71% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million. Despite the assumption of a higher placeholder price for Viaskin Peanut, more patients could be treated than with AR101, largely due to AR101's higher administration and monitoring costs in the first year of treatment. As shown in Table ES8, the annual potential budgetary impact of treating the entire eligible population over five years did not exceed the \$991 million ICER budget impact threshold at the prices to achieve \$150,000, \$100,000, and \$50,000 per QALY, reaching 98%, 65%, and 33% of the budget impact threshold, respectively.

Table ES8. Budget Impact of Viaskin Peanut at Threshold Prices

	Viaskin Peanut Percent of Budget Impact Threshold
\$150,000 per QALY Threshold Price	98%
\$100,000 per QALY Threshold Price	65%
\$50,000 per QALY Threshold Price	33%

Access and Affordability Alert

ICER is issuing an access and affordability alert for both AR101 and Viaskin Peanut. Currently, this alert is based on assumed prices, and it should be noted that the findings are subject to change if and when the actual prices become available (contingent upon FDA approval and launch).

For AR101, at the assumed price of \$4,200 per year, approximately 41% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million. If priced within the ICER value-based price range, only 25%-37% of eligible patients could be treated with AR101 before exceeding the potential budget impact threshold. For Viaskin Peanut, at the assumed price of \$6,500 per year, approximately 71% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million.

The purpose of an ICER affordability and access alert is to signal stakeholders and policy makers that the amount of added health care costs associated with a new service may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs that threaten sustainable access to high-value care for all patients.

Summary of the Votes and Considerations for Policy

At the June 11, 2019 meeting, the CTAF Panel discussed issues regarding the application of the available evidence to help patients, clinicians, and payers address important questions related to the use of oral immunotherapy and Viaskin Peanut for treating patients with peanut allergy. Following the evidence presentation and public comments, the CTAF Panel voted on key questions concerning the comparative clinical effectiveness and potential other benefits and contextual considerations related to peanut allergy therapies. The voting results are presented below. A full description of the deliberation is included in Section 8 of the full report.

1) Is the evidence adequate to demonstrate that the net health benefit of AR101 plus strict peanut avoidance is superior to continued avoidance alone?

Yes: 4 votes	No: 12 votes
--------------	--------------

2) Is the evidence adequate to demonstrate that the net health benefit of Viaskin Peanut plus strict peanut avoidance is superior to continued avoidance alone?

Yes: 4 votes	No: 12 votes
--------------	--------------

3) Is the evidence adequate to distinguish the net health benefit of AR101 and Viaskin Peanut?

Yes: 0 votes	No: 16 votes
--------------	--------------

3a) If the answer to Q3 is Yes: Based on the available evidence, which therapy has greater net health benefit: (a) AR101 plus strict peanut avoidance, or (b) Viaskin Peanut plus strict peanut avoidance?

No vote was taken, as the panel unanimously voted no on Question 3.

4) Is the evidence adequate to demonstrate that the net health benefit of AR101 is superior to oral immunotherapy as practiced currently?

Yes: 2 votes	No: 14 votes
--------------	--------------

5) Does desensitizing patients with Viaskin Peanut offer one or more of the following potential “other benefits” in comparison to strict peanut avoidance alone? (select all that apply)

This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.	9/16
This intervention will significantly reduce caregiver or broader family burden.	10/16
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	11/16
This intervention will have a significant impact on improving patients’ ability to return to work, school, and/or their overall productivity.	9/16
There are other important benefits or disadvantages that should have an important role in judgments of the value of Viaskin Peanut: _____.	12/16

6) Does desensitizing patients with AR101 offer one or more of the following potential “other benefits” in comparison to strict peanut avoidance alone? (select all that apply)

This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.	7/16
This intervention will significantly reduce caregiver or broader family burden.	11/16
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	5/16
This intervention will have a significant impact on improving patients’ ability to return to work, school, and/or their overall productivity.	8/16
There are other important benefits or disadvantages that should have an important role in judgments of the value of Viaskin Peanut: _____.	10/16

7) Are any of the following contextual considerations important in assessing the long-term value for money for Viaskin Peanut in comparison to strict peanut-avoidance alone? (select all that apply)

This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.	9/15
There is significant uncertainty about the long-term risk of serious side effects of this intervention.	13/15
There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.	13/15
There are additional contextual considerations that should have an important role in judgments of the value of this intervention: _____.	4/15

8) Are any of the following contextual considerations important in assessing the long-term value for money for AR101 in comparison to strict peanut-avoidance alone? (select all that apply)

This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.	8/15
There is significant uncertainty about the long-term risk of serious side effects of this intervention.	13/15
There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.	13/15
There are additional contextual considerations that should have an important role in judgments of the value of this intervention: _____.	3/15

9) Given the available evidence on comparative effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with AR101 plus strict peanut avoidance compared with continued avoidance alone?

No vote was taken, as AR101 did not have a publicly-known price at the time of the meeting.

10) Given the available evidence on comparative effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with Viaskin Peanut plus strict peanut avoidance compared with continued avoidance alone?

No vote was taken, as Viaskin Peanut did not have a publicly-known price at the time of the meeting.

Roundtable Discussion and Key Policy Implications

Following its deliberation on the evidence, the CTAF Panel engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on oral immunotherapy and Viaskin Peanut to policy and practice. The policy roundtable members included two patient advocates, two clinical experts, one payer, and two representatives from pharmaceutical manufacturers. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants. The top-line policy implications are presented below, and additional information can be found in the full report.

Manufacturers

- To provide fair value to patients and the health system, manufacturers should price desensitization therapies for peanut allergy so that they align with the added value they bring to patients.
- Manufacturers should pursue further evidence development in order to provide better certainty of their long-term safety and effectiveness. Evidence should not rely on short-term surrogate outcome measures like desensitization.
- Manufacturers should work with patient groups and the clinical research community to conduct studies that provide evidence on when and how to stop treatment.
- Manufacturers should collaborate with the patient community and clinical experts to develop educational materials for parents to understand the benefit-risk tradeoffs in undergoing desensitization, and not create undue guilt for individual families who decide not to initiate treatment.

Payers

- ICER is issuing an access and affordability alert for both AR101 and Viaskin Peanut. The purpose of an ICER affordability and access alert is to signal stakeholders and policy makers that the amount of added health care costs associated with a new service may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs that threaten sustainable access to high-value care for all patients.
- Prior authorization criteria should be based on clinical evidence, with input from clinical experts and patient groups. Options for specific elements of coverage criteria within insurance coverage policy are discussed in detail in Section 8.
 - **Patient Eligibility Criteria:**
 - **Diagnosis:** Payers may choose to accept clinician attestation for the diagnosis, particularly if limiting coverage to prescriptions from allergy specialists. Payers may also consider requiring prior pharmacy record of a refill of epinephrine as an indicator of confirmed peanut allergy diagnosis.
 - **Age:** Payers may consider limiting coverage for initiation of desensitization treatment to patients between the ages of four to 17 years who represent the population studied to date.
 - **Renewal criteria:** Payers should not stop coverage at age 18 for patients who have been on continuous desensitization therapy.
 - **Provider criteria:** Prescribing peanut desensitization therapies should be restricted to specialists (Allergy and Immunology Specialists); or for those patients with inadequate access to allergists, by primary care physicians only in consultation with a specialist.

Providers

- Shared-decision making is essential in the safe and appropriate prescribing of desensitization therapy.

Specialty Societies

- Specialty societies should develop a clear, evidence-based definition of desensitization to food allergy.
- Given the remaining uncertainties about the benefits and harms of these novel therapies, specialty societies should take the lead in organizing patient registries to capture treatment effects of desensitization therapies if they enter the market.
- Specialty societies should collaborate with patient organizations to develop materials for both patients and clinicians to support appropriate shared decision making that does not

create stigma for patients who decide for or against treatment with the current generation of desensitization therapies.

Patient Advocacy Organizations

- Patient organizations should help educate families and patients about these therapies, including both potential benefits and potential harms.
- Patient organizations should consider boycotting research sponsored by drug manufacturers that does not measure outcomes of direct relevance to patients for a period sufficient to provide a sound basis for shared clinical decision-making. Patients should strongly advocate that the FDA do better in ensuring that the research required for regulatory approval meets these standards.

Regulators

- The FDA should update its guidance for the assessment of outcomes in food allergy therapy to require a common definition of desensitization.
- The FDA should mandate additional randomized clinical trials that demonstrate clinically meaningful benefits for patients (reduction in severe allergic reactions, reduction in epinephrine use, reduction in ER visits/hospitalizations, and improvement in quality of life).

Researchers

- Longer placebo-controlled, randomized trials are needed to demonstrate that desensitization translates into outcomes that matter to patients.
- Research is needed to develop biomarkers both for initiation of therapy and to support the decision about when it is safe to go off desensitization treatment.

1. Introduction

1.1 Background

Background

Peanut is a common childhood allergen in the United States (US). According to recent estimates approximately 1.4-4.5% of children in the US suffer from peanut allergy.¹⁻³ It is more common in males (1.7% vs. 0.8%), people with lower income (1.7% vs. 1.2%), and there are race/ethnicity disparities in the prevalence of peanut allergies (2.8% non-Hispanic blacks, 1.7% Hispanics, and 0.9% non-Hispanic whites).¹⁵ In addition, peanut allergy is the leading cause of death from anaphylaxis due to food, particularly in teenagers, though the rate is low.⁴ The national food allergy death registry reports fewer than four deaths per year over the past 10 years in the US.⁵ Other sources report that the risk of death from peanut allergy is lower than the risk for accidental death in the general population.¹⁶

Food allergy reactions can range from mild cutaneous symptoms, to gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and diarrhea, on to anaphylaxis.^{17,18} The allergy usually begins early in life and only a minority of patients outgrow their food allergy.¹⁷ Furthermore, up to 55% of patients with peanut allergy suffer from additional food allergies.^{3,19} The economic cost of food allergies in the US is estimated at \$24.8 billion per year, of which only \$4.3 billion was direct medical costs.⁶ Non-medical costs accounted for \$20.5 billion and included out-of-pocket medical costs, the costs of special foods, and lost caregiver productivity. There are important economic disparities in the distribution of these costs: patients from lower income households have 2.5 times higher costs for emergency department visits and hospitalizations, but lower costs for visits to specialists and out of pocket costs.²⁰

The primary approach to managing food allergies is to avoid the trigger. Notably, avoidance of the trigger is not a treatment for children with food allergies, but rather a strategy to avert a reaction to accidental exposure, which in certain cases potentially can cause life-threatening patient reactions. However, up to 40% of those with peanut allergy may experience an accidental exposure with an annual incidence of 10% to 20%.^{2,3,17,21} However, that rate appears to have declined significantly according to recent studies (accidental exposures 4.7% per year, epinephrine use 1.1% per year).²² Antihistamines are used to manage mild to moderate symptoms and epinephrine is used first line for anaphylaxis, often administered by the patient or family using an autoinjector (e.g., EpiPen®, Auvi-Q®). Research has focused on desensitizing patients by exposing them to increasing amounts of the food, but no therapies are FDA approved. Desensitization means that patients are less likely to react to an accidental exposure to peanut protein with ongoing treatment, but does not imply

tolerance – the ability to eat any amount of food containing peanuts without risk of a serious reaction.

This evidence review examines the effectiveness and value of two technologies to desensitize patients with peanut allergy that are expected to be approved by the FDA – AR101 and Viaskin Peanut – as well as non-commercialized oral immunotherapy (OIT) for peanut allergy.⁷ The FDA granted Fast Track Designation to Viaskin Peanut in 2012 and to AR101 in 2014. Both AR101 and Viaskin Peanut were granted Breakthrough Therapy Designation by the FDA in 2015 to expedite the development and review of these therapies.

AR101 (Aimmune Therapeutics) is defatted, slightly roasted peanut flour produced using Good Manufacturing Practices, which comes in a capsule or sachet form and has a characterized allergen profile. The product is not ingested in capsule form; the peanut flour-containing capsule is pulled apart and the peanut flour mixed into pudding, applesauce, or other foods. The first day of therapy consists of five escalating oral doses separated by 30 minutes. Subsequently, the dose is gradually increased every two weeks to a goal dose of 300 mg daily. The initial dose escalation and each subsequent increase in dose must be observed by a health care professional (minimum of 12 total visits). The dose escalation phase may be extended due to symptoms requiring more than twelve weeks to resolve, illness that requires dose reduction, or missed doses. Given the current state of knowledge, therapy must be continued daily to maintain desensitization. AR101 is being studied primarily in pediatric patients ages four to 17 years.

Viaskin Peanut (DBV Technologies) is a patch applied daily to the upper back (rotating the location) that delivers 250 mcg of peanut antigen for desensitization treatment. The first patch is placed under the supervision of a medical professional, but subsequent patches can be applied at home. The patch is worn six hours a day for one week, then 12 hours a day for another week, and then 24 hours a day from then on. The dose escalation phase may be extended if patients have significant skin reactions. Given the current state of knowledge, therapy must be continued daily to maintain desensitization. Viaskin Peanut is being studied primarily in pediatric patients ages four to 11 years.

An FDA approval decision for AR101 is expected in January 2020. The timeline for Viaskin Peanut is currently unknown, but is expected to be sometime in 2020.

1.2 Scope of the Assessment

The proposed scope for this assessment is described on the following pages using the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. Evidence has been abstracted from randomized controlled trials. Our evidence review includes input from patients and patient advocacy organizations, information submitted by manufacturers, and other


grey literature that meets ICER standards (for more information, see <https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/grey-literature-policy/>).

All relevant evidence was synthesized qualitatively because of important differences in the populations studied and in the primary outcomes of the trials. There were no head-to-head studies of the interventions of interest. Full details regarding the literature search, screening strategy, and data extraction, and evidence synthesis are provided in Appendix D.

Analytic Framework

The general analytic framework for assessment of therapies for peanut allergies is depicted in Figure 1.1.

Figure 1.1. Analytic Framework: Therapies for Peanut Allergy



The diagram begins with the population of interest on the left.²³ Actions, such as treatment, are depicted with solid arrows which link the population to outcomes. For example, a treatment may be associated with specific health outcomes. Outcomes are listed in the shaded boxes; those within the rounded boxes are intermediate outcomes (e.g., tolerance on an oral food challenge), and those

within the squared-off boxes are key measures of benefit (e.g., quality of life, reduction in anxiety, prevention of anaphylaxis). The key measures of benefit are linked to intermediate outcomes via a dashed line, as the relationship between these two types of outcomes may not always be validated. Curved arrows lead to the adverse events of treatment which are listed within the blue ellipse.²³

When available, outcomes are reported separately by type of exposure: iatrogenic versus accidental.

Populations

The population of focus for the review is children between the ages of four and 17 with peanut allergy.

Interventions

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers on which drugs to include. The full list of interventions is as follows:

- AR101
- Viaskin Peanut
- OIT with other peanut products

Comparators

Each of the interventions is compared to standard of care, which consists of strict avoidance of peanuts and rapid access to epinephrine, and to each other.

Outcomes

The outcomes of interest are described in Table 1.1. As noted above, when possible, we report the outcomes separately for iatrogenic and accidental exposure.

Table 1.1. Outcomes and Harms

Outcomes	Key Harms
Death	Systemic allergic reactions
ER/hospitalization for peanut allergy reactions	Skin reactions
Quality of life	Gastrointestinal reactions
Parental time off from work	Serious adverse events
Expanded activities for child	Adverse events leading to treatment discontinuation
Anaphylaxis	
Angioedema	
Bronchospasm/wheezing	
Urticaria	
Use of epinephrine	
Parental anxiety	
Patient anxiety/depression	
Tolerance to challenge with peanut allergen	

Timing

Evidence on intervention effectiveness was derived from studies of at least one year's duration and evidence on harms from studies of at least three month's duration.

Settings

All relevant settings were considered, with a focus on outpatient settings in the US.

1.3 Definitions

Oral food challenge (OFC): Exposing a patient with suspected food allergy to the food in a doctor's office in gradually increasing doses. The Practical Allergy (PRACTALL) consensus report recommends starting at 3 mg of food protein and then increasing the dose every 20 minutes using the following amounts: 10, 30, 100, 300, 1000, and 3000 mg.²⁴ The food challenge is stopped if there are objective symptoms of an allergic reaction or subjective symptoms on three consecutive doses.

Double blind placebo-controlled food challenge (DBPCFC): This is the gold standard recommended in the PRACTALL consensus report for both the diagnosis of food allergy and as an outcome in therapeutic trials.²⁴ The protocol for an OFC is performed as described above, but the patient is randomized to receive either the suspected food allergen or an identical placebo that does not contain the suspected allergen. Neither the patient nor the person administering the test knows the contents of the food being used in the OFC. The OFC is repeated on a subsequent day with the other food.

Eliciting Dose: This is the dose (grams of peanut protein) at which an oral food challenge is stopped due to either objective symptoms or significant subjective symptoms.

Tolerated Dose: This is the dose (grams of protein) just prior to the eliciting dose in an oral food challenge.

Cumulative Reactive Dose: This is the sum of all the doses in an oral food challenge including the eliciting dose.

Tolerance: An individual who no longer has symptoms when eating the food or during an OFC months to years after any treatment has stopped has tolerance to that food.

Desensitization: This is the goal of the immunotherapies evaluated in this report. Patients who are desensitized do not have an allergic reaction to low doses of the food, but have not developed tolerance. They require ongoing therapy to maintain desensitization. There is no standard eliciting or tolerated dose that defines desensitization.

Eosinophilic esophagitis (EoE) refers to localized eosinophilic inflammation of the esophagus. In some patients, avoidance of specific foods will result in normalization of histopathology. EoE can present with feeding disorders, vomiting, reflux symptoms, and abdominal pain in children; and dysphagia and esophageal food impactions in adolescents and adults. EoE is a known complication of OIT.

1.4 Insights Gained from Discussions with Patients and Patient Groups

Several themes emerged from speaking with patients and patient representatives. First was the burden of day-to-day living with peanut allergy. Patients and their caregivers experience tremendous anxiety, stress, and report poor quality of life. Caregivers frequently miss time from work or even leave the workplace to help manage the safety of the places that their loved ones visit. Patients with peanut allergy may feel they are restricted in where they live: some will not travel beyond a short distance from their specialist or tertiary care center. Some children do not go on field trips or to birthday parties or restaurants out of fear of exposure; patients and families may choose not to travel via airplane or travel abroad. Patients and their caregivers often lead a lifestyle that may be heavily impacted by fear and anxiety. An important goal for patients is to be able to live and eat more freely.

While death from a food allergy is rare, adolescents may be at the highest risk for death due to both their risk-taking nature and the movement away from environments that can be carefully managed by their parents and other caregivers. While food labeling has improved since 2006, it is still challenging to know if food items contain traces of allergens because so many products are labeled as either “may contain” peanuts or have been manufactured using equipment potentially exposed

to peanuts, placing patients at risk from cross-contamination. All food labels must be read carefully and patients avoid many foods altogether, which may lead to restricted diet, extra expenses for food, and/or nutritional risks to the patient if avoidances are not carefully managed.

As noted above, many patients with peanut allergies suffer from other food allergies. Some of these patients expressed that decreasing just peanut sensitivity may have less impact on their quality of life.

Many within the patient community are excited to have FDA approved products with standardized treatment protocols because they perceive that they will be safer. Unregulated OIT that is practiced now may not always be reimbursed by insurance since it can be viewed as experimental and the majority of Allergists do not offer it. As a result, patients who pursue OIT often pay out of pocket, which can limit access to those who can afford it. Patients with a peanut allergy are particularly sensitized to the cost of therapy because of the recent increases in the price of EpiPen autoinjectors. Out of pocket expenses are a major issue for patients, both with regard to medications and food, and can have potential impact on managing disease and adherence to new treatments.


Asthma and Allergy Foundation of America (AAFA) Survey⁸

AAFA surveyed 853 caregivers of children with peanut allergies in April 2019. Roughly 77% of peanut allergy respondents were caregivers of children with peanut allergy between the ages of 5-17; 69% of respondents were white, 12% Latino, 5% Asian, and 4% black/African American. Finally, nearly all respondents (93%) had children with multiple food allergies, with the most prominent comorbid allergies including tree nut, egg, and milk.

According to the survey data, 86% of caregivers indicated that their child's peanut allergy was always on their mind, and over half of respondents said they were always fearful of accidental exposure to an allergen. In measuring the impact on their quality of life, over 60% of caregivers reported that their child's peanut allergy had a major or moderate impact on their own mental health – or a 4 or a 5 on a scale of 1-5 (with 1 being no impact, and 5 being major impact). In open comment fields throughout the survey, caregivers highlighted both anxiety and post-traumatic stress disorder (PTSD) in family members as a direct consequence of the peanut allergy.

Figure 1.2. AAFA Survey: Caregiver Beliefs About Their Child's Food Allergy

In thinking about your child's food allergy, which of the following do you believe?




Base: N=853

Caregivers also reported on the financial burden of their child's peanut allergy on their families. On a scale of 1-5, over 40% of respondents reported a moderate to major financial burden for their families.

Figure 1.3. Financial Burden of Peanut Allergy on Caregivers

On a scale of 1 to 5, how much of an impact do you think your child's food allergy has on [financial burden] of your life? (N=853)



Open-ended responses reinforced the economic hardship imposed on the family because of the peanut allergy of their children. The most common comments were about lost income because

caregivers gave up or limited their jobs: “I had to quit my job to care for my daughter” and similar comments were repeated many times. The second most common series of comments focused on the costs of special foods: “I can definitely say ‘safe’ foods are 4x the cost.”

Finally, AAFA asked survey respondents about not-yet approved treatments, including oral and epicutaneous immunotherapy. Most respondents had heard of the possible treatment options, with approximately 10% and 17% of caregivers indicating that his or her child was receiving epicutaneous or oral immunotherapy respectively. Interestingly, parents were almost evenly split about whether they would consider the treatment for their child. For epicutaneous immunotherapy, 35% indicated that, while they had heard of it, they had never considered it for their child; whereas 31% indicated they had considered it. For oral immunotherapy, 35% indicated that while they had heard of the treatment option, but never considered it, whereas 31% indicated that they had considered it. Over 80% of caregivers listed efficacy, safety, quality of life, and risk reduction to accidental exposure as their primary concerns in determining their willingness to try new food allergy treatments.

1.5. Potential Cost-Saving Measures in Peanut Allergy

As described in its Final Value Assessment Framework for 2017-2019, ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create additional resources in health care budgets for higher-value innovative services (for more information, see <https://icer-review.org/material/final-vaf-2017-2019/>). These services are ones that would not be directly affected by AR101 and Viaskin Peanut (e.g., emergency department management of an allergic reaction), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of peanut allergy beyond the potential offsets that arise from a new intervention.

Examples include relevant Choosing Wisely recommendations, such as the following from the AAAAI:

- *Don't perform unproven diagnostic tests, such as immunoglobulin G (IgG) testing or an indiscriminate battery of immunoglobulin E (IgE) tests, in the evaluation of allergy.*
- *Don't perform food IgE testing without a history consistent with potential IgE-mediated food allergy.*

ICER encourages all stakeholders to suggest services (including treatments and mechanisms of care) that could be reduced, eliminated, or made more efficient in order to offset the costs of desensitization therapy. We have not received any additional suggestions for this report.

2. Summary of Coverage Policies and Clinical Guidelines

2.1 Coverage Policies

To understand the insurance landscape for therapies for peanut allergy treatment and prevention, we reviewed publicly-available coverage policies for immunotherapy and epinephrine from the Centers for Medicare and Medicaid Services (CMS), California Department of Health Care Services (DHCS), and from regional and national commercial insurers (Aetna, Anthem, Blue Shield of California [BSCA], Cigna, Health Net, Humana, Kaiser Permanente, and United HealthCare [UHC]). At the time the draft Evidence report was published, we were unable to survey policies pertaining to AR101 and Viaskin Peanut because the FDA had not issued a decision regarding their applications for approval.

We were unable to locate any coverage criteria for oral immunotherapy from DHCS as well as Cigna, HealthNet, Kaiser Permanente, and UHC. CMS as well as Aetna, BSCA, and Humana do not cover oral immunotherapy.²⁵⁻²⁸ Several patients and advocates suggested that oral immunotherapy is currently more likely to be paid for out-of-pocket by the patient or their family at specialized clinics that provide the treatment.

Each of the commercial payers included in our search covered and did not have utilization management policies for the use of generic epinephrine. While epinephrine is covered in all plans surveyed, patients are still subject to out-of-pocket costs, based on their benefit design. A 2017 study evaluating nearly 200 million commercially insured claims from 2007-2014, found that the percentage of patients paying more than \$100 and \$250, jumped from 3.9% to 18%, and 0.1% to 7.4% respectively over that time period.²⁹ Patients and advocates reflected sensitivity to growing out-of-pocket spending in interviews.

2.2 Clinical Guidelines

We reviewed guidelines on peanut allergy issued by major clinical societies. Although many of the organizations also provided recommendations on when and how peanut allergy testing should occur, we have only summarized the guidance that pertain to the prevention and treatment of peanut allergies. At the time this report was published, we were unable to locate any guideline statements that pertained to the use of AR101 or Viaskin Peanut.

American Academy of Allergy, Asthma and Immunology (AAAAI), 2011³⁰

AAAAI summarized the available evidence for the practice of allergen immunotherapy for patients with allergic diseases. The Joint Task Force concluded that clinical trials do not support the use of subcutaneous immunotherapy for food hypersensitivity and that the safety and efficacy of oral and sublingual immunotherapy for food hypersensitivity is currently investigational. They recommend that allergen immunotherapy be administered with trained staff and on-hand medical equipment for treating and recognizing anaphylaxis.

National Academies of Sciences, Engineering, and Medicine (NASEM), 2017³¹

The National Academies of Sciences, Engineering, and Medicine in 2017 created a consensus study to clarify the nature of peanut allergy, its causes, and its current management. For individuals diagnosed with peanut allergy, they recommend strict-peanut avoidance to prevent a reaction. In cases of anaphylaxis, they recommend treatment with epinephrine, and additional therapies, such as bronchodilator medications, antihistamines, corticosteroids, vasopressors, glucagon, atropine, supplemental oxygen, intravenous fluids, and patient positioning. Furthermore, in cases of anaphylaxis, they recommend observation in the medical setting until complete resolution of symptoms, education on avoidance and management, and referral for additional testing and management.

National Institute of Allergy and Infectious Diseases (NIAID)/American Academy of Allergy, Asthma and Immunology (AAAAI), 2010, 2017^{32,33}

The National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), with support from more than thirty professional organizations in 2010, convened an expert panel to summarize the available evidence for the diagnosis and management of food allergies.

The expert panel did not recommend using allergen immunotherapy to treat food allergies. To treat anaphylaxis, they recommended epinephrine, and allowed for repeated use every five to 15 minutes. After epinephrine-use, they recommended immediate transfer to an emergency facility for observation for four to six hours or longer and possible further treatment. Bronchodilators (albuterol), antihistamines (diphenhydramine), supplemental oxygen therapy, and intravenous fluids can also be considered.

In 2017, the NIAID with support from the American Academy of Allergy, Asthma & Immunology (AAAAI) and twenty-four other organizations, issued an addendum to these guidelines that was informed by the Learning Early about Peanut Allergy (LEAP) trial. For infants at risk for peanut allergy, they recommended early introduction of peanut-containing food at four to six months of age (assessed as moderate quality evidence using GRADE).

British Society for Allergy and Clinical Immunology (BSACI), 2017³⁴

The British Society for Allergy and Clinical Immunology (BSACI) in 2017 summarized the available evidence for the diagnosis and management of peanut and tree nut allergies. In their guidelines, they find that peanut oral immunotherapy can induce desensitization in peanut-allergic children. The BSACI considered the strength of this recommendation to be an “A” meaning that the evidence included a well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.

European Academy of Allergy and Clinical Immunology (EAACI), 2014³⁵

In 2014 the European Academy of Allergy and Clinical Immunology developed a comprehensive set of documents on food allergy and severe allergic reactions. Food allergen immunotherapy is not currently recommended. Adrenaline, also known as epinephrine, must be promptly administered intramuscularly into the mid-outer thigh for emergency management of anaphylaxis. Repeat doses should be administered at least five minutes apart. If the patient does not respond to two or more doses of intramuscular adrenaline, adrenaline may be administered as an infusion with appropriate cardiac monitoring.

American Academy of Allergy, Asthma and Immunology (AAAAI), 2012²⁴

In 2012, the AAAAI compiled the available evidence for the practice of oral food challenges in the PRACTALL consensus report. During immunotherapy, they recommend having immediate access to epinephrine, oxygen, antihistamines, beta-agonists, corticosteroids, and intravenous fluids.

In their report, they recommend processes for assessing and treating mild, moderate, and severe reactions during oral food challenges. Mild skin reactions can result in scratching continuously for two minutes or more and faint erythema, but do not necessarily require altering dosing, or resolution of trial. Moderate reactions require caution, with a judgment as to whether to proceed, delay, repeat, escalate, or stop dosing altogether. If symptoms persist or recur after three doses, they are considered moderate reactions. Moderate reactions include at least three of the following: hard continuous scratching; hives; sneezing; throat clearing, cough, or persistent throat tightness; nausea or abdominal pain that may include an itchy mouth or throat; frequent nausea or gastrointestinal pain; notable gastrointestinal distress; emesis or diarrhea; and feeling weak or dizzy.

Severe reactions have objective symptoms likely to indicate a true reaction and usually an indication to stop dosing. Severe reactions include: more than three hives or significant lip or face edema; generalized urticaria or angioedema; generalized erythema; continuous rubbing of the nose or eyes; long bursts of sneezing; audible wheezing; hoarseness that may include a frequent dry cough; multiple episodes of emesis or diarrhea; drop in blood pressure; a significant change in mental status; cardiovascular collapse and/or unconsciousness.

3. Comparative Clinical Effectiveness

3.1 Overview

We abstracted evidence from RCTs of individuals ages four to 17 years with peanut allergy comparing desensitization therapy to strict peanut avoidance. Age is an important effect modifier for the efficacy of desensitization therapy. Early trial results led to a focus on children ages four to 11 years in the Phase 3 trial of Viaskin Peanut and ages four to 17 in the Phase 3 trial of AR101. Our review focused on clinical benefits (reduction in allergic reactions, epinephrine use, ER visits, hospitalizations, and quality of life) as well as potential harms (systemic allergic reactions due to the therapies, serious adverse events, and adverse events leading to discontinuation of therapy).

3.2 Methods

Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on therapies for peanut allergy followed established best research methods.^{36,37} We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.³⁸ The PRISMA guidelines include a checklist of 27 items, which are described further in Appendix Table A1.

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and Emtree terms in EMBASE), as well as free-text terms that are presented in Appendix Tables A2 and A3.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, <https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework/grey-literature-policy/>). Where feasible and deemed necessary, we also accepted data submitted by manufacturers “in-

confidence,” in accordance with ICER’s published guidelines on acceptance and use of such data (<https://icer-review.org/use-of-in-confidence-data/>).

Study Selection

Subsequent to the literature search and removal of duplicate citations using both online and local software tools, study selection was accomplished through two levels of screening, at the abstract and full-text level. Two reviewers independently screened the titles and abstracts of all publications using DistillerSR (Evidence Partners, Ottawa, Canada) and resolved any issues of disagreement through consensus. No study was excluded at abstract level screening due to insufficient information. For example, an abstract that did not report an outcome of interest in the abstract would be accepted for further review in full text.

Citations accepted during abstract-level screening were retrieved in full text for review. Reasons for exclusion were categorized according to the PICOTS elements during full-text review.

Data Extraction and Quality Assessment

Data were extracted into evidence tables (Appendix Tables D1-D6).

Data extraction was performed in the following steps:

- 1) Two reviewers extracted information from the full articles.
- 2) Extracted data was reviewed for logic, and data were validated by a third investigator for additional quality assurance.

We used criteria employed by the US Preventive Services Task Force ([USPSTF] see Appendix D) to assess the quality of clinical trials, using the categories “good,” “fair,” or “poor.”³⁹

Assessment of Level of Certainty in Evidence

We used the ICER Evidence Rating Matrix to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus (see Appendix D).⁴⁰

Assessment of Publication Bias

Given the emerging nature of the evidence base for these newer treatments, we scanned the ClinicalTrials.gov website to identify studies completed more than two years ago. None were identified.

Data Synthesis and Statistical Analyses

The studies are summarized in the text and in evidence tables of the Evidence Report. This summary is key to understanding the evidence base pertaining to the topic. Evidence tables are presented in Appendix Tables D1-D6. Relevant data include those listed in the data extraction section. Important differences between the studies in terms of the study design, patient characteristics, interventions (including dosing and frequency), outcomes (including definitions and methods of assessments), and study quality are noted in the text of the report.

Given the heterogeneity of the patients included in the trials and the lack of a consistent primary outcome, we did not perform any meta-analyses or network meta-analyses.

3.3 Results

The results are organized within benefits by therapy, then harms by therapy.

Study Selection

Appendix Figure A1 summarizes the search results and study selection using a PRISMA flow diagram. In brief, we identified 635 potential references of which 363 met criteria for full text review. We excluded 357 of these references due to patient populations outside of our scope, interventions outside our scope and lack of relevant outcomes. This left two trials of AR101,^{12,41} three trials of Viaskin Peanut,^{13,42,43} two RCTs of other forms of OIT,^{44,45} and two observational studies of OIT.^{46,47} We also summarized a recent systematic review of randomized trials of OIT for peanut allergy.⁴⁸

Key Studies

There are two key studies – the Phase 3 randomized trials for each of the therapies that have submitted documentation to the FDA for approval. They are summarized in detail below.

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization (PALISADE) Trial¹²

The PALISADE trial randomized 551 participants four to 55 years of age with peanut allergy in a 3:1 ratio to AR101 or placebo (oat flour).¹² Patients were required to have an eliciting dose of 100 g or less on DBPCFC at study entry. Important exclusion criteria included severe or uncontrolled asthma, severe or life-threatening anaphylaxis in the past 60 days, and eosinophilic esophagitis. The primary outcome was the proportion of participants four to 17 years of age who could ingest 600 g or more of peanut protein without dose-limiting symptoms in a DBPCFC after approximately one-year follow-up. Note that the 600 mg dose is an exception from the PRACTALL OFC dose escalation protocol, which increases as follows: 3, 10, 30, 100, 300, 1000, and 3000 mg. Because

the primary outcome focuses on patients four to 17 years of age and the expected FDA decision will be for patients four to 17, the remainder of the results described here will be for that age group (n=496). For patients 18 to 55 years of age, please see Appendix Tables D1 to D11.

On day one, participants underwent a dose escalation phase from 0.5 mg to 6 mg followed by an increasing-dose phase during which the dose was increased every two weeks from 3 mg to 300 mg a day over approximately 24 weeks. Each dose escalation was done under medical supervision and the participant was observed for a minimum of 90 minutes. This was followed by a 24-week dose maintenance phase of 300 mg of peanut protein per day. The study encouraged participants to take their dose with a meal at roughly the same time each day (within a four-hour period), to refrain from activities that can increase allergic reactivity (exercise, hot showers, or baths) within three hours of taking the dose, and not to go to sleep within two hours of taking the dose.

In the group of participants ages four to 17 years old, 66% were ages four to 11 years, and 34% were 12 to 17 years. There were more males (57%) and the majority had a history of peanut anaphylaxis (72%), asthma (53%), and multiple food allergies (66%). The median maximum tolerated dose at study entry was 10 mg of peanut protein.

In the active treatment group, 67.2% (250/372) of participants were able to tolerate 600 mg of peanut protein compared with 4.0% (5/124) in the placebo group (between group difference 63.2%, 95% CI 53.0% to 73.3%, $p<0.001$). The between group difference was slightly greater among participants ages four to 11 years (66.1%) compared with those ages 12 to 17 years (58.3%). No data on participant quality of life were reported.

Adverse events were graded using the National Cancer Institute Common Toxicity Criteria. Adverse events were common in both the active treatment and placebo groups (98.7% and 95.2%, respectively). Serious adverse events were more common in the active treatment group (2.2% vs. 0.8%). Systemic allergic reactions were more common in the active treatment group (14.2% vs. 3.2%) as was the use of epinephrine outside of the DBPCFC (14.0% vs. 6.5%). In the AR101 group 67% of epinephrine doses were administered at home. Withdrawal due to adverse events was more common in the active treatment group (11.6% vs. 2.4%) as was the overall withdrawal rate from the study (21.0% vs. 7.3%). The most common adverse events were GI, such as abdominal pain (52% AR101 vs. 24%) and vomiting (51% AR101 vs. 24%). Adverse event rates during the maintenance phase, which may reflect rates during long term follow-up remained high. For example, abdominal pain (15% AR101 vs. 6%), and vomiting (16% AR101 vs. 12%) remained common and higher in the AR101 group. This was also true for systemic allergic reactions (8.7% AR101 vs. 1.7%) during the maintenance phase.

In summary, the PALISADE trial demonstrated that AR101 markedly increased the percentage of patients who could tolerate a 600 mg dose of peanut protein (cumulative dose 1043 mg) in a

DBPCFC (67.2% vs. 4.0%, $p<0.001$). However, there were significantly higher rates of gastrointestinal side effects, systemic allergic reactions, and epinephrine use in the AR101 group even during the maintenance phase. In addition, the treatment requires a substantial investment in time for patients (at least 12 office visits over the initial 24 weeks with in-office observation for at least 90 minutes) and continued consumption of AR101 to maintain desensitization.

Peanut EPIT Efficacy and Safety (PEPITES) Trial¹³

The PEPITES trial randomized 356 participants four to 11 years of age with peanut allergy in a 2:1 ratio to Viaskin Peanut 250 mcg patch or placebo patch.¹³ Patients were required to have an eliciting dose of 300 g or less on DBPCFC at study entry. Important exclusion criteria included uncontrolled asthma and a history of severe anaphylaxis. The primary outcome was the proportion of participants with an eliciting dose at least 300 mg of peanut protein (tolerated dose of 100 g) in a DBPCFC after approximately one-year follow-up for those participants with a baseline eliciting dose of 10 mg or less or an eliciting dose at least 1000 mg (tolerated dose 300 mg) for those participants with a baseline eliciting dose of 30 mg or more.

On day one, the patch was applied for three hours under medical supervision. The length of time that the patch was applied was increased to six hours during week one, 12 hours during week two, and 24 hours thereafter. The dose escalation did not require additional visits to the physician's office, but the time to get to 24 hours of patch application could be extended additional weeks if needed.

The participants had a median age of seven years, 61% were male, and many had a history of asthma (47%), and multiple food allergies (85%). The median maximum tolerated dose at study entry was 30 mg of peanut protein (eliciting dose of 100 mg).

In the active treatment group, 35.3% (84/238) of participants met the primary outcome compared with 13.6% (18/118) in the placebo group (between group difference 21.7%, 95% CI 12.4% to 29.8%, $p<0.001$). No data on participant quality of life were reported.

Adverse events were graded using the International Conference on Harmonization-Good Clinical Practice definition. Adverse events considered related to the patch were common in both the active treatment and placebo groups (59.7% and 34.7% respectively). Overall adverse events were not reported for individual AEs, making comparisons with the PALISADES trial challenging. Serious adverse events related to the patch were more common in the active treatment group (1.3% vs. 0%). Systemic allergic reactions related to the patch were more common in the active treatment group (3.8% vs. 1.7%), but there were no serious systemic reactions. Epinephrine use was also more common in the Viaskin Peanut group (9.2% vs. 3.4%). Withdrawal due to adverse events was more common in the active treatment group (1.7% vs. 0%) as was the overall withdrawal rate from

the study (10.5% vs. 9.3%). The most common adverse events were dermatologic such as itching (34.5% Viaskin vs. 11.9%) and erythema (28.2% Viaskin vs. 16.9%) at the patch administration site.

In summary, the PEPITES trial demonstrated that Viaskin Peanut modestly increased the percentage of patients who met the primary endpoint compared with a placebo patch in a DBPCFC (35.3% vs. 11.9%, $p < 0.001$). The patch was well tolerated with low rates of adverse events – mostly cutaneous and few serious, although there were more systemic allergic reactions and more epinephrine use in the Viaskin Peanut group.

Key Differences Between the PALISADE and PEPITES Trials

It is challenging to compare the results in the PALISADE and PEPITES trials because of differences in the inclusion criteria of the trials, differences in the implementation in the DBPCFC, and differences in the systems used to categorize adverse events. However, several important differences should be highlighted (Table 3.1). First, the PALISADE trial included older patients (ages 12 to 17 years) who are less likely to respond to desensitization therapy. The PALISADE trial also enrolled participants with a lower eliciting dose (≤ 100 mg rather than 300 mg). Finally, the primary outcome in the PALISADE trial required a tolerated dose of 600 mg or higher compared with 100 mg for the low-eliciting dose group in PEPITES or 300 mg for the high-eliciting dose in PEPITES. Thus, if the study design for the PALISADE trial was the same as that of the PEPITES trial, the between group difference for AR101 compared to placebo would likely have been greater than the 63.2% observed in the PALISADE trial. Conversely, if the study design for the PEPITES trial was the same as that of the PALISADE trial, the between group difference for Viaskin Peanut would likely have been less than the 21.7% observed in the PEPITES trial.

Table 3.1. Comparison of the Phase 3 PALISADE and PEPITES Trials

	AR101	Viaskin Peanut
Key Study	PALISADE	PEPITES
Ages	4 – 17 years	4 – 11 years
Peanut Sensitivity	ED ≤100 mg	ED ≤300 mg
Median Baseline ED	10 mg	30 mg
Primary Outcome in DBPCFC	Tolerate 600 mg peanut protein	ED 300 mg if baseline ED ≤10 mg ED 1000 mg if baseline ED ≥30 mg
Dose Escalation*	3 mg to 300 mg daily with increases every 2 weeks for 24 weeks	250 mcg patch worn for 3 hours day 1, 6 hours week 1; 12 hours week 2; and 24 hours thereafter.
Maintenance Dose	300 mg orally every day	250 mcg by patch every day
Clinic Visits	Every dose escalation for at least 90 minutes	Day 1 only
Met Primary Outcome, Active vs. Placebo	67.2% vs. 4.0%	35.3% vs. 13.6%
Overall Withdrawal Rate, Active vs. Placebo	21.0% vs. 7.3%	10.5% vs. 9.3%
Epinephrine use	14.0% vs. 6.5%	9.2% vs. 3.4%
Severe or serious AEs	5.6% vs. 1.6%	4.7% vs. 0.8%

DBPCFC: double-blind, placebo-controlled food challenge, ED: eliciting dose

*This dose escalation is the ideal if no complications, but may be slowed for adverse events and adherence issues.

However, the treatment burden for AR101 is much greater – requiring more than 12 office visits and restrictions on the timing of dose administration. Moreover, the adverse events associated with AR101 appear to be significantly greater than those of Viaskin Peanut, even during the maintenance dose phase of the trial. For some patients, the adverse event rates associated with daily AR101 may be higher than those they would experience by strict adherence to a peanut avoidance strategy. This may be why the proportion of patients who withdrew during the first year of therapy for AR101 (21.0%) was twice that for Viaskin Peanut (10.5%), though this is not a direct, randomized comparison (Table 3.1).

Quality of Individual Studies

The two randomized trials of AR101 and the three randomized trials of Viaskin Peanut were all of good quality/low risk of bias, though all of the trials were at risk for partial unblinding due to adverse events. For the other OIT trials, both randomized trials were of poor quality and the other two studies were uncontrolled case series.

Clinical Benefits

AR101

There are two published studies of AR101: the Phase 3 PALISADE trial¹² described above in the Key Studies section and a multicenter Phase 2 trial ARC001.⁴¹

The Phase 2 trial enrolled a slightly different population (55 participants ages four to 26 years of age) and used a different primary outcome from the Phase 3 trial (able to tolerate at least 300 mg rather than 600 mg of peanut protein during a DBPCFC).⁴¹ In addition, the exit DBPCFC for the primary outcome was performed after only two weeks on the target daily maintenance dose of 300 mg of peanut protein rather than the 24 weeks of maintenance dosing in the PALISADE trial. Thus, the outcomes are not directly comparable.

In the Phase 2 trial, 79% of patients randomized to AR101 were able to tolerate 300 mg of peanut protein and 62% were able to tolerate 600 mg of peanut protein compared with 19% and 0% of participants randomized to placebo (oat protein). In the Phase 3 PALISADE trial, 76.6% of patients randomized to AR101 were able to tolerate 300 mg of peanut protein and 67.2% were able to tolerate 600 mg of peanut protein compared with 8.1% and 4.00% of participants randomized to placebo.

Quality of life outcomes were not reported for either trial.

Viaskin Peanut

There are three published studies of Viaskin Peanut: the Phase 3 PEPITES trial¹³ and two additional Phase 2 trials.^{42,43} The PEPITES trial results are described in detail above in the Key Studies section.

The Phase 2 studies are both dose finding studies that randomized patients to 50 mcg patches, 100 mcg patches, 250 mcg patches, or identical placebo patches. They also included a wider range of ages (six to 55 years in one; four to 25 years in the other). The primary outcomes also differed. In one, the primary outcome was an increase of at least tenfold in the eliciting dose of peanut protein or reaching at least 1000 mg after one year of treatment. In the other, the primary outcome was passing a 5044 mg peanut protein OFC or at least a tenfold increase in the eliciting dose of peanut protein after one year of treatment. Thus, none of the outcomes are directly comparable with each other or with those used in the trials of AR101.

Focusing in on the population of interest, in children ages six to 11 years, 15/28 (53.6%) of those treated with the 250 mcg patch met the primary outcome compared with 6/31 (19.4%) of those treated with the placebo patch.⁴³ In children ages four to 11 in the other Phase 2 trial, 11/18 (61.1%) of those treated with the 250 mcg patch met the primary outcome compared with 1/18

(5.6%) of those treated with the placebo patch.⁴² In both Phase 2 trials, the benefits of the Viaskin Peanut patch were smaller in the older participants.

Quality of life outcomes were not reported in any of the three trials.

Other Oral Immunotherapy

There have been many studies of OIT for peanut allergy using different peanut preparations, different dose escalation strategies, different maintenance doses (125 mg to 5000 mg peanut protein per day), different primary outcomes and different target populations.^{44,49-55} Two RCTs of OIT met our inclusion criteria.^{38,39}

The STOP II trial randomized 99 participants ages seven to 16 years with peanut allergy documented on DBPCFC to peanut flour (n=49) or strict peanut avoidance (n=50) in an open label study. The dose of peanut protein was increased every two weeks under MD observation from 2.5 mg to 5, 12.5, 25, 50, 100, 200, 400, then 800 mg and maintained at 800 mg for a total of 26 weeks (including the dose escalation phase). The primary outcome was defined as no reaction during a DBPCFC at a cumulative dose of 1400 mg. The PRACTALL guidelines were not cited and it is unclear what doses were used to reach a cumulative dose of 1400 mg. Ten patients randomized to the active intervention were excluded from the primary analysis because they did not complete the DBPCFC; and four of the controls were excluded because three declined participation when not randomized to the active arm, and one developed Crohn's disease. The reported successful desensitization rate was 62% (24/39) in the active treatment group and 0% (0/46 in the control group). Because both the PEPITES and PALISADE trials used a strict intention to treat analysis and considered anyone who was randomized and did not complete the final DBPCFC as a treatment failure, the equivalent desensitization rate would be 49% (24/49). Quality of life was assessed using the Food Allergy Quality of Life Questionnaire – Parent Form, which is intended to be used for the parents of affected children ages zero to 12 years. Thus, it was reported for the subset of participants ages seven to 12 years. Scores on the questionnaire range from 0 to 6, with lower scores indicating better quality of life and a change of at least 0.5 points representing the minimum clinically important difference. The quality of life score on this scale improved significantly for both groups (-1.61 active group vs. 1-.41 control group). This study was considered poor quality because of the lack of blinding, differential loss to follow-up, and not following a strict intention to treat analysis.

Table 3.2. Comparison of the Outcomes of Other OIT Trials in Children

Trial	Desensitization	Immunotherapy	Control
Anagnostou 2014	Tolerate cumulative dose of 1400 mg in DBPCFC	62% reported, 49% ITT	0%
Reier-Nilsen 2017	Reach maintenance dose of 5000 mg	21%	NA

The TAKE-AWAY trial⁴⁵ randomized 77 children ages five to 15 years with peanut allergy confirmed reactive to 3 mg or more of peanut protein on DBPCFC to peanut flour (n=57) or observation only (n=20). The dose escalation phase had increasing doses of peanut flour every two weeks until about 65-100 mg when patients switched to eating roasted peanuts and continued to increase their dose to a goal of 5000 mg per day over 50 to 78 weeks. Participants were maintained on their maximally tolerated maintenance dose for 36 months. The primary outcome was the feasibility of reaching a maximum maintenance dose of 5000 mg per day. The primary outcome was reached by 21% of the participants (12/57). Of the remaining participants, 54.4% reached a lower maintenance dose and 24.5% discontinued therapy. The most common reason for not reaching 5000 mg was taste aversion (66.7%). Taste aversion was a challenge for 77.2% of the participants. Quality of life outcomes were not reported. This study was considered poor quality because of the lack of blinding, lack of follow-up of the control group, and not following a strict intention to treat analysis.

Expert reviewers suggested the inclusion of two retrospective case series of real-world OIT for peanut allergy that did not meet our original inclusion and exclusion criteria.^{46,47} Neither study included control patients. The first study is a retrospective cohort describing the experience of 352 patients three through 24 years of age treated at five centers that vary in the selection criteria for patients, the source of peanut protein, the dose escalation protocol, and the maintenance dose.⁴⁶ For example the target maintenance dose ranged from a low of 415 mg of peanut protein to a high of 8000 mg daily. Overall, 85% of patients reached their maintenance dose. During the dose escalation phase, 12% of patients required epinephrine, but only 6% required epinephrine during the maintenance phase. The rate of epinephrine administration was 0.7 per 1,000 doses or 0.26 per person-year of treatment during dose escalation and 0.086 per person-year during maintenance. Risk factors for epinephrine use included exercise and viral illnesses. No data on quality of life or reactions to accidental exposure were presented.

The second study summarizes additional data from 270 consecutive patients ages four to 19 treated at one of the five centers described in the first publication (Texas).⁴⁷ Eighty-one percent of patients reached the target dose of 3000 mg per day in a median of 25.8 weeks. Twenty-three percent of patients required epinephrine during dose escalation. Ten percent of patients required epinephrine during the maintenance phase (28/270), which translated into a rate of 0.10 per person-year during maintenance. During dose escalation, 13.7% of patients experience symptoms consistent with eosinophilic esophagitis. Again, no data on quality of life or reactions to accidental exposure were

presented. Among 105 patients treated for three or more years of maintenance therapy, 17% required epinephrine during the maintenance phase, but only one experienced symptoms consistent with eosinophilic esophagitis. Predictors of reaching the maintenance dose included younger age and lower peanut specific IgE level, but not prior reaction history.

Finally, Chu et al, recently published a systematic review and meta-analysis of randomized trials of OIT for peanut allergy.⁴⁸ The authors summarized the results of 12 randomized trials (n=1041, median age of participants 8.7 years). They reported that a higher proportion of patients receiving OIT were desensitized using a variety of definitions based on an OFC (OR 12.4 , 95% CI 6.8-22.6). However, there were no reported clinical benefits such as a reduction in allergic reactions due to accidental peanut exposure or a reduction in anaphylaxis. There were no significant differences in quality of life between the OIT and placebo groups.

Harms

AR101

The harms of the Phase 3 PALISADE trial are summarized in the Key Studies section above and are detailed in Appendix Tables D7 – D11. The most common adverse events were gastrointestinal (52% abdominal pain, nausea, vomiting), though most were mild to moderate and the incidence declined in the dose maintenance phase compared with the dose escalation phase, they remained high. Withdrawal rates overall (21.0%) and withdrawals due to adverse events (11.6%) were substantially higher than those observed in the placebo group. Systemic allergic reactions (14.2% vs. 3.2% placebo) and the use of epinephrine (14.0% vs. 6.5% placebo) were substantial and more common in the AR101 group.

The adverse events observed in the Phase 2 ARC001 trial were similar to those observed in the PALISADES trial.

Viaskin Peanut

The harms of the Phase 3 PEPITES trial are summarized in the Key Studies section above and are detailed in Appendix Tables D7 – D11. The most common adverse events were skin reactions at the site of the patches including itching (34.5%) and redness (28.2%). Most of these adverse events were mild to moderate. The specific adverse events reported in the PEPITES trial are those that the investigators thought could be related to the patch, which is different from most clinical trials. Grouped overall adverse event rates are reported in the supplementary online materials for the publication, but not the specific events, such as itching and redness. This can impact comparisons across trials. For instance, there were 27 adverse events leading to use of epinephrine in the Viaskin Peanut patch group, but only seven of these were considered related to the patch. Systemic allergic reactions related to the patch were uncommon (3.8%), though epinephrine use was more

frequent in the Viaskin Peanut group (9.2% vs. 3.4% placebo) as were serious or severe adverse events (4.7% vs. 0.8%). Withdrawal due to adverse events was uncommon in the active treatment group (1.7%), but more than 10% of patients randomized to Viaskin Peanut withdrew from the study during one year of follow-up.

As in the Phase 3 trial, the majority of the adverse events across the trials were skin reactions related to the patch site and they were mild. One of the trials included a two-year, open-label extension during which 57/171 patients (31.6%) discontinued therapy. Skin reactions continued to be the most common adverse event, but they decreased with time.

Other Oral Immunotherapy

The harms in the OIT studies mirrored those of AR101. The primary adverse events leading to discontinuation were gastrointestinal, including abdominal pain, nausea, and vomiting. In studies with very high maintenance doses, food aversion also played an important role. No new adverse events were identified. The systematic review reported increases in the risk for anaphylaxis (OR 3.1, 95% CI 1.8-5.6), epinephrine use (OR 2.2, 95% CI 1.3-3.8), and serious adverse events (OR 1.9, 95% CI 1.0-3.7). The authors of the systematic review concluded, “In patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitization.”

Controversies and Uncertainties

The primary benefit of desensitization to peanuts in patients with peanut allergy is likely to be the improvements in quality of life for both the patient and caregivers. However, the quality of life outcomes for the Phase 3 trials have not yet been published. It is challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.

Despite the PRACTALL consensus guidelines and the use of the DBPCFC to evaluate the effectiveness of immunotherapy, there is no consensus on what tolerated dose represents a clinically meaningful outcome for desensitization. A recent review of immunotherapy trials for peanut allergy described 18 different studies with large variations in the definitions used for their primary outcomes.⁵⁶ In the PALISADE trial for AR101, successful desensitization was defined by tolerance of a 600 mg dose of peanut protein, which is equivalent to an eliciting dose of at least 1000 mg. In the PEPITES trial for Viaskin Peanut, successful desensitization was defined at two different thresholds based on the baseline eliciting dose. For participants with a baseline eliciting dose ≤ 10 mg, successful desensitization was defined by a post-treatment eliciting dose of at least 300 mg, which is equivalent to a tolerated dose of at least 100 mg. For participants with a baseline eliciting dose >10 mg, successful desensitization was defined by a post-treatment eliciting dose of at least 1000 mg, which is equivalent to a tolerated dose of at least 300 mg. Modeling studies suggest


that achieving the endpoint in the PEPITES trial will prevent reactions to between 95% and 99.9% of accidental exposures.⁵⁷ However, neither AR101 nor Viaskin Peanut has long term follow-up data demonstrating this degree of a reduction in allergic reactions and the generalizability of the modeling predictions to the real world is questionable. One study estimated the median dose of peanut protein from an accidental exposure triggering symptoms to be 125 mg (interquartile range 34 mg to 177 mg).⁵⁸ The FDA working with specialty societies could provide guidance on a standard outcome for future studies of immunotherapy for food allergies in general, not just peanut allergies.

Furthermore, desensitization is a surrogate outcome for the clinically meaningful outcomes of a decrease in reactions to accidental exposure to peanuts, a reduction in use of epinephrine, and an improvement in quality of life. Studies have not yet demonstrated that desensitization to peanut protein improves these outcomes.

Finally, there is considerable uncertainty about the long-term outcomes for both AR101 and Viaskin Peanut. There is hope that a subset of patients may develop sustained unresponsiveness, but for now the assumption is that patients will remain on these therapies indefinitely. This raises issues about long-term adherence to therapy, particularly during adolescence and young adulthood. If patients are not continuously adherent, they may no longer be desensitized and could have a serious allergic reaction to the therapy itself. With oral immunotherapy, food aversion can be an issue in a subset of patients and eosinophilic esophagitis may become more common. The true incidence of eosinophilic esophagitis is unknown as most patients do not undergo endoscopy with biopsy. Other unexpected adverse events may occur during long follow up or with larger numbers of patients undergoing therapy.

3.4 Summary and Comment

Figure 3.1. ICER Evidence Rating Matrix



AR101

The substantial increase in patients treated with AR101 who are able to tolerate 600 mg of peanut protein during an OFC compared with those treated with placebo (67.2% vs. 4.0%) is balanced by a significant increase in gastrointestinal symptoms, systemic allergic reactions, and epinephrine use. The net health benefits of AR101 will be driven by changes in quality of life and reductions in reactions to accidental exposure to peanuts, neither of which has been demonstrated. Thus, there is only moderate certainty of a comparable, small, or substantial net health benefit and a small (but non-zero) likelihood of a negative net health benefit for AR101 compared with strict avoidance and rapid use of epinephrine (P/I, promising, but inconclusive). Given the need for frequent visits to doctors during the dose escalation phase and the frequent adverse events, it will be important to ensure that patients receive adequate informed consent and that their preferences are carefully elicited prior to initiating desensitization therapy with AR101.

Viaskin Peanut

The small increase in patients able to tolerate 100 to 300 mg of peanut protein compared with those treated with placebo (35.3% vs. 13.6%) is balanced by relatively few adverse events, but significant increases in systemic allergic reactions, and epinephrine use. As with AR101, the net health benefits are likely to be driven by changes in quality of life and reductions in reactions to accidental exposure to peanuts, neither of which has been demonstrated. Thus, there is only moderate certainty of a comparable, small, or substantial net health benefit and a small (but non-zero) likelihood of a negative net health benefit for Viaskin Peanut compared with strict avoidance and rapid use of epinephrine (P/I, promising, but inconclusive).

Oral Immunotherapy (OIT)

The studies of OIT, other than AR101, were relatively small, unblinded poor quality studies that used peanut protein not subject to Good Manufacturing Practices. There were differences in the dose escalation phase and in the maintenance dose as well as differences in the outcomes used to define desensitization. Finally, there were significant increases in adverse events, anaphylaxis, and epinephrine use associated with OIT and no clear net improvements in quality of life. Thus, the level of certainty in the evidence for OIT is low (I, insufficient).

Comparisons Among Therapies

There are no head to head trial between these agents, and the patient populations and primary outcomes differed sufficiently to preclude indirect comparisons. Based on surrogate outcomes (oral food challenges), AR101 appears more efficacious than Viaskin Peanut, but appears to have more adverse effects. However, the level of certainty in the comparative evidence is low (I, insufficient).

4. Long-Term Cost Effectiveness

4.1 Overview


The primary aim of this analysis was to estimate the lifetime cost-effectiveness of the two peanut allergy immunotherapies from a US health care sector perspective. The cost-effectiveness model included two comparisons: 1) AR101 oral immunotherapy plus avoidance compared to avoidance alone, and 2) Viaskin Peanut plus avoidance compared to avoidance alone. These two immunotherapies were modeled independently; i.e., all incremental values, including incremental cost-effectiveness ratios (ICERs), solely reflect comparisons to the placebo control from the respective trials. Participant survival, quality-adjusted survival, serious adverse events (anaphylaxis), and health care costs were summarized over a lifetime time horizon for each treatment option. All costs and outcomes were discounted at 3% per year. We modeled a variety of scenarios beyond the base case, including a modified societal perspective to capture the quality of life and economic impacts of peanut allergy on parents and/or caregivers. The analytic framework for this assessment is depicted in Figure 4.1 below.

4.2 Methods

Model Structure

We developed a *de novo* decision analytic model in Microsoft Excel (Version 1902) that includes five health states: 1) on treatment or placebo with peanut sensitivity, 2) untreated with peanut sensitivity, 3) peanut desensitized, 4) peanut tolerant, and 5) death (Figure 4.1). Health states and transitions among them are modeled using a Markov model approach, a type of economic model used to follow a hypothetical cohort of participants through time as they move among a set of mutually exclusive health states. The number of cycles that individuals reside in each state was used in conjunction with health state values (e.g., life-years, health-related quality-of-life, rate of allergic reactions, and cost) to estimate life expectancy, quality-adjusted life expectancy, and expected costs.⁵⁹

Figure 4.1. Model Framework



The first year was modeled with weekly cycles to more accurately capture immunotherapy costs, adverse events, and treatment discontinuation as reported by the clinical trials. All transitions beyond the first year were modeled with annual cycles. The two immunotherapies were evaluated in separate models that utilize the same model structure. For each treatment regimen, a hypothetical peanut-allergic population began the model in health state (1) on treatment or placebo with peanut sensitivity, where they remain until they:

- became desensitized to peanuts at the end of the first modeled year, then remained desensitized and on treatment;
- discontinued treatment within or at the end of year one and were not desensitized to peanuts at the end of year one;
- spontaneously became peanut tolerant (allergy resolves); or
- died from a severe allergic reaction or other causes (i.e., age-specific mortality).

At one year, all surviving individuals who had not discontinued immunotherapy and successfully passed the exit food challenge were transitioned to the peanut desensitized health state; the remainder who failed the exit food challenge were transitioned to the untreated with peanut sensitivity health state. During subsequent cycles some individuals transitioned to the peanut tolerant health state from both the untreated with peanut sensitivity and peanut desensitized states. Individuals were allowed to transition to death from any of the alive health states.

The first year of the model was created using the clinical trial data separately for AR101 and Viaskin Peanut. In that year, the placebo patients from each trial experienced the events and the food challenges that were recorded in the trials, with these events being used to estimate the avoidance alone patient's experience. After the first year, all placebo patients who were not successful in completing the exit food challenge moved to the untreated with peanut sensitivity health state.

Treatments

The list of modeled interventions was developed with input from patient organizations, clinicians, manufacturers, and payers. The full list of interventions considered in the model was:

- AR101 oral immunotherapy plus avoidance versus avoidance alone, based on the PALISADE trial¹²
- Viaskin Peanut plus avoidance versus avoidance alone, based on the PEPITES trial¹³

Target Population

The population of focus was children between the ages of four to 17 years with peanut allergy. For the AR101 comparison, the modeled population represented the PALISADE trial's prespecified primary analysis population, comprised of children age four to 17 years who had a clinical history of peanut allergy.¹² The primary analysis in the Viaskin Peanut Phase 3 trial was for participants age four to 11 years.¹³ We lacked direct estimates of the mean ages in the trials; therefore, due to the similarities in age ranges, we assumed a starting age of seven years in both models for all comparators. A scenario analysis of starting ages from one to 25 years can be found in Appendix E Table E4.

Table 4.1. Clinical Trial Population Characteristics^{12,13}

Participant Population	Median Maximum Peanut Protein Dose	Median Peanut-Specific IgE	Multiple Food Allergies
AR101 ¹²	10 mg (tolerated dose)*	69 kUA/liter	65.9%
Placebo ¹²	10 mg (tolerated dose)*	75 kUA/liter	64.5%
Viaskin Peanut ¹³	100 mg (eliciting dose)†	78 kUA/liter	86.1%
Placebo ¹³	100 mg (eliciting dose)†	101 kUA/liter	84.7%

*Maximum peanut protein ingested in a single dose without dose-limiting symptoms.

†Maximum peanut protein dose at which a patient exhibited objective signs or symptoms of an immediate hypersensitivity reaction.

Key Model Characteristics and Assumptions

The first modeled year reproduced trial-reported outcomes. Model cycle length was one week in the first year (52 cycles in year one) to capture dose escalation-related costs and adverse events, as well as immunotherapy discontinuation. Subsequent model cycle lengths (year 2+) were one year.

Survival was weighted by health state utilities to model quality of life. The model included separate utilities for participants: 1) with peanut sensitivity, 2) peanut desensitized, and 3) peanut tolerant. Additionally, disutility decrements were applied based on rates of severe treatment-emergent side effects and the rate of epinephrine utilization.

The model included all treatment costs associated with each individual immunotherapy regimen, including drug acquisition costs, clinical visit costs, and food challenge costs. The model also included adverse event costs for events that occurred in at least 5% of participants in at least one of the included regimens.

Other key model assumptions are listed in Table 4.2, along with the rationale for each.

Table 4.2. Key Model Assumptions

Assumption	Rationale
Individuals who successfully complete AR101 or Viaskin Peanut regimens and pass the exit food challenge at one year are assumed to remain on maintenance immunotherapy for the remainder of the modeled time horizon.	Real-world treatment and adherence rates beyond the trials' follow-up periods are currently unknown. We also include a scenario in which individuals discontinue immunotherapy after the first year, no longer incurring treatment costs but maintaining desensitization based on trial-reported rates.
Avoidance alone (placebo arm) participants who pass the exit food challenge at one year are assumed to have the same health state utility and risk of future allergic reactions in years 2+ as desensitized participants who received and continue administration of immunotherapy.	Although it is plausible that desensitized participants who received immunotherapy are different from desensitized participants who did not, we are unaware of sufficient long-term data to make this distinction in the model.
Epinephrine use will be based on trial-reported usage rates, independent of modeled adverse events.	There is a lack of epinephrine usage data stratified by type of adverse event.
Participant behavior, e.g., increased risk tolerance for or aversion to peanut exposure, does not change based on modeled health state.	Participants are expected to continue avoidance of peanut exposure and maintain access to epinephrine regardless of desensitization.

Model Inputs

Clinical Inputs

Clinical Trial Evidence

In the AR101 comparison, the transition from the treatment plus avoidance with peanut sensitivity health state to the peanut desensitized health state at the end of year one was modeled using the primary efficacy end point of the PALISADE trial, with data from the placebo arm used for the transition from the avoidance alone with peanut sensitivity health state to the peanut desensitized health state. In the trial, 250 of 372 participants (67.2%) who received AR101 were able to ingest a dose of 600 mg or more of peanut protein without dose-limiting symptoms at the exit food challenge, compared to five of 124 participants (4.0%) who received placebo. The between-group difference was 63.2% (95% CI, 53.0% to 73.3%; $P < 0.001$) (Table 4.3). In the model, the between-group difference was added to the proportion of desensitized placebo participants at one year to derive the proportion of desensitized AR101 participants at one year. We used the secondary end points in a scenario analysis, including tolerating the 300 mg dose and the 1000 mg dose during the exit food challenge; the response rates in the treatment group were 76.6% and 50.3%, respectively, as compared with 8.1% and 2.4%, respectively, for the placebo control.

Table 4.3. Results of the PALISADE Trial¹² (AR101)

Dose of Peanut Protein Ingested without Dose-Limiting Effects	Placebo Proportion Tolerating Single Dose	AR101 Between-Group Difference vs. Placebo
600 mg (Base Case)	4.0% (95% CI: 0.6% - 7.5%)	63.2% (95% CI: 53.0% - 73.3%)
300 mg	8.1% (95% CI: 3.3% - 12.9%)	68.5% (95% CI: 62.1% - 74.9%)
1000 mg	2.4% (95% CI: 0.0% - 5.1%)	47.9% (95% CI: 42.1% - 53.7%)

CI: confidence interval

The primary efficacy end point of the Viaskin Peanut PEPITES trial was used in the Viaskin Peanut comparison to model the transition from the treatment plus avoidance with peanut sensitivity health state to the peanut desensitized health state at the end of year one, and data from the placebo arm for transition from the avoidance alone with peanut sensitivity health state to the peanut desensitized health state. Of the 238 Viaskin Peanut recipients in the PEPITES trial, 35.3% were treatment responders after 12 months of therapy, compared to 13.6% who received placebo. The between-group risk difference was 21.7% (95% CI: 12.4% - 29.8%) (Table 4.4). As in the AR101 comparison, the between-group difference was added to the proportion of desensitized placebo participants at one year to derive the proportion of desensitized Viaskin Peanut participants at one year.

Table 4.4. Results of the PEPITES Trial¹³

	Placebo Treatment Response at Month 12	Viaskin Peanut Between-Group Difference vs. Placebo
Eliciting Dose of 1000+ mg or 10x Initial Eliciting Dose	13.6% (95% CI: 7.4% - 19.8%)	21.7% (95% CI: 12.4% - 29.8%)

CI: confidence interval

Survival

Participant survival was modeled using United States Centers for Disease Control (CDC) life tables⁹ for age-based background mortality, and we also applied a small (5.77×10^{-7}) annual probability of death from an allergic reaction to the peanut sensitivity and desensitized health states (but not the peanut tolerant health state) in years 2+ of the model; both estimates were converted to and applied as a weekly probability for year one.¹⁰

Spontaneous Peanut Tolerance

The rate of spontaneous tolerance to peanuts (resolution of the allergy) was applied to both the untreated with peanut sensitivity and peanut desensitized health states in years 2+. The same transition probability of 1.1% per year was applied to each state.¹¹

Discontinuation of Immunotherapy

The rate of immunotherapy discontinuation in the first year reflects the trial-reported number of participants who did not complete the trial. In the case of AR101 versus avoidance alone, we utilized available discontinuation data stratified by dose escalation phase from the PALISADE trial.¹² For Viaskin Peanut, discontinuation rates were based on the reported discontinuation rates at year one in the PEPITES trial.¹³ The rates of discontinuation for each time period were converted to weekly transition probabilities (Tables 4.5 and 4.6) that were used to transition participants from the treatment or avoidance alone with peanut sensitivity health state to the untreated with peanut sensitivity health state during modeled year one.

Table 4.5. Derivation of Trial Discontinuation Transition Probabilities (AR101 vs. Avoidance Alone)¹²

	Discontinuations/ Total Participants	Weeks in Phase	Calculated Weekly Rate	Conversion to Weekly Transition Probability†
AR101 Initial Phase to Updosing Phase	6/372	0.14 (1 day)	--	--
AR101 Updosing Phase to Maintenance Phase	56/366	20	0.00903	0.00899
AR101 Maintenance Phase to 1-Year Exit Food Challenge	18/310	32*	0.00193	0.00192
Placebo Initial Phase to Updosing Phase	1/124	0.14 (1 day)	--	--
Placebo Updosing Phase to Maintenance Phase	5/123	20	0.00212	0.00212
Placebo Maintenance Phase to 1-Year Exit Food Challenge	4/118	32	0.00110	0.00110

*The stated maintenance duration in the PALISADE trial is 24 weeks. However, the primary outcome was measured at approximately one year. We have based treatment discontinuation rates on the exit food challenge occurring at exactly one year, not at 44 weeks as could be implied.

†Some weekly transition probabilities appear equal to their rates due to rounding.

Table 4.6. Derivation of Trial Discontinuation Transition Probabilities (Viaskin Peanut vs. Avoidance Alone)¹³

	Discontinuations/ Total Participants	Weeks in Phase	Calculated Weekly Rate	Conversion to Weekly Transition Probability*
Viaskin Peanut at 1 Year	25/238	52	0.00225	0.00225
Placebo at 1 Year	11/118	52	0.00197	0.00197

*Some weekly transition probabilities appear equal to their rates due to rounding.


Immunotherapy Utilization

The estimation of drug utilization was derived from dosing schedules reported in the trials (Table 4.7 and Figure 4.2). Each regimen was assumed to be administered over a lifetime for participants who remain in the peanut desensitized health state post-trial, though a scenario analysis also evaluated continued treatment discontinuation in years 2+. Drug unit costs were applied to the utilization estimates to calculate total estimated treatment costs per model cycle. AR101's dose escalation was modeled based on Table 4.7 whereas Viaskin Peanut will use a 250- μ g dose throughout treatment.

Table 4.7. Immunotherapy Regimen Recommended Dosage

	AR101 ¹²	Viaskin Peanut ¹³
Manufacturer	Aimmune Therapeutics	DBV Technologies
Route of Administration	Oral	Epicutaneous
Regimen	1 day supervised initial escalation phase Increasing-dose phase, dose increased gradually every 2 weeks, up to 300 mg daily Ongoing maintenance of 300 mg daily	250- μ g patch administered daily

Figure 4.2. Modeled Dosing of AR101 and Viaskin Peanut



EFC: exit food challenge

Health State Utilities

Health state utilities were derived from publicly available literature and applied to the four alive disease states. The model base case used the same health state utility estimates across the two treatments evaluated in the model. The preference-weighted health-related quality of life literature in food allergy is extremely limited. While many manuscripts report changes in quality of life using various instruments, those instruments lack proper modeling studies to cross-walk them to preference weights that can be used to estimate QALYs.⁶⁰⁻⁶² We identified only one study across the food allergy literature that included a preference-weighted measure. The age-specific estimates, from Protudjer et al.,⁶³ compared a sample of children in Sweden with food allergies to a convenience sample of non-food allergic children aged zero to 17 years (stratified into two groups: children age zero to 11 years and adolescents age 12-17 years). The estimates of utility were derived using parent-reported (for children) and adolescent-reported EuroQol-5-Dimension (EQ-5D) responses.

Participants in peanut sensitivity health states received the utility value of food allergy participants, and peanut tolerant participants received the non-food allergic utility value from Protudjer et al. (Table 4.8). We also assumed that participants in the peanut desensitized health state had an improvement in utility that was 60% of the difference between utilities for the untreated with peanut sensitivity and peanut tolerant health states. This is a conservative assumption based on the available data and with the expectation that while desensitization reduces risk, there is still an underlying potential risk of reaction to exposure and the need to avoid exposure to peanuts and to carry epinephrine.⁸ We also noted that the utility values for ages 12+ were higher than those for the same health state for children age 0-11, which is difficult to reconcile. However, the differences between the health states within each age group are approximately equal. Thus, for the purpose of the model, this difference in absolute utility values between the age groups does not result in differences in incremental QALYs. Using the 0-11-year-old utility values for the entire model time horizon or switching values at age 12 results in the same incremental difference in QALYs between the two treatments.

The assumptions for the utility values were explored in the one-way sensitivity analysis using broad ranges for all three utility input values. Uncertainty in the utility values, where overlap occurs between the bounds and the next health state, were programmatically handled in the probabilistic sensitivity analysis. Forcing health states assumed to be ordinal to each other was accomplished by selecting the larger of either a) the maximum drawn from the health state's utility distribution, or b) the value drawn for the next worse health state.

Disutility estimates associated with serious treatment-emergent AEs are shown in Table 4.11. We also included an assumed disutility of 0.1 for a duration of one day for each epinephrine injection.

Table 4.8. Quality of Life (Utility) Inputs

Health State	Utility Value Estimate	Lower Bound	Upper Bound
Children (Age 0-11) Treatment or Avoidance Alone with Peanut Sensitivity ⁶³	0.840	0.819	0.861
Children (Age 0-11) Treatment or Avoidance Alone with Peanut Desensitization*	0.900	0.878	0.923
Children (Age 0-11) Peanut Tolerant ⁶³	0.940	0.917	0.964
Adolescents/Adults (Age 12+) Treatment or Avoidance Alone with Peanut Sensitivity ⁶³	0.910	0.887	0.933
Adolescents/Adults (Age 12+) Treatment or Avoidance Alone with Peanut Desensitization*	0.964	0.940	0.988
Adolescents/Adults (Age 12+) Peanut Tolerant ⁶³	1.0	0.975	1.0

*Assumption that participants in the peanut desensitized health state received the average of the utilities for the untreated with peanut sensitivity and peanut tolerant health states.

Economic Inputs

Immunotherapy Cost Inputs

The costs of immunotherapy with AR101 and Viaskin Peanut are currently unknown as they have not been made commercially available. However, analyst estimates have recently forecasted an expected cost for AR101 of \$5,000 to \$10,000 for the first six months of use, and \$300 to \$400 per month after. Analysts also predict that Viaskin Peanut will cost more than \$6,000 for a year's supply.¹⁴ Based on these estimates, we assumed AR101 placeholder costs of \$350 per month (\$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter).¹⁴ For Viaskin Peanut, we assumed a placeholder cost of \$6,500 per year.¹⁴ We also present the model-calculated, value-based prices necessary to meet the willingness-to-pay thresholds of \$50,000, \$100,000, and \$150,000 per QALY for each of the two comparisons.

Health Care Resource Utilization Inputs

Health care resource utilization was modeled based on available data from the trials and published sources. Health care resource use included the maintenance of an on-hand prescription for an epinephrine auto-injector (replaced upon use) and the administration of epinephrine for an allergic reaction (using a probability of epinephrine administration per cycle, Table 4.9). In non-desensitized participants, we assumed a rate of accidental peanut exposure of 11.7% per year, with

52% of those exposures resulting in a moderate-to-severe reaction requiring use of a single epinephrine pen, a 0.18% per year risk of hospitalization from a severe allergic reaction, and a 20.4% per year likelihood of outpatient visit per year with an allergic reaction.¹¹ We assumed a 95% risk reduction in moderate-to-severe reactions (and thus epinephrine use) in participants who were desensitized.⁶⁴ In scenario analyses, we present a range of decreased risks of moderate-to-severe reaction in the treatment with desensitization health state, as well as a modeled increased risk of accidental exposure in the treatment with desensitization health state to explore increased risk tolerance.

Table 4.9. Epinephrine Utilization

	Count of Epinephrine Uses	Person-Years of Trial Exposure	Annual Rate	Conversion to Weekly Probability	Administrations: 1 2 3
AR101 Year 1 ¹²	82	307.0	0.267	0.0051	92.7% 6.1% 1.2%
Placebo Year 1 ¹²	9	108.8	0.083	0.0016	100% 0% 0%
Viaskin Peanut Year 1 ¹³	27	235.8	0.115	0.0022	100% 0% 0%
Placebo Year 1 ¹³	5	115.2	0.043	0.0008	100% 0% 0%

The cost of the epinephrine auto-injector was taken from Redbook/IBM Micromedex.⁶⁵ Unit costs for medical services utilized estimates from the peer-reviewed literature and the Centers for Medicare and Medicaid Services fee schedules.^{66,65,62,60}

Table 4.10. Other Healthcare Resource Utilization and Costs

Healthcare Costs		Cost
Annual Physician Visit ¹¹		\$98
Annual Immunotherapy Services ¹¹		\$146
Allergic Reaction Events & Costs (Years 2+)	Probability	Cost
Annual Accidental Peanut Exposure ¹¹	11.7%	--
↳ Moderate to Severe Reaction (Epinephrine Use) ¹¹	52.0%	--
↳ Hospitalization after Severe Reaction ¹¹	0.18%	\$5,360*
↳ Emergency Department Visit ⁶⁷	2.7%	\$661
↳ Ambulance Transport ⁶⁷	0.50%	\$561
↳ Outpatient Treatment ⁶⁷	20.4%	\$231
Epinephrine Pen Replacement (2-Pack) ⁶⁵	--	\$300

*Assuming that the cost of hospitalization after a severe AE is the average cost for anaphylactic reaction, systemic allergic reaction, and asthma exacerbation (see Table 4.11).

Although trial participants who completed the trials underwent an exit food challenge, we did not model this cost since it is unlikely that the exit food challenge will be employed in real-world clinical practice for every treated patient.

Adverse Events

For each of the two comparisons, the model included all reported treatment-related serious AEs that occurred in >5% of participants in at least one of the comparators. Each serious AE had an associated cost that was applied for each occurrence of the event. Costs of serious AEs were based on resource utilization associated with appropriate treatments as reported in previous analyses, and unit prices from the Centers for Medicare and Medicaid Services (CMS) Final Rule and Correction Notice Tables for the fiscal year 2019.⁶⁶

The PALISADE trial reported a detailed list of AEs stratified by dose escalation phase (Table 4.11). For the AR101 comparison, we assessed the full cost estimates of each AE in the first model cycle of each dose escalation phase (initial: model cycle 0; increasing: model cycle 1; maintenance: model cycle 21). The PEPITES trial did not report any severe anaphylactic reactions or asthma exacerbation, but did report that no systemic allergic reactions were severe.¹³

Table 4.11. Modeled Severe Adverse Events

	CMS Diagnosis-Related Group	Serious AE Cost ⁶⁶	Serious AE Disutility ⁶⁸	AR101 ¹²	Avoidance Alone ¹²	Viaskin Peanut ¹³	Avoidance Alone ¹³
Anaphylactic Reaction	DRG 915: ALLERGIC REACTIONS WITH MCC	\$9,332.46	0.311 for 3 days	0.3%	0%	0%	NR
Systemic Allergic Reaction	DRG 916: ALLERGIC REACTIONS WITHOUT MCC	\$3,535.64	0.311 for 3 days	0.5%	0%	0%	0%
Asthma Exacerbation	DRG 203: BRONCHITIS & ASTHMA WITHOUT CC/MCC	\$3,879.02	0.311 for 3 days	0.5%	0%	0%	NR

CC: complications and comorbidities, DRG: Diagnosis Related Group, MCC: major complications and comorbidities, NR: not reported

Model Analysis

The model estimated the average amount of time each participant spent desensitized to peanut exposure, as well as the time that participants remained sensitive to peanut exposure and time tolerant to peanut exposure. Time spent in each health state was summed to provide estimates of life expectancy and quality-adjusted life expectancy. In addition to presenting undiscounted results, long-term estimates of costs, QALYs, and life-years were discounted at 3% per year. We calculated the ICERs for each intervention versus avoidance alone as the incremental cost per quality-adjusted life year and also incremental cost per serious adverse event (anaphylaxis) avoided.

Societal Perspective Analysis

Peanut allergy results in significant medical, out-of-pocket, and opportunity costs to payers, parents, and employers. In a societal perspective analysis, we explored the impact due to caregiver co-payments and deductibles, special diets, and childcare costs related to peanut allergy, as well as annual opportunity costs due to lower caregiver work productivity. These costs were derived from a recent economic and burden of disease study (Table 4.12).⁶⁹

We also performed a modified societal analysis in which we applied utility values for parents/caregivers of children with peanut allergy for each health state. As with patient utilities, preference-weighted values for parents/caregivers of peanut sensitive children are absent in the literature. Previous studies report changes in parent/caregiver quality of life using various instruments, but lack proper modeling studies to cross-walk them to preference weights that can be used to estimate QALYs.^{62,70-72} Therefore, we derived placeholder parent/caregiver utilities by 1)

assigning the mean EQ-5D index score for 30-39-year-olds from a well-known catalogue of community-based preference scores⁷³ for the caregiver of a child in the peanut tolerant health state (utility = 0.901), 2) subtracting a range of assumed disutilities (disutility range: 0.01 to 0.05) to derive the utility for the caregiver of a child in the peanut sensitive health state, and 3) as with patient utilities, assuming a utility improvement of 60% of the difference between 1) and 2) to derive the desensitized health state.

Table 4.12. Annual Costs for Societal Perspective Analysis

Societal Cost	Cost Estimate
Annual Out-of-Pocket Costs ⁶⁹	\$931
Annual Productivity Loss ⁶⁹	\$2,399
Total Annual Cost	\$3,330

Sensitivity Analyses

We conducted one-way sensitivity analyses to identify the impact of parameter uncertainty and key drivers of model outcomes. Probabilistic sensitivity analyses were also performed by jointly varying all model parameters over 5,000 simulations, then calculating 95% credible range estimates for each model outcome based on the results. We also performed threshold analyses for drug costs to estimate the price for each immunotherapy that would achieve specific willingness-to-pay thresholds (from \$50,000 to \$150,000 per QALY).

Scenario Analyses

Multiple scenario analyses were conducted to evaluate the impact of key model choices and assumptions on the robustness of the results and conclusions, including the following:

- Time horizon
- Patient age (range: one to 25)
- Post-year-one discontinuation and impact on desensitization (repeating the discontinuation rates from year one through the remaining time horizon)
- PALISADE secondary outcomes (for 300 mg, 1000 mg)
- No post-year-one spontaneous peanut tolerance
- Increased risk of accidental exposure in the treatment with desensitization health state to explore the relationship between value and the possibility of increased risk tolerance
- Range of 50% increase/decrease in rate of epinephrine use in years 2+
- Modified societal perspective: Caregiver utility added to the societal perspective

Model Validation

We used several approaches to validate the model. First, we provided preliminary methods and results to manufacturers, patient groups, and clinical experts. Based on feedback from these groups, we refined data inputs used in the model. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations using internal reviewers. Finally, we compared results to other cost-effectiveness models in this therapy area.

4.3 Results

Base-Case Results

Immunotherapy with AR101 resulted in increased QALYs due to the utility benefit of more patients having peanut desensitization, with 0.75 incremental QALYs versus avoidance alone (Table 4.13). We did not model a difference in mortality among comparators, therefore both AR101 and avoidance alone resulted in 28.69 life years gained and there was no gain in overall survival for AR101. Using the available placeholder price, the total lifetime cost was \$72,000 for AR101 versus \$6,000 for avoidance alone, and the incremental cost-effectiveness ratio was \$88,000.

Table 4.13. Discounted Base-Case Results: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$72,000	27.19	28.69	\$88,000
Avoidance Alone	\$0	\$6,000	26.44	28.69	
Incremental	\$65,000	\$66,000	0.75	0.00	

Immunotherapy with Viaskin Peanut resulted in increased QALYs due to the utility benefit of increased peanut desensitization, with 0.26 incremental QALYs versus avoidance alone (Table 4.14). As noted above, there was no difference in overall survival, therefore both Viaskin Peanut and avoidance alone resulted in 28.69 life years gained. Using the available placeholder price, the total cost was \$62,000 for Viaskin Peanut versus \$6,000 for avoidance alone, and the incremental cost-effectiveness ratio was \$216,000.


Table 4.14. Discounted Base-Case Results: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$62,000	26.81	28.69	\$216,000
Avoidance Alone	\$0	\$6,000	26.55	28.69	
Incremental	\$56,000	\$56,000	0.26	0.00	

Sensitivity Analysis Results

We performed one-way sensitivity analysis to evaluate the impact of single parameter uncertainty on the incremental cost-effectiveness ratios for immunotherapy versus avoidance alone (Figure 4.3). For the comparison of AR101 versus avoidance alone, the parameters with the greatest impacts on the ICER were utilities associated with peanut sensitivity and peanut desensitization, the cost of immunotherapy, and results of the exit food challenge. For the comparison of Viaskin Peanut versus avoidance alone, the parameters with the greatest impacts on the ICER were very similar to those driving the AR101 comparison. We performed probabilistic sensitivity analyses to evaluate the impacts of joint parameter uncertainty over 5,000 model simulations; detailed results of the probabilistic sensitivity analysis can be found in the Appendix, Tables E4 and E5.

Figure 4.3. One-Way Sensitivity Analyses for Immunotherapy versus Avoidance Alone Using Placeholder Prices



Scenario Analyses Results

Time Horizon

The incremental costs and outcomes for AR101 were sensitive to the model time horizon with both growing in a logarithmic form, stabilizing at between a 50 and 70-year time horizon. In the Viaskin Peanut analysis, the time horizon length was less impactful on the model results than the above analysis. See Tables E2 and E3 in the Appendix for results of the time horizon scenario analysis.

Extending Discontinuation Beyond One Year

The base case above includes only the discontinuation rates seen in the trials during year 1. This scenario replicates those rates beyond one year, by assuming that same discontinuation rate each subsequent year. In these scenarios, the treatment discontinuation rates observed in the clinical trials were repeated annually to simulate treatment discontinuation, with no change in the baseline assumption of maintenance of treatment effect. Thus, the QALYs estimated for both AR101 and Viaskin Peanut are the same in their respective scenarios as in the base case. However, the immunotherapy treatment costs are lower than the base case due to the continuous rate of treatment discontinuation.

Table 4.15. Post-Year-One Treatment Discontinuation Scenario: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$61,000	\$69,000	27.19	28.69	\$83,000
Avoidance Alone	\$0	\$6,000	26.44	28.69	
Incremental	\$61,000	\$62,000	0.75	0.00	

Table 4.16. Post-Year-One Treatment Discontinuation Scenario: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$51,000	\$57,000	26.81	28.69	\$196,000
Avoidance Alone	\$0	\$6,000	26.55	28.69	
Incremental	\$51,000	\$51,000	0.26	0.00	

Post-Year-One Spontaneous Tolerance Turned Off

These scenarios evaluated the impact of the assumption that 1.1% of people per year experience total resolution of their peanut allergy spontaneously in both the immunotherapy treated and avoidance alone groups. Assuming no spontaneous resolution, the incremental differences in QALYs were slightly larger than the base-case estimates, with less improvement in the avoidance alone groups. Immunotherapy costs were estimated to be higher because more patients continued on treatment rather than being transitioned to the tolerant (and untreated) health state.

Table 4.17. Spontaneous Tolerance Scenario: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$82,000	\$91,000	26.87	28.69	\$86,000
Avoidance Alone	\$0	\$8,000	25.91	28.69	
Incremental	\$82,000	\$83,000	0.96	0.00	

Table 4.18. Spontaneous Tolerance Scenario: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$70,000	\$77,000	26.38	28.69	\$212,000
Avoidance Alone	\$0	\$8,000	26.05	28.69	
Incremental	\$70,000	\$70,000	0.33	0.00	

Increase/Decreased Risk of Accidental Exposure in the Treatment with Desensitization Health State

We modeled a range of relative differences in the probability of accidental exposure, from -100% to 100%. However, the impact of risky behavior, in either direction, was minimal given the already low probability of moderate-severe adverse events from exposures due to the 95% risk reduction conferred by peanut desensitization.⁶⁴ We also note that as seen in the one-way sensitivity analyses, varying the probability of annual accidental peanut exposure had very little impact on model results.

Societal Perspective

For this analysis, we included the annual societal costs listed in Table 4.12. The addition of societal costs notably decreased the incremental cost-effectiveness ratios at each value-based price anchor point, as seen in Tables 4.19 and 4.20.

Table 4.19. Societal Perspective: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$99,000	27.19	28.69	\$27,000
Avoidance Alone	\$0	\$79,000	26.43	28.69	
Incremental	\$65,000	\$20,000	0.75	0.00	

Table 4.20. Societal Perspective: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$112,000	26.81	28.69	\$155,000
Avoidance Alone	\$0	\$72,000	26.55	28.69	
Incremental	\$56,000	\$40,000	0.26	0.00	

Modified Societal Perspective

For this analysis, we included parental/caregiver utilities in addition to the annual societal costs listed in Table 4.12. The derivation of utilities is described above. Increases in the disutility associated with the peanut sensitive health state led to increased incremental QALYs for both immunotherapies, which led to decreased incremental cost-effectiveness ratios.

Figure 4.4 Modified Societal Perspective: AR101 versus Avoidance Alone Using Placeholder Price





Figure 4.5 Modified Societal Perspective: Viaskin Peanut versus Avoidance Alone Using Placeholder Price



Threshold Analysis Results

The annual cost at which the immunotherapies would reach cost-effectiveness thresholds ranging from \$50,000 to \$150,000 per QALY gained are presented below.

Table 4.21. Threshold Analysis Results

	Annual Cost to Achieve \$50,000 per QALY	Annual Cost to Achieve \$100,000 per QALY	Annual Cost to Achieve \$150,000 per QALY
AR101	\$2,369	\$4,808	\$7,248
Viaskin Peanut	\$1,508	\$3,010	\$4,513

Model Validation

Model validation followed standard practices in the field. We tested all mathematical functions in the model to ensure they were consistent with the report (and supplemental Appendix materials). We also conducted sensitivity analyses with null input values to ensure the model was producing findings consistent with expectations. Further, independent modelers tested the mathematical functions in the model as well as the specific inputs and corresponding outputs.

Model validation was also conducted in terms of comparisons to other model findings. We searched the literature to identify models that were similar to our analysis, with comparable populations, settings, perspective, and treatments.

Prior Economic Models

In our review of prior economic models, we found a cost-effectiveness analysis that assessed commercial epicutaneous peanut immunotherapy (EPIT) and peanut oral immunotherapy (POIT) compared to no immunotherapy treatment and strict peanut avoidance with self-injectable epinephrine in children (at four years) with peanut allergy from a societal perspective.⁷⁴ A Markov model was used with a cycle length of one year and a time horizon of 80 years. Baseline utility estimates for participants with food allergy as well as disutility estimates resulting from a severe allergic reaction were incorporated in the model. Estimates of predictive biomarkers or oral challenges were incorporated after the first year of therapy with analyses of immunotherapy risk reduction of anaphylaxis and probability of sustained unresponsiveness to peanut after four years.⁷⁴

The rates of therapy-associated adverse reactions and quality-of-life improvements associated with changes in eliciting or tolerated peanut doses were modeled along with QALYs, anaphylaxis, including therapy-associated anaphylaxis and related fatalities. The rate of treatment-emergent adverse events was modeled at 59.7% of participants with a rate of anaphylaxis of 3.4% and treatment discontinuation of 1.7%.⁷⁴ The rate of anaphylaxis (described as “systemic hypersensitivity”) for POIT was 14.2% (20.4% discontinuation rate, total 98.7% adverse event

rate).⁷⁴ Also, the health state disutility estimate, applied to treatment-induced anaphylaxis, was -0.09 per occurrence and per yearly cycle.

Costs associated with peanut allergy included epinephrine autoinjector preparedness, visits to primary care clinicians, nutritionists, and health professionals, while societal costs included grocery costs and job-related costs.⁷⁴ The ICERs were \$216,061 and \$255,431 for EPIT and POIT, respectively. The authors estimated cost ranges (at a willingness-to-pay threshold of \$100,000 per QALY) between \$1,568 and \$6,568 for EPIT and between \$1,235 and \$5,235 for POIT.⁷⁴ Cost-effectiveness results of both interventions were sensitive to rates of sustained unresponsiveness, treatment costs, health state utility estimates, and risk reduction of anaphylaxis.

Although the modelling approach, assumptions and inputs were different than those included in our cost-effectiveness analysis, overall conclusions of this study were similar to our findings. The main differences stemmed from the broader definition and higher rates of anaphylaxis (in the first year); including lifetime rates of anaphylaxis and anaphylaxis-related death for treatment and no-treatment groups. Other influential differences were related to adverse events, disutility estimate applied to treatment induced anaphylaxis (-0.09 per event per year), the use of biomarkers and the choice of efficacy measures.

We also found an economic analysis of an oral immunotherapy study in 62 children with peanut allergy (age one to 10 years), with 56 completing the trial.⁶⁷ The primary outcome was possible sustained unresponsiveness which occurred in 82.1% of those receiving immunotherapy and in 3.6% in the avoidance group ($p < .001$).⁷⁵ Desensitization occurred in 89.7% of the treated patients and 7.1% of those in the avoidance group ($p < .001$).⁷⁵ A mean number of 12.3 (95% CI, 12.0-12.5) and 2.0 (95% CI, 1.9-2.1) allergic reactions occurred in the immunotherapy and avoidance groups over 20 years of simulation, with 2.3 (95% CI, 2.2-2.3) episodes of anaphylaxis treated with intramuscular epinephrine per subject in the immunotherapy group and 1.1 (95% CI, 1.0-1.2) episodes per subject in the avoidance group.⁷⁵ At a \$50,000 per QALY threshold, oral immunotherapy was cost-effective (ICER: \$2,142 per QALY gained), although it was reported that treated patients may experience a greater rate of peanut-associated allergic reactions and anaphylaxis. In sensitivity analyses, oral immunotherapy was associated with lower rates of anaphylaxis than strict avoidance when the annual rate of accidental allergic reactions in the peanut avoidance group exceeded 25%, the annual rate of anaphylaxis in the immunotherapy group dropped below 6%, or the probability of sustained unresponsiveness after four years of immunotherapy was 68% or greater.⁷⁵ The results were sensitive to the cost of therapy increases overtime, rates of accidental allergic reactions, therapy-associated adverse events, and likelihood of therapy-induced tolerance.⁷⁵

Other published economic evaluations included a threshold analysis which calculated the value-based price of epinephrine autoinjectors for children with peanut allergy,⁷⁶ and an evaluation of

immediate versus non-immediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis.⁷⁷

The results of our literature search also yielded a number of studies that were aimed to focus solely on costs not cost-effectiveness analysis. The most relevant studies that reported costs (i.e., direct, indirect, societal) were considered and included in our cost-effectiveness model analysis.^{6,10,11,63,69}

4.4 Summary and Comment

Our analysis indicates that the long-term cost-effectiveness of AR101 or Viaskin Peanut is dependent on the prices at which these technologies come to market. The analysis estimated that treatment with AR101 resulted in 0.75 incremental QALYs compared to no immunotherapy treatment over a lifetime time horizon. The analysis of Viaskin Peanut estimated that it resulted in 0.26 incremental QALYs compared to no immunotherapy treatment over a lifetime time horizon. The results of both analyses were most sensitive to the health state utility values and the proportion of patients who passed the exit food challenge at the end of the first year.

Using placeholder prices of \$350 per month (\$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter) for AR101 and \$6,500 per year for Viaskin Peanut, we estimated the total cost of AR101 to be \$66,000 over a lifetime, and an incremental cost-effectiveness ratio of \$88,000. The estimated lifetime cost for Viaskin Peanut was \$56,000, and its incremental cost-effectiveness ratio to be \$216,000.

Our scenario analyses indicate that the proportion of patients who are assumed to have responded (choice of threshold for desensitization) and continue treatment is an important parameter, as this predicts the size of the treated population. Furthermore, the background rate of spontaneous tolerance among patients with peanut allergy may be a key driver in the estimation of incremental value for new immunotherapies.

Limitations

We undertook this analysis in the presence of several important limitations that relate to assumptions and uncertainties. First, the utility estimates used for the base-case model come from a food allergy, but not necessarily peanut allergy, patient population. It is possible that peanut allergy patients specifically hold slightly different preferences for treatment. Unfortunately, the literature has a paucity of preference-weighted health-related quality of life estimates in food allergy patients and their caregivers. This represents a valuable opportunity for technology developers and policy makers alike.

Second, we lacked any long-term treatment data to inform decisions such as the length of treatment. Therefore, we took the conservative assumption of continuing lifetime treatment for

those who were desensitized and acknowledge that this parameter may influence the calculation of value-based prices. We also modeled a scenario with treatment discontinuation with the maintenance of benefit for a lifetime.

Third, the analysis assumes a high level of risk reduction associated with desensitization measured in the two products' clinical trials, based on post-hoc analyses of trial data. While we recognize this potential limitation, it must be considered in the context that the events being avoided are already of very low incidence rate. Therefore, the assumption does not produce a large influence on the findings of the analysis.

Conclusions

Both AR101 and Viaskin Peanut are predicted to produce incremental benefit for people with peanut allergy relative to standard care (no desensitization treatment). These benefits are due to improved subjective quality of life despite the relative rarity with which serious events occur. The ultimate value of these products will be determined by the prices that are set by the manufacturers and their long-term effectiveness.

5. Potential Other Benefits and Contextual Considerations

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. We also recognize that there may be broader contextual issues related to the severity of the condition, whether other treatments are available, and ethical, legal, or other societal priorities that influence the relative value of illnesses and interventions. These general elements are listed in the table below, and the subsequent text provides detail about the elements that are applicable to AR101 and Viaskin Peanut. We sought input from stakeholders, including individual patients, patient advocacy organizations, clinicians, and manufacturers, to inform the contents of this section.

Each ICER review culminates in a public meeting of an independent voting Council of clinicians, patients, and health services researchers. As part of their deliberations, Council members will judge whether a treatment may substantially impact the considerations listed in Table 5.1. The presence of substantial other benefits or contextual considerations may shift a council member's vote on an intervention's long-term value for money to a different category than would be indicated by the clinical evidence and cost-effectiveness analyses alone. For example, a council member may initially consider a therapy with an incremental cost-effectiveness ratio of \$150,000 per QALY to represent low long-term value for money. However, the Council member may vote for a higher value category if they consider the treatment to bring substantial other benefits or contextual considerations. Conversely, disadvantages associated with a treatment may lead a Council member to vote for a lower value category. A Council member may also determine that there are no other benefits or contextual considerations substantial enough to shift their vote. All factors that are considered in the voting process are outlined in ICER's [value assessment framework](#). The content of these deliberations is described in the last chapter of ICER's Final Evidence Report, which is released after the public meeting.

This section, as well as the Council's deliberation, provides stakeholders with information to inform their decisions on a range of issues, including shared decision-making between patients and clinicians, coverage policy development, and pricing negotiations.

Table 5.1. Potential Other Benefits or Contextual Considerations (Not Specific to Any Disease or Therapy)

Potential Other Benefits
This intervention offers reduced complexity that will significantly improve patient outcomes.
This intervention will reduce important health disparities across racial, ethnic, gender, socio-economic, or regional categories.
This intervention will significantly reduce caregiver or broader family burden.
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.
This intervention will have a significant impact on improving return to work and/or overall productivity.
Other important benefits or disadvantages that should have an important role in judgments of the value of this intervention.
Potential Other Contextual Considerations
This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
This intervention is the first to offer any improvement for patients with this condition.
Compared to strict avoidance, there is significant uncertainty about the long-term risk of serious side effects of this intervention.
Compared to strict avoidance, there is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
There are additional contextual considerations that should have an important role in judgments of the value of this intervention.

5.1 Potential Other Benefits

Both AR101 and Viaskin Peanut have the potential to reduce the economic disparities that lead to higher emergency department visits and hospitalization in patients from low income households if they are given access to these therapies. In addition, the prevalence of peanut allergy is greater in non-Hispanic Blacks, and Hispanics than in non-Hispanic whites and in low-income families. These disparities have the potential to be reduced with FDA approval of these therapies.

Viaskin Peanut uses a novel mechanism of action by delivering immunotherapy transcutaneously. Prior immunotherapy approaches have been oral, sublingual, or subcutaneous.

There are inadequate data to assess whether these therapies will reduce caregiver psychosocial burden, physical burden, and anxiety, as well as improve quality of life and productivity, though both therapies have the potential to do so. However, it is worth noting that in the AAFA survey, caregivers reported experiencing tremendous anxiety. For some caregivers, these therapies may reduce anxiety about accidental exposure.

5.2 Contextual Considerations

Both AR101 and Viaskin Peanut will be the first therapies approved by the FDA to treat peanut allergy. The current method to manage peanut allergy is avoidance, which is not treatment and can result in potentially life-threatening accidental exposure to peanut allergens.

Peanut allergy has a significant, lifelong impact on patients' and families and caregivers' quality of life and these therapies have the potential to improve their quality of life.

There is significant uncertainty about the long-term risks and benefits for both therapies as the placebo-controlled comparisons are only one year in length and the data from the extension trials are sparse.

6. Value-Based Price Benchmarks

Our value-based benchmark annual prices for AR101 and Viaskin Peanut are presented in Table 6.1. As noted in the initial ICER methods document (<http://icer-review.org/wpcontent/uploads/2016/02/Value-Assessment-Framework-slides-for-July-29-webinar-FINALcorrected-8-22-1.pdf>), the value-based benchmark price for a drug is defined as the price range that would achieve incremental cost- effectiveness ratios between \$100,000 and \$150,000 per QALY gained.

Table 6.1. Value-Based Benchmark Prices for AR101 and Viaskin Peanut for the Treatment of Peanut Allergy

	Annual Cost to Achieve \$100,000 per QALY	Annual Cost to Achieve \$150,000 per QALY
AR101	\$4,808	\$7,248
Viaskin Peanut	\$3,010	\$4,513

No wholesale acquisition costs are currently available for either product. Therefore, no estimates of price discounts are provided.

7. Potential Budget Impact

7.1 Overview

We used the cost-effectiveness model to estimate the potential total budgetary impact of AR101 and Viaskin Peanut in children with peanut allergy, ages four to 17 years and ages four to 11 years, respectively. We calculated the budget impact using the placeholder prices and those estimated to achieve willingness-to-pay (WTP) thresholds between \$50,000 to \$150,000 per QALY gained. As in the cost-effectiveness analysis, we also used placeholder prices from publicly available analysts' estimates. We assumed a placeholder price of \$350 per month for AR101 (i.e., \$6,595 for months 1-6 including clinical visits for dose escalation; \$4,200 per year thereafter).¹⁴ For Viaskin Peanut, we assumed a placeholder price of \$6,500 per year.¹⁴ Note that these placeholder prices for both AR101 and Viaskin Peanut may not reflect the actual prices at launch, and therefore the actual budget impact of these technologies may differ from our estimates.

7.2 Methods

We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact. Potential budget impact was defined as the total differential cost of using each new technology, rather than relevant existing treatments, for the eligible population in this indication, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. We assumed that all children ages four to 17 years with peanut allergy would be eligible for AR101, and that all children ages four to 11 years with peanut allergy would be eligible for Viaskin Peanut, based on the trial populations. All costs were undiscounted and estimated over a five-year time horizon, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of children eligible for these technologies.

For AR101, the potential budget impact analysis included children ages four to 17 years with peanut allergy. To estimate the size of the potential population for our budget impact analysis, we first used an estimate of the prevalence (2%) of peanut allergy in children from the guidelines for the prevention of peanut allergy in the United States.³³ We then applied this estimate to the projected 2019 to 2023 US population estimates for children ages four to 17 years to derive the average population over the next five years. This resulted in an eligible population size for AR101 of 1,152,930 children over five years, or an estimated 230,586 children each year.

For Viaskin Peanut, the potential budget impact analysis included children ages four to 11 years with peanut allergy. We used the same estimate of the prevalence (2%) of peanut allergy in children from the guidelines for the prevention of peanut allergy in the United States.³³ We then

applied this estimate to the projected 2019 to 2023 US population estimates for children ages four to 11 years to derive the average population over the next five years. This resulted in an eligible population size for Viaskin Peanut of approximately 650,480 children over five years, or an estimated 130,096 children each year.

ICER's methods for estimating potential budget impact are described in detail elsewhere⁷⁸ and have been [recently updated](#). The intent of our revised approach to budgetary impact is to document the percentage of patients who could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy. For 2018-19, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately \$991 million per year for new drugs.


To estimate potential budget impact, we evaluate a new therapy that would take market share from one or more existing therapies/treatments and calculate the blended budget impact associated with displacing use of existing therapies with the new intervention. For this analysis, we evaluated the potential budget impact of AR101 and Viaskin Peanut, each compared to avoidance in children with peanut allergy. For each treatment, we assumed equal uptake over five years (20% each year), with treatment duration ranging from one year (for the year-five cohort) to five years (for the year-one cohort). In other words, patients initiating therapy in year one would accrue all drug costs and cost offsets over the full five years, but those initiating in other years would only accrue a proportional amount of five-year costs.

7.3 Results

For AR101, per-patient budget impact calculations are based on the placeholder price of \$4,200 per year and the prices to reach \$150,000, \$100,000, and \$50,000 per QALY thresholds (at \$7,248, \$4,808, and \$2,369 per year, respectively). The average five-year annualized potential budgetary impact when using the placeholder price was approximately \$3,700 per patient. The average five-year annualized potential budgetary impact at the three cost-effectiveness threshold prices ranged from approximately \$6,000 per patient using the annual price to achieve \$150,000 per QALY to approximately \$2,400 using the annual price to achieve a \$50,000 per QALY cost-effectiveness threshold.

As shown in Figure 7.1, approximately 41% of eligible patients could be treated in a given year with AR101 without crossing the ICER budget impact threshold of \$991 million at the placeholder price (\$4,200/year). Approximately 25%, 37% and 67% of patients could be treated in a given year without crossing the budget impact threshold at the \$150,000, \$100,000, and \$50,000 per QALY threshold prices (at \$7,248, \$4,808, and \$2,369 per year, respectively).

Figure 7.1. Budget Impact of AR101 at Placeholder* and Threshold Prices



*Placeholder price is used until list or net prices become available.

For Viaskin Peanut, per-patient budget impact calculations were based on the placeholder price (\$6,500 per year) and the prices to reach \$150,000, \$100,000, and \$50,000 per QALY thresholds (at \$4,513, \$3,010, and \$1,508 per year, respectively). Across the five-year timeframe, the weighted annualized potential budgetary impact (i.e., adjusted for differing periods of drug utilization and associated cost offsets) when using the placeholder price was approximately \$4,100 per patient. The average five-year annualized potential budgetary impact at the three cost-effectiveness threshold prices ranged from approximately \$2,800 per patient using the annual price to achieve \$150,000 per QALY to approximately \$950 using the annual price to achieve a \$50,000 per QALY cost-effectiveness threshold.

At the placeholder price (\$6,500/year) for Viaskin Peanut, approximately 71% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million. Despite the assumption of a higher placeholder price for Viaskin Peanut, more patients could be treated than with AR101, largely due to AR101's higher administration and monitoring costs in the first year of treatment. As shown in Table 7.1, the annual potential budgetary impact of treating the entire eligible population over five years did not exceed the \$991 million ICER budget impact threshold at the prices to achieve \$150,000, \$100,000, and \$50,000 per QALY, reaching 98%, 65%, and 33% of the budget impact threshold, respectively.

Table 7.1. Budget Impact of Viaskin Peanut at Threshold Prices

	Viaskin Peanut Percent of Budget Impact Threshold
\$150,000 per QALY Threshold Price	98%
\$100,000 per QALY Threshold Price	65%
\$50,000 per QALY Threshold Price	33%

7.4 Access and Affordability Alert

ICER is issuing an access and affordability alert for both AR101 and Viaskin Peanut. Currently, this alert is based on assumed prices, and it should be noted that the findings are subject to change if and when the actual prices become available (contingent upon FDA approval and launch).

For AR101, at the assumed price of \$4,200 per year, approximately 41% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million. If priced within the ICER value-based price range, only 25%-37% of eligible patients could be treated with AR101 before exceeding the potential budget impact threshold. For Viaskin Peanut, at the assumed price of \$6,500 per year, approximately 71% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of \$991 million.

The purpose of an ICER affordability and access alert is to signal stakeholders and policy makers that the amount of added health care costs associated with a new service may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs that threaten sustainable access to high-value care for all patients.

8. Summary of the Votes and Considerations for Policy

8.1 About the CTAF Process

During CTAF public meetings, the CTAF Panel deliberates and votes on key questions related to the systematic review of the clinical evidence, an economic analysis of the applications of treatments under examination, and the supplementary information presented. Panel members are not pre-selected based on the topic being addressed and are intentionally selected to represent a range of expertise and diverse perspectives.

Acknowledging that any judgment of evidence is strengthened by real-life clinical and patient perspectives, subject matter experts are recruited for each meeting topic and provide input to CTAF Panel members before the meeting to help clarify their understanding of the different interventions being analyzed in the evidence review. The same clinical experts serve as a resource to the CTAF Panel during their deliberation, and help to shape recommendations on ways the evidence can apply to policy and practice.

After the CTAF Panel votes, a policy roundtable discussion is held with the CTAF Panel, clinical experts, patient advocates, payers, and manufacturers. The goal of this discussion is to bring stakeholders together to apply the evidence to guide patient education, clinical practice, and coverage and public policies. Participants on policy roundtables are selected for their expertise on the specific meeting topic, are different for each meeting, and do not vote on any questions.


At the June 11, 2019 meeting, the CTAF Panel discussed issues regarding the application of the available evidence to help patients, clinicians, and payers address important questions related to the use of oral immunotherapy and Viaskin Peanut for treating patients with peanut allergy. Following the evidence presentation and public comments (public comments from the meeting can be accessed [here](#), starting at 1:32:05), the CTAF Panel voted on key questions concerning the comparative clinical effectiveness and potential other benefits and contextual considerations related to peanut allergy therapies. These questions are developed by the ICER research team for each assessment to ensure that the questions are framed to address the issues that are most important in applying the evidence to support clinical practice, medical policy decisions, and patient decision-making. The voting results are presented below, along with specific considerations mentioned by CTAF Panel members during the voting process.

The CTAF Panel did not deliberate on any votes related to value as neither AR101 nor Viaskin Peanut had publicly-known prices at the time of the meeting. There are four elements to consider when deliberating on long-term value for money (see Figure 8.1 below):

1. Comparative clinical effectiveness is a judgment of the overall difference in clinical outcomes between two interventions (or between an intervention and placebo), tempered by the level of certainty possible given the strengths and weaknesses of the body of evidence. CTAF uses the [ICER Evidence Rating Matrix](#) as its conceptual framework for considering comparative clinical effectiveness.
2. Estimated incremental cost-effectiveness is the average incremental cost per patient of one intervention compared to another to achieve a desired “health gain,” such as an additional stroke prevented, case of cancer diagnosed, or gain of a year of life. Alternative interventions are compared in terms of cost per unit of effectiveness, and the resulting comparison is presented as a cost-effectiveness ratio. Relative certainty in the cost and outcome estimates continues to be a consideration. As a measure of cost-effectiveness, the CTAF voting panel follows common academic and health technology assessment standards by using cost per quality-adjusted life year (QALY), with formal voting on “long-term value for money” when the base case incremental cost-effectiveness ratio is between \$50,000 per QALY and \$175,000 per QALY.
3. Potential other benefits refer to any significant benefits or disadvantages offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that would not have been considered as part of the evidence on comparative clinical effectiveness. Examples of potential other benefits include better access to treatment centers, mechanisms of treatment delivery that require fewer visits to the clinician’s office, treatments that reduce disparities across various patient groups, and new potential mechanisms of action for treating clinical conditions that have demonstrated low rates of response to currently available therapies. Other disadvantages could include increased burden of treatment on patients or their caregivers. For each intervention evaluated, it will be open to discussion whether potential other benefits or disadvantages such as these are important enough to factor into the overall judgment of long-term value for money. There is no quantitative measure for potential other benefits or disadvantages.
4. Contextual considerations include ethical, legal, or other issues (but not cost) that influence the relative priority of illnesses and interventions. Examples of contextual considerations include whether there are currently any existing treatments for the condition, whether the condition severely affects quality of life or not, and whether there is significant uncertainty

about the magnitude of benefit or risk of an intervention over the long term. There is no quantitative measure for contextual considerations.

Figure 8.1. Conceptual Structure of Long-Term Value for Money



8.2 Voting Results

1) Is the evidence adequate to demonstrate that the net health benefit of AR101 plus strict peanut avoidance is superior to continued avoidance alone?

Yes: 4 votes	No: 12 votes
--------------	--------------

A majority of the panel determined that the evidence was inadequate to demonstrate a superior net health benefit of AR101 plus strict avoidance compared to continued avoidance alone. The panel cited the lack long term data that could demonstrate that the increased risk in treatment-related reactions during the one-year trial (six months of dose escalation, followed by six months of maintenance) could lead to reduced reactions beyond the first year of treatment. Panelists argued that they needed more evidence to demonstrate that the surrogate outcome of desensitization led to lower rates of harms long term, especially because the rates of severe reactions were similar in the dose escalation phase as they were in the maintenance phase and in the six-month follow up study. The panelists also cited the lack of data on stopping therapy, and the uncertainty on how

stopping therapy impacts patient risk of harms after discontinuing therapy. Finally, the panel discussed the lack of quality of life data to demonstrate how desensitization impacts anxiety for patients and their families, especially since patients are still required to avoid foods. Panelists emphasized that in voting no, they were not voting that these therapies were not effective; rather, they were voting that the data was insufficient to tie desensitization to an observed clinical benefit, despite the risk of harms, or quality of life improvements.

The panelists who voted in favor of the net health benefit of AR101 versus continued avoidance stressed that they trusted clinical expert opinion that desensitization is currently the most effective treatment to mitigate the risks of accidental exposures related to peanut allergy. One panel member noted that the harms shown in the clinical trials were routine for oral immunotherapy, and moreover, are offset by the perceived benefits of treatment, such as reduced fear and anxiety among patients and caregivers.

2) Is the evidence adequate to demonstrate that the net health benefit of Viaskin Peanut plus strict peanut avoidance is superior to continued avoidance alone?

Yes: 4 votes	No: 12 votes
--------------	--------------

A majority of the panel judged that the evidence was inadequate to demonstrate a superior net health benefit of Viaskin Peanut plus strict avoidance compared to continued avoidance alone. Panelists continued to reiterate the short term duration of the trial despite the need to demonstrate longer term clinical benefit in observed clinical and quality of life outcomes such as reactions due to accidental exposures, epinephrine use, hospitalizations. Panelists also expressed dissatisfaction that Viaskin Peanut did not meet its prespecified primary outcome in the PEPITES trial.

The panelists who voted in favor of Viaskin Peanut versus avoidance reiterated their rationale from Question 1, and stressed that having an immunotherapy regulated by protocols is critical.

3) Is the evidence adequate to distinguish the net health benefit of AR101 and Viaskin Peanut?

Yes: 0 votes	No: 16 votes
--------------	--------------

The panel unanimously voted that there was inadequate evidence to distinguish the net health benefit of AR101 and Viaskin Peanut. Panel members noted the lack of head-to-head studies and emphasized that the respective trials for each therapy differed in study design, patient population, and outcomes, and were thus not comparable.

3a) If the answer to Q3 is Yes: Based on the available evidence, which therapy has greater net health benefit: (a) AR101 plus strict peanut avoidance, or (b) Viaskin Peanut plus strict peanut avoidance?

No vote was taken, as the panel unanimously voted no on Question 3.

4) Is the evidence adequate to demonstrate that the net health benefit of AR101 is superior to oral immunotherapy as practiced currently?

Yes: 2 votes	No: 14 votes
--------------	--------------

A majority of the panel concluded that the evidence was inadequate to demonstrate a superior net health benefit of AR101 compared to oral immunotherapy as practiced currently. Panelists cited the poor quality of studies, the lack of head-to-head trials, and differing patient populations and primary outcomes. For those who voted yes, there was discussion at the meeting of the inconsistencies in dosing protocols in OIT as it is currently practiced, which contrasts with AR101 which may offer standardization to the practice of OIT.

5) Does desensitizing patients with Viaskin Peanut offer one or more of the following potential “other benefits” in comparison to strict peanut avoidance alone? (select all that apply)

This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.	9/16
This intervention will significantly reduce caregiver or broader family burden.	10/16
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	11/16
This intervention will have a significant impact on improving patients’ ability to return to work, school, and/or their overall productivity.	9/16
There are other important benefits or disadvantages that should have an important role in judgments of the value of Viaskin Peanut: _____.	12/16

A majority of the panel judged that treatment with Viaskin Peanut will reduce health disparities across racial, ethnic, gender, socioeconomic, and/or regional categories. Panelists cited the disproportionate disease burden among people of color and low-income households, including higher overall prevalence of peanut allergy, higher rates of hospitalizations, and inadequate access to safe foods which can be prohibitively expensive. According to these panelists, Viaskin Peanut could reduce important health disparities by providing these patients with treatment that could potentially reduce ER visits and save families significant time and resources. Furthermore, as there is no FDA-approved therapy for peanut allergy, some panelists suggested that since patients and caregivers must pay out of pocket for unregulated oral immunotherapy, which can be cost-prohibitive for many families, approved treatments could improve insurance access to therapies to alleviate disparities in peanut-allergic households based on income. However, many panelists also

acknowledged that treatment could in fact exacerbate disparities, since treatment also requires access to an allergist who can administer treatment, and are underrepresented among safety net care providers. These panelists cautioned that without a trained allergist administering treatment, disparities could in fact worsen if low income patients have access to poorly trained clinicians who are administering treatment.

Many panelists also acknowledged that treatment with Viaskin Peanut may positively impact caregiver and family burden, as well as reduce the psychological burden among patients with peanut allergy. Once desensitized with Viaskin Peanut, parents and caregivers may worry less about the risk of an unexpected attack, as well as the costs of ER visits and specialty diets. For patients, desensitization may confer a greater sense of independence. Further, treatment may help alleviate the sense of guilt that patients experience, believing that their allergy places an undue burden on their parents, siblings, and society at large.

6) Does desensitizing patients with AR101 offer one or more of the following potential “other benefits” in comparison to strict peanut avoidance alone? (select all that apply)

This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.	7/16
This intervention will significantly reduce caregiver or broader family burden.	11/16
This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.	5/16
This intervention will have a significant impact on improving patients’ ability to return to work, school, and/or their overall productivity.	8/16
There are other important benefits or disadvantages that should have an important role in judgments of the value of Viaskin Peanut: _____.	10/16

A majority of the panel reiterated that treatment with AR101 may reduce caregiver and family burden, and have the potential for a positive psychological benefit for patients who experience guilt due to their allergy. Unlike the previous vote evaluating Viaskin Peanut, panelists did not vote by majority that AR101 would reduce health disparities. Several noted that the treatment could worsen disparities due to the potential difficulty accessing a trained allergy.

7) Are any of the following contextual considerations important in assessing the long-term value for money for Viaskin Peanut in comparison to strict peanut-avoidance alone? (select all that apply)

This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.	9/15
There is significant uncertainty about the long-term risk of serious side effects of this intervention.	13/15
There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.	13/15
There are additional contextual considerations that should have an important role in judgments of the value of this intervention: _____.	4/15

A large majority of the panel expressed concern regarding the uncertainty about the long-term risk of serious side effects and the durability of the long-term benefits of treatment with Viaskin Peanut. Several panelists questioned whether desensitization could exacerbate the allergy in the long-term and considered the potential impact of frequent use of epinephrine. In addition, since patients might wear the patch throughout their lifetime, concerns arose about the lack of long-term data demonstrating safety and efficacy. Many panelists also reiterated their worry and frustration with the reliance on surrogate outcomes, which engender further uncertainty.

8) Are any of the following contextual considerations important in assessing the long-term value for money for AR101 in comparison to strict peanut-avoidance alone? (select all that apply)

This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.	8/15
There is significant uncertainty about the long-term risk of serious side effects of this intervention.	13/15
There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.	13/15
There are additional contextual considerations that should have an important role in judgments of the value of this intervention: _____.	3/15

A large majority of the panel expressed concern regarding the uncertainty about the long-term risk of serious side effects and the durability of the long-term benefits of treatment with AR101. The panel largely offered the same rationale for this vote. The panel reiterated concern over the lack of long-term data demonstrating durability of desensitization, as well as the potential for post-marketing side effects stemming from systemic allergic reactions and frequent epinephrine use. The panel also expressed concern over the substantially higher rates of withdrawal (compared to placebo) due to adverse events in the clinical trials.

9) Given the available evidence on comparative effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with AR101 plus strict peanut avoidance compared with continued avoidance alone?

No vote was taken, as AR101 did not have a publicly-known price at the time of the meeting.

10) Given the available evidence on comparative effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with Viaskin Peanut plus strict peanut avoidance compared with continued avoidance alone?

No vote was taken, as Viaskin Peanut did not have a publicly-known price at the time of the meeting.

8.3 Roundtable Discussion and Key Policy Implications

Following its deliberation on the evidence, the CTAF Panel engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on oral immunotherapy and Viaskin Peanut to policy and practice. The policy roundtable members included two patient advocates, two clinical experts, one payer, and two representatives from pharmaceutical manufacturers. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants. The names of the Policy Roundtable participants are shown below, and conflict of interest disclosures for all meeting participants can be found in Appendix G.

Table 8.1. Policy Roundtable Participants

Name	Title and Affiliation
Todd Green, MD, FAAAA	Vice President Medical Affairs North America, DBV Technologies
Matthew Greenhawt, MD	Associate Professor of Pediatrics, University of Colorado School of Medicine, Section of Allergy/Immunology, Children's Hospital Colorado; Director, Food Challenge and Research Unit
Ruchi Gupta, MD, MPH	Professor of Pediatrics and Medicine, Northwestern University Feinberg School of Medicine; Clinical Attending, Ann & Robert H. Lurie Children's Hospital of Chicago; Director, Center for Food Allergy & Asthma Research; Director, Science & Outcomes of Allergy & Asthma Research Program
Nurry Hong	Chief of Strategy and Innovation, Food Allergy Research & Education
Caroline Moassessi	Patient Advocate
Stephen Tilles, MD	Senior Director of Medical Affairs, Aimmune Therapeutics
John S. Yao, MD, MPH, MBA, MPP, CPC, FACP	Regional Vice President and Chief Medical Officer, Anthem Blue Cross

The roundtable discussion was facilitated by Dr. Steven Pearson, MD, MSc, President of ICER. The main themes and recommendations from the discussion are organized by audience and summarized below.

Manufacturers

- 1. To provide fair value to patients and the health system, manufacturers should price desensitization therapies for peanut allergy so that they align with the added value they bring to patients.**

There is unmet need for treating patients with peanut allergy. Patients and their families feel intense anxiety about accidental exposure to peanuts, especially in uncontrolled environments outside of their homes, such as at school, social events, restaurants, or while traveling. While life threatening reactions are extremely rare, they are unpredictable, and in current practice, patients and their families are constantly insulating themselves from the risk of an accidental exposure to peanuts to prevent a reaction that they think could be fatal. Given the impact on quality of life, and the lack of alternative treatment options, patients and their families will seriously consider undergoing the process of desensitization. However, high prices for these drugs would likely trigger constraints by insurers on access, which will impose an unfair burden on patients and their families. Manufacturers should bring reasonable prices to the negotiating table with insurers in return for broader access for patients who may benefit from these treatments.

- 2. Manufacturers should pursue further evidence development in order to provide better certainty of their long-term safety and effectiveness. Evidence should not rely on short-term surrogate outcome measures like desensitization.**

Short term trials have not established the benefits of these therapies. After one year, both trials demonstrated net harm to patients compared with strict avoidance: higher rates of epinephrine use, more systemic allergic reactions, more treatment specific adverse events, and no evidence of improvements in quality of life. Clinical experts suggested that reactions during treatment were expected, and that it would take up to three years before reductions in epinephrine use and anaphylaxis would be seen in the treatment group compared with those seen in the placebo group. Given that desensitization therapies may need to be taken indefinitely by patients, manufacturers have an obligation to patients, caregivers, and decisionmakers to demonstrate that the long-term benefits in undergoing treatment outweigh the short-term harms. It is incumbent upon manufacturers to prove that desensitization therapy mitigates accidental exposures, including epinephrine use and anaphylaxis, and improves patient and family quality of life.

3. Manufacturers should work with patient groups and the clinical research community to conduct studies that provide evidence on when and how to stop treatment.

Manufacturers have already conducted short term, unpublished follow up studies in a small group of patients to evaluate sustained unresponsiveness after a short break in treatment. Clinical experts expressed hope that patients will be able to come off desensitization therapy while maintaining the benefits of therapy, however, this is not yet proven, and many questions remain about how and if patients can stop treatment, or take a break in treatment, without their sensitivity to peanuts regressing, heightening their risk to accidental exposure. It is critical that manufacturers pursue high quality studies so that patients can understand the impact of stopping treatment on their sustained unresponsiveness, risk of accidental exposures, epinephrine use and anaphylaxis. At this time, there is no evidence to indicate a time frame in which patients can consider stopping therapy, nor are there validated biomarkers to guide this decision. Without this information, patients and clinicians will feel obligated to continue treatment indefinitely.

4. Manufacturers should collaborate with the patient community and clinical experts to develop educational materials for parents to understand the benefit-risk tradeoffs in undergoing desensitization, and not create undue guilt for individual families who decide not to initiate treatment.

Caregivers need to understand the benefit and risks of their child undergoing treatment, including the potential benefits of desensitization, as well as the long-term uncertainties and the risks of serious health events, especially during dose escalation. During the meeting, we heard from parents that there is already pressure within the patient community to pursue desensitization for affected children. This is inappropriate given the current evidence base for existing therapies. Given the delicate balance of benefits and harms and the differing values and preferences of individual patients and their caregivers, the right choice for one patient will likely not be the right choice for the next patient. Parents need to be fully informed in making this important treatment decision for their child.

Payers

5. ICER is issuing an access and affordability alert for both AR101 and Viaskin Peanut.

The purpose of an ICER affordability and access alert is to signal stakeholders and policy makers that the amount of added health care costs associated with a new service may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs that threaten sustainable access to high-value care for all patients.

ICER is issuing an access and affordability alert for both AR101 and Viaskin Peanut. Currently, this alert is based on assumed prices, and it should be noted that the findings are subject to change if and when the actual prices become available (contingent upon FDA approval and launch).

- 6. Prior authorization criteria should be based on clinical evidence, with input from clinical experts and patient groups. Options for specific elements of coverage criteria within insurance coverage policy are discussed below.**

Patient Eligibility Criteria:

- a. Diagnosis:** Payers may choose to accept clinician attestation for the diagnosis, particularly if limiting coverage to prescriptions from allergy specialists. Alternatively, payers can consider requiring skin testing and documented positive IgE tests before approving coverage, both of which have high sensitivity. Clinical experts, however, noted the poor specificity of these tests and their inability to predict the risk of severe accidental anaphylaxis. Therefore, there is no evidence-based method to define a severity threshold for coverage.

Payers may also consider requiring prior pharmacy record of a refill of epinephrine as an indicator of confirmed peanut allergy diagnosis. Regardless of prior use of epinephrine, all patients undergoing desensitization therapy for food allergy should have access to epinephrine considering the increased risks for serious reactions, and payers may wish to consider requiring concomitant active epinephrine prescription as a prerequisite for coverage of peanut allergy treatments.

- b. Age:** Payers may consider limiting coverage for initiation of desensitization treatment to patients between the ages of four and 17 years who represent the population studied to date. The PEPITES trial for Viaskin Peanut assessed patients between the ages of four through 11; the PALISADE study assessed patients between the ages of four and 17. There is therefore no direct evidence on safety or effectiveness among adults or patients younger than age four. Clinical experts note that a sizeable proportion of patients under the age of four may grow out of their food allergy, and so initiating long-term treatment in that age range poses additional concerns. Adult patients with food allergy may be assumed to be more competent at recognizing early signs of anaphylaxis and self-administering epinephrine, but for some adult patients with frequent or particularly severe accidental anaphylaxis, extending coverage for the initiation of desensitization beyond the age of 17 may be reasonable. However, desensitization appears to be less effective in older patients.
- c. Other clinical criteria:** Not applicable.

- d. **Renewal criteria:** Payers should not stop coverage at age 18 for patients who have been on continuous desensitization therapy. To date, data suggest that patients must remain on daily therapy to preserve desensitization. Any lapse in therapy, followed by re-initiation puts patients at risk for a serious allergic reaction.

Provider Criteria

- a. **Provider criteria:** Prescribing peanut desensitization therapies should be restricted to specialists (Allergy and Immunology Specialists); or for those patients with inadequate access to allergists, by primary care physicians only in consultation with a specialist.

Patients may be misdiagnosed with peanut allergy before they are referred to a specialist. These new treatments are potentially dangerous and expensive as well, and therefore it is not unreasonable for payers to consider limiting coverage to patients diagnosed with peanut allergy and managed by an allergy specialist. However, payers may also consider a requirement of specialist consultation for coverage of therapy for patients with limited access to specialists within their provider networks or geographic regions.

Providers

7. Shared-decision making is essential in the safe and appropriate prescribing of desensitization therapy.

Given the clear early harms, these therapies should only be prescribed following appropriate shared decision making with sufficient time given to the explanation of expected adverse events, including an early increase in systemic allergic reactions and use of epinephrine with both therapies. Differences between the two therapies should be highlighted including differences in the expected rates of desensitization at one year, differences in therapy discontinuation rates, and differences in the types of side effects experienced. The need for long-term daily treatment and the uncertainties about long term benefits with both therapies should also be communicated with patients. Based on the patient's values, a decision can be reached about beginning therapy with AR101, Viaskin Peanut, or continuing with strict peanut avoidance and early use of epinephrine at the onset of a reaction. If patients decide to pursue desensitization, providers should continue to counsel patients on the importance of carrying epinephrine and ensure they have access to a valid prescription with the desired number of refills, and patients should ensure they keep an appropriate supply of epinephrine on hand.

Specialty Societies

8. Specialty societies should develop a clear, evidence-based definition of desensitization to food allergy.

The PRACTALL guidelines established the double-blind oral food challenge as the primary outcome for food allergy desensitization trials. However, there is no agreed upon definition for the eliciting dose or maximum tolerated dose that defines adequate desensitization. There should be clinical trials that demonstrate the utility of desensitization as a surrogate marker for a long-term reduction in allergic reactions to accidental exposure to the food allergen. In addition, standard stopping rules for the oral food challenge should be established and used in all future clinical trials.

9. Given the remaining uncertainties about the benefits and harms of these novel therapies, specialty societies should take the lead in organizing patient registries.

There is an important role for registries to measure long term outcomes including systemic reactions, use of epinephrine, ER visits, hospitalizations, mortality, quality of life, and treatment discontinuation. Specialty societies can lead on working with patient groups to organize patient registries that capture treatment effects of desensitization therapies if they enter the market.

10. Specialty societies should collaborate with patient organizations to develop materials for both patients and clinicians to support appropriate shared decision making that does not create stigma for patients who decide for or against treatment with the current generation of desensitization therapies.

The practice of oral immunotherapy and desensitization is not currently widespread among allergists. As therapies are approved, it will likely become more widespread, and allergists need the tools to help patients and their caregivers understand the benefit and risk tradeoffs of undergoing treatment, including the potential benefit of desensitization therapy, as well as the uncertainty long term and risk of harms. Desensitization therapy is not the “right” decision for every family, since there is clear evidence of early harms of therapy compared with strict peanut avoidance. For those who elect desensitization therapy, there are tradeoffs between oral and transcutaneous therapy in terms of the rates of successful desensitization, and the rates and types of side effects make for a difficult decision. Families need unbiased information and thoughtful reflection on their risk tolerance to guide their decision-making. They should not feel undue pressure from others in the patient community or from providers.

Patient Advocacy Organizations

11. Patient organizations should help educate families and patients about these therapies, including both potential benefits and potential harms.

Patients on therapy are still at risk for accidental exposure and must practice strict peanut avoidance in their daily living. Patient organizations can help to educate within the patient community about the continued risk of reaction, despite desensitization, to prevent overestimation of treatment benefit, and prevent potentially risky behavior. Furthermore, patient groups can play a central role in the education of patients and their caregivers about the tradeoffs in deciding if to pursue therapy. Careful attention should be paid to short term harms, the requirement for long term daily therapy, and that successful desensitization still requires avoidance of peanuts and rapid availability of epinephrine. In addition, patient organizations should help to create an environment in which families do not feel pressured through social media or other campaigns either to use or to avoid treatment.

12. Patient organizations should consider boycotting research sponsored by drug manufacturers that does not measure outcomes of direct relevance to patients for a period sufficient to provide a sound basis for shared clinical decision-making. Patients should strongly advocate that the FDA do better in ensuring that the research required for regulatory approval meets these standards.

As noted above, current clinical trials have demonstrated net harm with desensitization. To ensure that the balance of benefits and harms favors the patient, patients should advocate for trials that demonstrate unequivocally that desensitization therapy translates into a reduction in allergic reactions to accidental exposures to peanuts and to improvements in quality of life.

Regulators

13. The FDA should update its guidance for the assessment of outcomes in food allergy therapy to require a common definition of desensitization.

The heterogeneity across the trials of therapies for desensitization of peanut allergy introduces uncertainty about their translation into clinical effectiveness and precludes high quality comparative effectiveness analyses between therapies for the same indication. The FDA should work with specialty societies and manufacturers to update the guidance for peanut allergy trials to ensure that the primary outcome translates into clinically meaningful benefits for patients.

- 14. The FDA should mandate additional randomized clinical trials that demonstrate clinically meaningful benefits for patients (reduction in severe allergic reactions, reduction in epinephrine use, reduction in ER visits/hospitalizations, and improvement in quality of life).**

Given that desensitization has not yet been demonstrated to reliably translate into meaningful benefits to patients, additional trials should be required demonstrating these benefits. The FDA requires cardiovascular endpoint trials for therapies initially approved on the basis of LDL-cholesterol reductions and should do something similar for food allergy desensitization therapies.

Researchers

- 15. Longer placebo-controlled, randomized trials are needed to demonstrate that desensitization translates into outcomes that matter to patients.**

One-year trials of peanut desensitization consistently demonstrate an increase in anaphylaxis, systemic allergic reactions, epinephrine use and other adverse events without any clinically meaningful improvements for patient. In addition, the trials have not demonstrated improvements in quality of life for patients or their caregivers. Given the natural history of desensitization, it is clear that clinical trials must be longer than one year in duration in order to demonstrate clinically meaningful benefits.

- 16. Research is needed to develop biomarkers both for initiation of therapy and to support the decision about when it is safe to go off desensitization treatment.**

Current tests for peanut allergy are sensitive, but not specific, and cannot indicate which patients would benefit from desensitization therapy. Furthermore, once therapy is initiated, there are no tests that identify patients with sustained unresponsiveness who may safely stop daily therapy.

This is the first ICER review of oral immunotherapy and Viaskin Peanut for peanut allergy.

References

1. Bunyavanich S, Rifas-Shiman SL, Platts-Mills TA, et al. Peanut allergy prevalence among school-age children in a US cohort not selected for any disease. *J Allergy Clin Immunol*. 2014;134(3):753-755.
2. Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. *Pediatrics*. 2011;128(1):e9-17.
3. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. *Pediatrics*. 2018;142(6).
4. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol*. 2007;119(4):1016-1018.
5. National Food Death Allergy Registry. <https://www.nationalfoodallergydeathregistry.org/the-registry>. Accessed March 2019.
6. Gupta R, Holdford D, Bilaver L, Dyer A, Holl JL, Meltzer D. The economic impact of childhood food allergy in the United States. *JAMA Pediatr*. 2013;167(11):1026-1031.
7. Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A. Allergen-specific oral immunotherapy for peanut allergy. *The Cochrane database of systematic reviews*. 2012(9):Cd009014.
8. Asthma and Allergy Foundation of America. My Kids' Life with Food Allergy Survey Results: select data from caregivers of peanut-allergic children. April 2019.
9. Centers for Disease Control. *United States Life Tables, 2013*.
10. Shaker M, Bean K, Verdi M. Economic evaluation of epinephrine auto-injectors for peanut allergy. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2017;119(2):160-163.
11. Shaker M, Greenhawt M. The Health and Economic Outcomes of Peanut Allergy Management Practices. *The journal of allergy and clinical immunology In practice*. 2018;6(6):2073-2080.
12. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy. *New England Journal of Medicine*. 2018.
13. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. *Jama*. 2019.
14. Luthra S. Will I Always Face The Threat Of A Peanut-Laden Kiss Of Death? 2019; <https://khn.org/news/will-i-always-face-the-threat-of-a-peanut-laden-kiss-of-death/>.
15. Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. *J Allergy Clin Immunol*. 2010;126(4):798-806 e713.
16. Umasunthar T, Leonardi-Bee J, Hodes M, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. *Clin Exp Allergy*. 2013;43(12):1333-1341.
17. Panel NI-SE, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. *J Allergy Clin Immunol*. 2010;126(6 Suppl):S1-58.
18. Sampson HA, Aceves S, Bock SA, et al. Food allergy: a practice parameter update-2014. *J Allergy Clin Immunol*. 2014;134(5):1016-1025 e1043.
19. Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. *Pediatrics*. 1998;102(1):e6.

20. Bilaver LA, Kester KM, Smith BM, Gupta RS. Socioeconomic Disparities in the Economic Impact of Childhood Food Allergy. *Pediatrics*. 2016;137(5).
21. Green TD, LaBelle VS, Steele PH, et al. Clinical characteristics of peanut-allergic children: recent changes. *Pediatrics*. 2007;120(6):1304-1310.
22. Neuman-Sunshine DL, Eckman JA, Keet CA, et al. The natural history of persistent peanut allergy. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2012;108(5):326-331 e323.
23. Woolf S. An organized analytic framework for practice guideline development: using the analytic logic as a guide for reviewing evidence, developing recommendations, and explaining the rationale. In: McCormick K, Moore S, Siegel R, eds. *Methodology Perspectives*. Vol AHCPR Pub. No. 95-0009. Rockville, MD: Agency for Health Care Policy and Research; 1995:105-113.
24. Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. *J Allergy Clin Immunol*. 2012;130(6):1260-1274.
25. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD): Allergy Testing and Treatment (110.11). 2019; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=266&ncdver=1&bc=AAAAgAAAAA&>.
26. Aetna. Allergy and Hypersensitivity. 2018; http://www.aetna.com/cpb/medical/data/1_99/0038.html. Accessed March 13, 2019.
27. Blue Shield of California. Sublingual Immunotherapy for Allergen-Specific Therapy. 2019.
28. Humana. Human Medical Plan Open Access Health Maintenance Organization Summary of Benefits. 2019; <https://www.opm.gov/healthcare-insurance/healthcare/plan-information/plan-codes/2019/brochures/73-278.pdf>. Accessed March 13, 2019.
29. Chua KP, Conti RM. Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014. *JAMA internal medicine*. 2017;177(5):736-739.
30. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. *Journal of Allergy and Clinical Immunology*. 2011;127(1):S1-S55.
31. National Academies of Sciences Engineering and Medicine. Finding a Path to Safety in Food Allergy: Assessment of the Global Burden, Causes, Prevention, Management, and Public Policy. *The National Academies Press*. Washington, DC:2017.
32. Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. *J Allergy Clin Immunol*. 2010;126(6 Suppl):S1-58.
33. Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. *The World Allergy Organization Journal*. 2017;10(1).
34. Stiefel G, Anagnostou K, Boyle RJ, et al. BSACI guideline for the diagnosis and management of peanut and tree nut allergy. *Clin Exp Allergy*. 2017;47(6):719-739.
35. Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. *Allergy*. 2014;69(8):1008-1025.
36. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med*. 1997;126(5):376-380.
37. Higgins JPT GSe. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]*. The Cochrane Collaboration. Available from <http://handbook.cochrane.org>; 2011.

38. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg.* 2010;8(5):336-341.
39. Agency for Healthcare Research and Quality. U.S. Preventive Services Task Force Procedure Manual. 2008.
40. Ollendorf DA, Pearson SD. An Integrated Evidence Rating to Frame Comparative Effectiveness Assessments for Decision Makers. *Medical Care.* 2010;48(6):S145-S152.
41. Bird J, Spergel JMJSMRRAaAHWJLSALSSKEHV. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. *Journal of allergy and clinical immunology: in practice.* 2017;(no pagination).
42. Jones S, Sicherer SHBAWLDYLRWDPHAKBMCCDVB. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. *Journal of allergy and clinical immunology.* 2016;139(4):1242.
43. Sampson HA, Shreffler WG, Yang WH, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: a Randomized Clinical Trial. *Jama.* 2017;318(18):1798.
44. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. *Lancet (London, England).* 2014;383(9925):1297-1304.
45. Reier-Nilsen T, Michelsen MM, Lødrup Carlsen KC, et al. Feasibility of desensitising children with severe peanut allergy by OIT. *Allergy: European Journal of Allergy and Clinical Immunology.* 2017;72:141-142.
46. Wasserman RL, Factor JM, Baker JW, et al. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. *The journal of allergy and clinical immunology In practice.* 2014;2(1):91-96.
47. Wasserman RL, Hague AR, Pence DM, et al. Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. *The journal of allergy and clinical immunology In practice.* 2019;7(2):418-426 e414.
48. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet.* 2019;393(10187):2222-2232.
49. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. *Clinical and Experimental Allergy.* 2011;41(9):1273-1281.
50. Blumchen K, Trendelenburg V, Ahrens F, et al. Efficacy, safety and quality of life in a multi-center, randomized, placebo-controlled trial on peanut oral immunotherapy in peanut allergic children. Conference Abstract presented at Allergy: European Journal of Allergy and Clinical Immunology; 2017.
51. Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. *The Journal of allergy and clinical immunology.* 2010;126(1):83-91.e81.
52. Jones SM, Scurlock AM, Pons L, et al. Double-Blind, Placebo-Controlled (DBPC) trial of Oral Immunotherapy (OIT) in peanut allergic children. *Journal of Allergy and Clinical Immunology.* 2009;123(2):S211.
53. Narisety S, Frischmeyer-Guerrero PAKCAGMSJHRGWRA. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. *Journal of allergy and clinical immunology.* 2015;135(5):1275.

54. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. *The Journal of allergy and clinical immunology*. 2011;127(3):654-660.
55. Vickery B, Scurlock AM, KMSPHKJB, PBCHAC, SCLPTT. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. *Journal of allergy and clinical immunology*. 2014;133(2):468.
56. Rodriguez Del Rio P, Escudero C, Sanchez-Garcia S, Ibanez MD, Vickery BP. Evaluating primary end points in peanut immunotherapy clinical trials. *J Allergy Clin Immunol*. 2019;143(2):494-506.
57. Remington BC, Krone T, Koppelman SJ. Quantitative risk reduction through peanut immunotherapy: Safety benefits of an increased threshold in Europe. *Pediatr Allergy Immunol*. 2018;29(7):762-772.
58. Deschildre A, Elegbede CF, Just J, et al. Peanut-allergic patients in the MIRABEL survey: characteristics, allergists' dietary advice and lessons from real life. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2016;46(4):610-620.
59. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2012;15(6):812-820.
60. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. *Lancet*. 2014;383(9925):1297-1304.
61. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol*. 2003;14(5):378-382.
62. Walkner M, Warren C, Gupta RS. Quality of Life in Food Allergy Patients and Their Families. *Pediatric clinics of North America*. 2015;62(6):1453-1461.
63. Protudjer JL, Jansson SA, Heibert Arnlin M, et al. Household costs associated with objectively diagnosed allergy to staple foods in children and adolescents. *The journal of allergy and clinical immunology In practice*. 2015;3(1):68-75.
64. Baumert JL, Taylor SL, Koppelman SJ. Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy. *The journal of allergy and clinical immunology In practice*. 2018;6(2):457-465 e454.
65. Red Book Online Search. Truven Health Analytics; 2018. <http://www.micromedexsolutions.com>. Accessed January 15, 2018.
66. Centers for Medicare and Medicaid Services. *2019 Final Rule and Correction Notice Tables. Tables 1A-1E and Table 5*. 2019.
67. Shaker MS. An Economic Analysis of a Peanut Oral Immunotherapy Study in Children. *The journal of allergy and clinical immunology In practice*. 2017;5(6):1707-1716.
68. Orr S, Butt T, Longworth L. FSA Study on the Use of Quality Adjusted Life Years for Food Safety Risks (Phase 1). 2015; <https://old.food.gov.uk/sites/default/files/fs102087p1finrep.pdf>. Accessed 4/12/2019, 2019.
69. Cannon HE. The economic impact of peanut allergies. *The American journal of managed care*. 2018;24(19 Suppl):S428-s433.
70. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, team Ps. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. *Allergy*. 2018;73(3):560-568.
71. Otani IM, Begin P, Kearney C, et al. Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects. *Allergy Asthma Clin Immunol*. 2014;10(1):25.

72. Stensgaard A, Bindslev-Jensen C, Nielsen D, Munch M, DunnGalvin A. Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectives. *Clin Exp Allergy*. 2017;47(4):530-539.
73. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. *Medical decision making : an international journal of the Society for Medical Decision Making*. 2006;26(4):410-420.
74. Shaker M, Greenhawt M. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis. *JAMA network open*. 2019;2(5):e193242.
75. Shaker MS. An Economic Analysis of a Peanut Oral Immunotherapy Study in Children. *The journal of allergy and clinical immunology In practice*. 2017;5(6):1707-1716.
76. Shaker M, Greenhawt M. Association of Fatality Risk With Value-Based Drug Pricing of Epinephrine Autoinjectors for Children With Peanut Allergy: A Cost-effectiveness AnalysisPricing of Epinephrine Autoinjectors and Fatality Risk for Peanut AllergyPricing of Epinephrine Autoinjectors and Fatality Risk for Peanut Allergy. *JAMA network open*. 2018;1(7):e184728-e184728.
77. Shaker M, Kanaoka T, Feenan L, Greenhawt M. An economic evaluation of immediate vs non-immediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2019;122(1):79-85.
78. Pearson SD. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2018;21(3):258-265.
79. Nurmatov U, Venderbosch I, Devereux G, Simons FER, Sheikh A. Allergen-specific oral immunotherapy for peanut allergy. *Cochrane Database of Systematic Reviews*. 2012(9).
80. Aimmune. European Phase 3 Trial of Aimmune Therapeutics' AR101 Meets Primary Endpoint. *Biospace*. March 25, 2019.
81. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical TrialEffect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein in Children With Peanut AllergyEffect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein in Children With Peanut Allergy. *JAMA - Journal of the American Medical Association*. 2019.
82. Reier-Nilsen T, Michelsen MM, Lødrup Carlsen KC, et al. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy. *Allergy: European Journal of Allergy and Clinical Immunology*. 2018.
83. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. 2016;316(10):1093-1103.

APPENDICES

Appendix A. Search Strategies and Results

Table A1. PRISMA 2009 Checklist

	#	Checklist Item
TITLE		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT		
Structured Summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
INTRODUCTION		
Rationale	3	Describe the rationale for the review in the context of what is already known.
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
METHODS		
Protocol and Registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Eligibility Criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information Sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study Selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data Collection Process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data Items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.

Risk of Bias in Individual Studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary Measures	13	State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of Results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.
Risk of Bias Across Studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional Analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS		
Study Selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study Characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of Bias within Studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
Results of Individual Studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Synthesis of Results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Risk of Bias Across Studies	22	Present results of any assessment of risk of bias across studies (see Item 15).
Additional Analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
DISCUSSION		
Summary of Evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.
FUNDING		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

Search Strategies for Peanut Allergy

Table A2. Search Strategy of MEDLINE 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials


No.	Search Terms
#1	Exp peanut hypersensitivity/ or exp peanut allergy/
#2	(peanut* or groundnut* or arachis hypogaea).ti,ab.
#3	(allerg* or hypersen*).ti,ab.
#4	(peanut* and allerg*).ti,ab.
#5	(peanut-allerg* or peanut allerg* or peanut-hypersen* peanut hypersen* or groundnut-allerg* or groundnut-hypersen* or groundnut allerg* or groundnut hypersen* or arachis hypogaea allergy or legume-allerg* or legume-hypersen*).ti,ab.
#6	((peanut* adj2 allerg*) or (peanut* adj2 hypersen*) or (groundnut* adj2 allerg*) or (groundnut* adj2 hypersen*) or (legume* adj2 allerg*) or (legume* adj2 hypersen*)).ti,ab
#7	(viaskin or 'dbv712' or 'dbv 712' or 'dbv-712').ti,ab
#8	('ar101' or 'ar 101' or 'ar-101').ti,ab.
#9	('arc-101' or 'arc 101' or 'acr101').ti,ab.
#10	('viaskin peanut' or 'peanut patch' or 'peanut-patch').mp.
#11	exp immunotherapy/
#12	('oral immune tolerance' or 'oral tolerance').ti,ab.
#13	2 and 3
#14	1 or 13
#15	4 or 5 or 6 or 10
#16	7 or 8 or 9
#17	11 or 12
#18	14 and 17
#19	15 and 16
#20	18 or 19
#21	(clinical trial or clinical trial, phase I or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or multicenter study or randomized controlled trial).pt. or double-blind method/ or clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/ or early termination of clinical trials as topic/ or multicenter studies as topic/ or ((randomi?ed adj7 trial*) or (controlled adj3 trial*) or (clinical adj2 trial*) or ((single or doubl* or tripl* or treb*) and (blind* or mask*))).ti,ab,kw. or (4 arm or four arm).ti,ab,kw.
#22	cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or retrospective.ti,ab. or case-control studies/ or control groups/ or matched-pair analysis/ or retrospective studies/ or ((case* adj5 control*) or (case adj3 comparison*) or control group*).ti,ab,kw.
#23	21 or 22
#24	20 and 23
#25	(abstract or addresses or autobiography or bibliography or biography or clinical trial, phase I or comment or congresses or consensus development conference or duplicate publication or editorial or guideline or

	in vitro or interview or lecture or legal cases or legislation or letter or news or newspaper article or patient education handout or periodical index or personal narratives or portraits or practice guideline or review or video audio media).pt.
#26	24 not 25

Table A3. Search Strategy of EMBASE Search

No.	Search Term
#1	'peanut allergy' /exp
#2	'peanut' and (allerg* OR hypersens*)
#3	'oral immune tolerance' OR 'oit' OR 'oral tolerance' OR 'immune tolerance' OR 'immunological tolerance'
#4	'dvh712' OR 'dhv 712' OR 'dhv-712'
#5	'viaskin' OR 'viaskin peanut'
#6	'transdermal patch' OR 'viaskin peanut'
#7	'viaskin' AND 'patch'
#8	'ar-101' or 'ar 101' or 'ar101'
#9	'arc-101' OR 'arc 101' OR 'arc101'
#10	1 OR 2
#11	3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
#12	10 AND 11
#13	'chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'review'/it OR 'short survey'/it
#14	12 NOT 13

Figure A1. PRISMA flow Chart Showing Results of Literature Search for Viaskin Peanut, AR101, and Other OIT for Peanut Allergy



Appendix B. Previous Systematic Reviews and Technology Assessments

We identified two systematic reviews for the treatment of Peanut Allergy summarized below.

**Nurmatov, U., et al. (2012). “Allergen-Specific Oral Immunotherapy for Peanut Allergy.”
Cochrane Database for Systematic Reviews.⁷⁹**

Cochrane conducted a systematic review to evaluate the current treatments for peanut allergy. Only one trial matched their inclusion criteria and was summarized in the review. The US-based study, Varshney 2011, enrolled 28 children ages one to 16 years who had a clinical history of peanut allergy. Patients with a history of severe peanut anaphylaxis and moderate-to-severe persistent asthma were excluded from the study. Patients were randomized to receive either peanut flour (n=19) or oat flour placebo (n=9). Dosing began on day one with an escalation of 0.1 mg of peanut flour, doubled every 30 minutes until 6 mg was reached or the patient showed symptoms. Day two started at the dose reached during day one, and continued to be ingested daily in food, with dose escalation occurring every two weeks (50 to 100% increase until 75 mg dose, 25-33% increase until 400 mg maintenance dose). The primary endpoint, tolerating the maximum cumulative dose (5000 mg) in a double-blind, placebo-controlled food challenge, was achieved by 16 participants in the intervention arm and no participants in the placebo arm. Three of the 19 participants in the intervention arm withdrew from the study. Two participants failed the dose escalation phase and one additional patient withdrew due to gastrointestinal symptoms. Nine (47%) of the patients in the intervention arm experienced treatment-related adverse events during the initial day one escalation. At the end of study oral food challenge (OFC), one participant in the peanut flour arm showed upper respiratory symptoms and moderate urticaria. The reviewers note that the limited evidence based makes it difficult to inform care decisions, and with safety concerns there may be limited applicability of the evidence. The small trial size may also affect external validity and there was no evidence found on the management of treatment for peanut allergy in adults.

Note: The trial that met criteria for this Cochrane review, did not meet the inclusion trial for the ICER review because the age range included patients younger than those in the scope of the ICER review.

Chu, D.K., et al. (2019). “Oral Immunotherapy for Peanut Allergy (PACE): A Systematic Review and Meta-Analysis of Efficacy and Safety”⁴⁸

Investigators conducted a systematic review and meta-analysis to evaluate the efficacy and safety of treatments currently available for peanut allergy with main outcomes including anaphylaxis, allergic or adverse reactions, epinephrine use and quality of life. 12 RCTs (nine published and three unpublished) were included in their meta-analysis, with a total of 1041 patients enrolled and a median age across studies of 8.7 years (5.9-11.2) with a median follow-up of one year. Starting doses across trials varied with a median starting dose of 0.5mg daily and a median target dose of 2000 mg (376-4000). Across studies, patients took a median time of 31 weeks (25-51) to achieve the target maintenance dose. All studies required patients to strictly avoid peanut consumption other than what was required by the study. Nine trials (n=950) reported data on anaphylaxis with patients randomized to receive peanut OIT experiencing a large increase compared to patients on placebo or avoidance alone (RR 3.13; 95% CI: 1.76 to 5.55). Nine trials (n= 984) also reported on epinephrine use, where patients randomized to receive peanut OIT, again, saw a larger increase compared to patients with no OIT or avoidance alone (RR 2.21; 95% CI: 1.27 to 3.83). Peanut oral immunotherapy increased the risk of serious adverse events compared to no OIT, with all 12 trials (n=1041) reporting data on harms (RR 1.92; 95% CI: 1.00 to 3.66). Across five trials (n=719) there were three events of eosinophilic esophagitis, but this was too few to determine a treatment effect. Two placebo-controlled trials reported on quality of life data; however, oral immunotherapy did not improve quality of life in patients compared to no oral immunotherapy by any measure and there was no additional difference in quality of life scores between groups. Researchers concluded that current peanut oral immunotherapy treatments increase the chance and frequency of allergic reactions such as anaphylaxis, epinephrine use and serious adverse events. Any evidence of a benefit or harm was only visible after data was meta-analyzed for all studies and results were inconclusive when studies were analyzed alone.

Appendix C. Ongoing Studies

Title/Trial Sponsor	Study Design	Comparators	Patient Population	Primary Outcomes	Estimated Completion Date
AR101					
ARTEMIS Peanut Allergy in Children Aimmune Therapeutics, Inc. NCT03201003	Phase III, randomized, parallel assignment, quadruple masking <u>Study Duration:</u> 9-14 months <u>Estimated enrollment:</u> 175	<u>Intervention :</u> AR101	<u>Inclusions:</u> 4-17 years Clinical history of allergy to peanuts Serum SPT >3 mm greater than control Dose limiting symptoms at or before 444 mg peanut protein at the screening DBPCFC <u>Exclusions:</u> History of cardiovascular disease History of severe or life-threatening episode of anaphylaxis History of eosinophilic esophagitis History of mast cell disorder Any other condition that precludes participation for reasons of safety	<u>Primary Outcome</u> Efficacy of AR101: proportion of subjects who tolerate specified challenge doses with on AEs of mild severity at the exit DBPCFC.	Press Release Announcing results (March 2019) ⁸⁰

AR101 Real-World Open-Label Extension Study Aimmune Therapeutic, Inc. NCT03337542	Phase III, multicenter, open-label, long-term, safety extension, single group assessment <u>Study Duration:</u> 6 months <u>Estimated Enrollment:</u> 330	<u>Intervention:</u> AR101	<u>Inclusion Criteria</u> Received AR101 in study ARC007 Completed ARC007 study Use of effective birth control by sexually active female subjects of childbearing age <u>Exclusion Criteria</u> Developed a clinically significant change in health status during the ARC007 study Receiving prohibited medication or anticipated use of prohibited medication Currently in the buildup phase of immunotherapy for any nonfood allergen Currently participating in any other interventional clinical study outside of the ARC007 study that was just completed	<u>Primary Outcomes</u> Incidence of treatment-emergent adverse events including serious adverse events during the overall study period	April 2019
PALISADE Follow-On Study (ARC004) Aimmune Therapeutics, Inc. NCT02993107	Phase III, international, multicenter, open-label, 2 arm follow-on study <u>Study Duration:</u> 9-14 months <u>Estimated enrollment:</u> 500	<u>Intervention:</u> AR101	<u>Inclusion Criteria</u> Completion of the ARC003 study Written informed consent Effective birth control <u>Exclusion Criteria</u> Early discontinuation from the ARC003 trial Meets any longitudinally applicable ARC003 study exclusion criteria (Group 2 only) failure to tolerate >443 mg cumulative peanut protein with no or mild symptoms in ARC003 study exit DBPC	<u>Primary Outcomes</u> Incidence of adverse events including serious adverse events	December 2020
Study in Pediatric Subjects with Peanut Allergy to Evaluate the safety and Efficacy of	Phase II, randomized, parallel assignment,	<u>Arm 1:</u> Dupilumab + AR101 <u>Arm 2:</u>	<u>Inclusion Criteria</u> Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo	<u>Primary Outcomes</u> Change in cumulative tolerated dose of peanut protein	March 2021

Dupilumab as Adjunct to AR101 Sanofi Aimmune Therapeutics, Inc. NCT03682770	quadruple masking <u>Study Duration:</u> 28 weeks <u>Estimated enrollment :</u> 156	Placebo + AR101	Serum Immunoglobulin E (IgE) to peanut of ≥ 24 kUA/L and/or a skin prick test (SPT) to peanut ≥ 10 mm compared to a negative control Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study <u>Exclusion Criteria</u> History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock Asthma at time of enrollment Use of systemic corticosteroids within 2 months prior to screening	Proportion of participants treated with Dupilumab plus AR101 vs. placebo plus AR101 who reach the dose of AR101 Patients who “pass” DBPCFC Percent change in peanut specific IgE Proportion of participants experiences mild, moderate, or severe symptoms	
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization Aimmune Therapeutics, Inc. NCT03736447	Phase III, randomized, parallel alignment, triple masking <u>Study Duration:</u> <u>Estimated Enrollment:</u> 105	<u>Intervention:</u> AR101	<u>Inclusion Criteria</u> Aged 1 to <4 years at randomization Written informed consent Documented history of physician-diagnosed IgE mediated peanut allergy <u>Exclusion Criteria</u> History of severe or life-threatening anaphylaxis History of hemodynamically significant cardiovascular or renovascular disease Moderate or severe asthma Mild asthma that is uncontrolled	<u>Primary Outcomes</u> The proportion of subjects treated with AR101 compared with placebo who tolerate at least 600 mg single dose peanut protein with no more than mild allergy symptoms at the exit DBPCFC.	November 2021
Long-term Safety Study of AR101 in Subjects who Participated in a Prior AR101 study (ARC008)	Multicenter, open-label, long-term safety study <u>Study Duration:</u>	<u>Intervention:</u> AR101	<u>Inclusion Criteria</u> Prior participation in an Aimmune AR101 clinical study that identifies ARC008 a follow-on study option in the protocol Written informed consent	<u>Primary Outcome</u> The frequency of treatment-related adverse events and serious adverse	December 2021

Aimmune Therapeutics, Inc. NCT03292484	3 years <u>Estimated Enrollment</u> : 1100		Use of effective Birth control <u>Exclusion Criteria</u> Did not complete a minimum of 3 months of AR101 maintenance therapy if the subject was assigned to AR101 in the parent study Early discontinuing from the parent study Currently receiving or received within 5 years prior to screening any time of peanut or other food allergen immunotherapy.	events during the overall study period	
Viaskin Peanut					
Safety and Efficacy Study of Viaskin Peanut in Peanut-Allergic young children 1-3 years of age (EPITOPE) DBV Technologies NCT03211247	Phase 3, randomized, parallel assignment, triple masking <u>Study Duration</u> : 12 months <u>Estimated enrollment</u> : 331	<u>Arm 1</u> Viaskin Peanut 250 mcg <u>Arm 2</u> : Viaskin Peanut 100 mcg <u>Arm 3</u> : Placebo	<u>Inclusion Criteria</u> Male or female 1-3 years of age Physician-diagnosed peanut allergy Peanut specific IgE level >0.7 kU/L Positive peanut SPT with a largest wheel diameter ≥6mm Positive DBPCFC at ≤300 mg peanut protein <u>Exclusion Criteria</u> Uncontrolled asthma History of severe anaphylaxis to peanut Prior immunotherapy to any food or other immunotherapy Generalized severe dermatologic disease	Differences between the percentage of treatment responders in the selected active Viaskin Peanut group compared to the placebo group	May 30, 20202
Follow-up of the EPITOPE Study to Evaluate Long-Term Efficacy and Safety of DBV712 in Young Children (EPOPEX) DBV Technologies	Phase 3, single group, open-label <u>Study Duration</u> : 32 months	<u>Intervention</u> : DBV712 250 mcg	<u>Inclusion Criteria</u> Completion of the EPITOPE study <u>Exclusion Criteria</u> Generalized dermatologic disease Diagnosis of asthma that evolved to severe, unstable, or uncontrolled asthma	Proportion of subjects reaching an ED ≥1000 mg in 12, 24, and 36 months	June 2023

NCT03859700	<u>Estimated enrollment:</u> 330				
Follow-up of the PEPITES Study to Evaluate Long-Term Efficacy and Safety of Viaskin Peanut in Children (PEOPLE) DBV Technologies	Phase 3, single group, open-label <u>Study Duration:</u> 24 months <u>Estimated enrollment:</u> 300	<u>Intervention:</u> Viaskin Peanut 250 ug	<u>Inclusion Criteria</u> Subjects who completed the PEPITES study <u>Exclusion Criteria</u> Generalized dermatologic disease extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches Diagnosis of asthma that evolved to severe, unstable, or uncontrolled asthma	% of subjects originating from the active arm of PEPITES reaching an eliciting dose (ED) ≥ 1000 mg after 24 months of additional treatment in PEOPLE	February 2020
NCT03013517 Safety Study of Viaskin Peanut to Treat Peanut Allergy (REALISE) DBV Technologies	Phase 3, parallel assignment, triple masking <u>Study Duration:</u> 3 years <u>Estimated enrollment:</u> 393	<u>Arm 1:</u> Viaskin 250 mcg <u>Arm 2:</u> Placebo	<u>Inclusion Criteria</u> Physician-diagnosed peanut allergy A peanut skin prick test (SPT) with a wheal largest diameter ≥ 8 mm A peanut-specific immunoglobulin E (IgE) ≥ 12 kU/L Subjects follow a strict peanut-free diet <u>Exclusion Criteria</u> Generalized dermatologic disease Spirometry forced expiratory volume in second $< 80\%$ receiving beta-blocking agents, angiotensin-converting enzyme inhibitors etc. Prior or concomitant history of an immunotherapy to any food allergy	Adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	September 22, 2017 (Last Update posted: February 21, 2019)
Other					
The Grown-Up Peanut Immunotherapy Study (GUPI) Guy's and St. Thomas' NHS Foundation Trust	Phase 2, single arm, open-label <u>Study Duration:</u> 7-8 months	<u>Intervention:</u> Peanut oral immunotherapy - daily dose of peanut flour	<u>Inclusion Criteria</u> Adults aged 18-40 years A positive skin prick test to peanut abstract Elevated (>0.35) serum specific Immunoglobulin (IgE) to Ara h 2 major peanut allergen Positive DBPCFC to 30 mg or less of peanut protein	Tolerance of cumulative dose of 1.4 g peanut protein without reaction on DBPCFC post OIT after minimum of 1-	September 30, 2020

NCT03648320	<u>Estimated Enrollment:</u> 40		<p>Well controlled asthma</p> <p><u>Exclusion Criteria</u></p> <p>Anaphylaxis to food other than peanut</p> <p>History of life-threatening anaphylaxis or angioedema</p> <p>Asthmatic treated with higher than moderate dose of ICS</p> <p>Any asthmatic if uncontrolled or difficult to control</p> <p>Non-adherence with asthma treatment from general practitioner</p> <p>Participants who react to placebo during DBPCFC</p> <p>On-going use of beta-blockers</p> <p>Regular use of NSAIDs for a chronic condition</p>	month maintenance dosing on peanut OIT	
-----------------------------	------------------------------------	--	--	--	--

Source: www.ClinicalTrials.gov (NOTE: studies listed on site include both clinical trials and observational studies).

Appendix D. Comparative Clinical Effectiveness

Supplemental Information

We performed screening at both the abstract and full-text level. A single investigator screened all abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

We used criteria published by the US Preventive Services Task Force (USPSTF) to assess the quality of RCTs and comparative cohort studies, using the categories “good,” “fair,” or “poor” (see Appendix Table F2).³⁹ Guidance for quality ratings using these criteria is presented below, as is a description of any modifications we made to these ratings specific to the purposes of this review.

Good: *Meets all criteria: Comparable groups are assembled initially and maintained throughout the study; reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention is paid to confounders in analysis. In addition, intention to treat analysis is used for RCTs.*

Fair: *Studies were graded "fair" if any or all of the following problems occur, without the fatal flaws noted in the "poor" category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred with follow-up; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are addressed. Intention to treat analysis is done for RCTs.*

Poor: *Studies were graded "poor" if any of the following fatal flaws exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. For RCTs, intention to treat analysis is lacking.*

Note that case series are not considered under this rating system – because of the lack of comparator, these are generally considered to be of poor quality.

ICER Evidence Rating

We used the [ICER Evidence Rating Matrix](#) (see Figure D1) to evaluate the evidence for a variety of outcomes. The evidence rating reflects a joint judgment of two critical components:

- The **magnitude** of the difference between a therapeutic agent and its comparator in “net health benefit” – the balance between clinical benefits and risks and/or adverse effects AND
- The level of **certainty** in the best point estimate of net health benefit.⁴⁰

Figure D1. ICER Evidence Rating Matrix




Table D1. Study Quality Metrics

Quality										
Study	Comparable Groups	Adequate Randomization	Adequate Concealment	Patient Blinding	Physician Blinding	Outcome Adjudication Blinding	Non-Differential Follow-Up	ITT Analysis	Handling of Missing Data	Overall Quality
AR101/Aimmune										
Bird 2017	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Good
PALISADE 2018 ¹² (age 4-17)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
PALISADE 2018 ¹² Age 18-55	--	--	--	--	--	--	--	--	PALISADE 2018 Age 18-55	--
Viaskin Peanut/DBV Technologies										
Jones, 2016 ⁴²	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
Sampson, 2017 ⁴³	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
Fleischer 2019 ⁸¹ PEPITES	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
Other Oral Immunotherapy										
Anagnostou, 2014 ⁶⁰ STOP II	Yes	Yes	Yes	No	No	No	No	No	No	Poor
Reier-Nilsen, 2018 ⁸²	Yes	Yes	No	No	No	No	No	No	No	Poor

Supplemental Data

Table D2. Study Design

Author, Journal Year	Phase	Funding	Total Follow-Up (Weeks)	Primary Outcome	Inclusion Criteria (List Subgroups)	Exclusion Criteria
AR101/Aimmune						
Bird 2017 ⁴¹	2	Industry	6-9 months	The response rate, defined as the proportion of subjects who were able to successfully consume a single dose of ≥ 300 mg of peanut protein with no dose-limiting symptoms	Subjects aged 4-26 with a clinical history of peanut allergy and either serum peanut-specific IgE ≥ 0.35 kU/L or peanut skin prick test wheel diameter ≥ 3 mm	History of frequent or repeated, severe, or life-threatening anaphylaxis, gastrointestinal disease, or severe or uncontrolled asthma.
PALISADE, 2018 ¹² (age 4-17)	3	Industry	48-68 weeks	Proportion of participants 4 to 17 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms.	Peanut allergy age 4-17, serum IgE level at least 0.35 kUA per liter, mean wheal diameter at least 3 mm larger than negative control, allergic reaction to no more than 100 mg peanut protein	Clinical history of a severe anaphylactic reaction known or suspected to be caused by ingestion of peanut that required treatment with 2 or more administrations of epinephrine or hospitalization, moderate or severe asthma, poorly controlled asthma, diagnosis of other severe or complicating medical problems.
PALISADE, 2018 ¹² (age 18-55)	3	Industry	48-68 weeks	Proportion of participants 18 to 55 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms.	Peanut allergy age 18-55, serum IgE level at least 0.35 kUA per liter, mean wheal diameter at least 3 mm larger than negative control, allergic reaction to no more than 100 mg peanut protein	Clinical history of a severe anaphylactic reaction known or suspected to be caused by ingestion of peanut that required treatment with 2 or more administrations of epinephrine or hospitalization, moderate or severe asthma, poorly controlled asthma, diagnosis of other severe or complicating medical problems.

Author, Journal Year	Phase	Funding	Total Follow-Up (Weeks)	Primary Outcome	Inclusion Criteria (List Subgroups)	Exclusion Criteria
Viaskin Peanut/DBV Technologies						
Jones, 2016 ⁴²	2	NIH and DBV technologies	52 weeks	Proportion of participants with a successful outcome after 52 weeks defined as either passing a double-blind, placebo-controlled food challenge with 5044 mg of peanut protein at week 52 or by a 10-fold or greater increase in successfully consumed dose (SCD) of peanut protein compared with the baseline OFC.	Age 4-25 and physician diagnosed peanut allergy or convincing clinical history of peanut allergy and response to peanut (≥ 3 mm greater than control) or peanut specific IgE $> .35$ kU/l and positive baseline OFC result to a cumulative dose of 1044 mg or less of peanut protein	Severe anaphylaxis (previous hypotension, neurologic compromise or mechanical ventilation) to peanut; severe or poorly controlled atopic dermatitis or severe asthma (2017 NHLBI criteria steps 5 or 6; mild to moderate asthma that is uncontrolled or difficult to control (FEV1 $< 80\%$ predicted or FEV1/FVC $< 75\%$ with or without controller OR inhaled ICS > 500 mcg fluticasone or one asthma hospitalization in the past year or ER visit in past 6 months, steroids for more than a month in past year or burst within past 3 months OR inability to discontinue antihistamines OR other chronic disease
Sampson, 2017 ⁴³	2b	DBV technologies Industry	12 months (2-year open label extension)	Percentage of treatment responders (1000 mg or more initial dose at exit food challenge and/or 10-times or greater eliciting dose) after 12 months of therapy	Peanut allergy age 6-55; peanut skin prick test wheal 8 mm or greater; peanut specific IgE level > 0.7 Ku/L and eliciting dose of 300 mg or less of peanut protein	chronic disease, unstable asthma, and Severe anaphylaxis to peanut
Fleischer 2019 ⁸¹ PEPITES	3	DBV technologies Industry	12-month treatment + 2-week follow-up	Response (post-treatment eliciting dose of 300 mg or more or 1000 mg or more of peanut protein for low or high groups respectively) rate difference between active and placebo treatment groups after 12 months	Age 4-11 years with a physician diagnosis of peanut allergy or well documented medical history of IgE-mediated symptoms. Peanut specific IgE level > 0.7 kU/L	History of severe anaphylaxis to peanut with any of the following symptoms: hypotension, hypoxia, neurological compromise. Uncontrolled persistent asthma.

Author, Journal Year	Phase	Funding	Total Follow-Up (Weeks)	Primary Outcome	Inclusion Criteria (List Subgroups)	Exclusion Criteria
Other Oral Immunotherapy						
Anagnostou, 2014 ⁴⁴	2	Medical Research Council National Institute for Health Research	26 weeks	Proportion of desensitized (no reaction during peanut DBPCFC with cumulative dose of 1400 mg peanut protein) participants in each group at the end of the first phase	7-16 with immediate hypersensitivity reaction after peanut ingestion, positive skin prick test to peanuts and positive by double blind placebo-controlled food challenge	major chronic illness (except eczema, rhinitis, or asthma), care provider or present household member had suspected or diagnosed allergy to peanuts, unwillingness, or inability to comply with study procedures (those with severe asthma, tree nut allergy or previous life threatening reaction not excluded)
Reier-Nilsen, 2018 ⁸²	3	Foundations and Norwegian Health Authority	--	Feasibility of reaching MMD, defined as the proportion of children who reached the predefined MMD of 5000 mg peanut protein.	Age 5-15 with history of systemic reaction to peanut and or sensitization to peanut by a peanut skin prick test ≥ 3 mm or a peanut IgE ≥ 0.35 kUA/L	Uncontrolled asthma or severe chronic disease

Table D3. Baseline Characteristics

Author, Year	Intervention	N	Age, Mean (SD) or Median [IQR]	Male, n (%)	Median Size Average Wheal on Skin Prick Testing [IQR] (mm)	Median Level of Peanut Specific IGE kUA/liter	Median Maximum Tolerated Dose of Peanut Protein [OQR] mg	History of Peanut Anaphylaxis no (%)	Previous or Current Asthma no (%)	Multiple Food Allergies no (%)	Lost to Follow Up n (%)
AR101/Aimmune											
Bird 2017 ⁴¹	AR101	29	7 y (4-21)	20 (69)	14 (5-30)	63.4	13 (3-43)	15 (52)	12 (41)	7 (24) other food, drug	NR
	Placebo	26	8 y (4-14)	16 (62)	13 (5-26)	100.0	28 (3-43)	15 (56)	11 (41)	4 (15) other food, drug	NR
PALISADE, 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	--	208 (56%)	11 (9.0, 14.0)	69	10 mg (3-30)	72	53.8	64.6	21.00%
	placebo	124	--	76 (61%)	12 (9.0, 15.0)	75	10 mg (3-30)	72	55.8	65.2	7.30%
PALISADE, 2018 ¹² (Age 18-55)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	42	--	--	--	--	--	74.30%	--	--	9.50%
	placebo	14	--	--	--	--	--	72.50%	--	--	0%

Author, Year	Intervention	N	Age, Mean (SD) or Median [IQR]	Male, n (%)	Median Size Average Wheal on Skin Prick Testing [IQR] (mm)	Median Level of Peanut Specific IGE kUA/liter	Median Maximum Tolerated Dose of Peanut Protein [OQR] mg	History of Peanut Anaphylaxis no (%)	Previous or Current Asthma no (%)	Multiple Food Allergies no (%)	Lost to Follow Up n (%)
Viaskin/DBV Technologies											
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	8.4 (4.1, 16.6)	58%	11.8 (4.5,32)	84.6	44 mg	only severe excluded	16 (66.7%)	20 (80%)	0
	Epicutaneous peanut patch Peanut 250 mcg	25	7.7 (4.2,14.4)	64%	12.5 (6.0,25.5)	92.1	14 mg	NR	13 (52%)	21 (87.5%)	0
	placebo	25	8.5 (4.8, 20.3)	64%	13.5 (3,29.5)	58	44 mg	NR	12 (48%)	20 (80%)	1 (4%)
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg (daily for 12 months)	53	10 [8.0,16.0]	31 (58.5%)	12.0 [9.5, 15.0]	83	100 mg	0	NR	NR	0
	Epicutaneous peanut patch 100 mcg (daily for 12 months)	56	12 [10.0,17.0]	33 (58.9%)	11.6 [9.0,13.8]	66.1	100 mg	0	NR	NR	1
	Epicutaneous peanut patch 250 mcg (daily for 12 months)	56	11.5 [9.0, 16.0]	38 (67.9%)	12.0 [10.0, 13.3]	79.9	100 mg	0	NR	NR	0
	placebo (daily for 12 months)	56	11 [8.7, 14.0]	36 (64.3%)	11.0 [9.5, 13.3]	68.5	100 mg	0	NR	NR	0
PEPITES 2019 ⁸¹	Peanut Patch	238	7 (6,9)	149 (62.6)	NR	77.9 (20,192)	NR	NR	117 (49.2)	205 (86.1)	3

Author, Year	Intervention	N	Age, Mean (SD) or Median [IQR]	Male, n (%)	Median Size Average Wheal on Skin Prick Testing [IQR] (mm)	Median Level of Peanut Specific IGE kUA/liter	Median Maximum Tolerated Dose of Peanut Protein [OQR] mg	History of Peanut Anaphylaxis no (%)	Previous or Current Asthma no (%)	Multiple Food Allergies no (%)	Lost to Follow Up n (%)
	Placebo Patch	118	7 (5,9)	69 (58.5)	NR	101 (29.1, 232)	NR	NR	52 (44.1)	100 (84.7)	3
	Placebo	12	5.8	100%	7 (5.5,13)	57	NR	NR	78%	89%	0
Other OIT											
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	49	12.4 (2.2)	34 (69%) %	8.92 (3.02)	37.9	151.9	NR	29 (59%)	10 (20%)	0
	Placebo	50	11.9 (2.67)	36 (72%) %	8.43 (3.08)	41.6	99.8	NR	29 (58%)	13 (26%)	0
	Placebo SLOT/active ORIT up to 2000 mg peanut protein/day	11	11.1 (7.2,12.4)	64%	12 (7.5,19)	169	21 mg	6/11 (55%)	9/11 (82%)	10/11 (91%)	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	10.1 (5.2,15.2)	31 (54%)	9.8 (8.6, 11.0)	110.6	18.4 mg	79%	42%	47%	NR
	Observation	20	8.9 (5.1,13.3)	13 (65^))	9.3 (7.4, 11.7)	52.2	5 mg	90%	45%	58%	NR

Table D4. Outcomes I

Author, Year	Intervention	N	Timepoint	Proportion of Participants who Could Tolerate Challenge Dose of 600 mg or More	Proportion of Participants who Could Tolerate 1400 mg Peanut Protein	Proportion of Patients who Could Tolerate Challenge ≥10 Times Increase and or Reaching ≥1000 mg
AR101						
Bird 2017 ⁴¹	AR101	29	6-9 months	62% ITT, 78% completer	NR	NR
	Placebo	26	6-9 months	NR	NR	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg	372	24 weeks	67.2%	NR	50.3%
	placebo	124	24 weeks	4.0%	NR	2.4%
PALISADE 2018 ¹² (Age 18-55)	AR101 in escalating dose program to achieve 300 mg	42	24 weeks	41.5%	NR	NR
	placebo	14		14.3%	NR	NR
Viaskin /DBV Technologies						
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	25	12 months	NR	NR	NR
	placebo	25	12 months	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	NR	45.3
	Epicutaneous peanut patch 100 mcg	56		NR	NR	41.1
	Epicutaneous peanut patch 250 mcg	56		NR	NR	50.0
	placebo (daily for 12 months)	56		NR	NR	25
PEPITES 2019 ⁸¹	Peanut Patch	238	12 months	NR	NR	NR
	Placebo Patch	118		NR	NR	NR
	placebo	12	12 months	NR	NR	NR

Author, Year	Intervention	N	Timepoint	Proportion of Participants who Could Tolerate Challenge Dose of 600 mg or More	Proportion of Participants who Could Tolerate 1400 mg Peanut Protein	Proportion of Patients who Could Tolerate Challenge ≥ 10 Times Increase and or Reaching ≥ 1000 mg
Other OIT						
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to 800 mg daily	49	6 months	NR	62%	NR
	placebo	50		NR	0%	NR
	Placebo SLOT/active ORIT up to 2000 mg peanut protein/day	11		NR	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach MMD	NR	NR	NR
	Observation	20	time to reach MMC	NR	NR	NR

Table D5. Outcomes II

Author, Year	Intervention	N	Timepoint	Proportion of Patient Who Could Tolerate 5044 mg Peanut Challenge or ≥ 10 -fold Increase from Baseline	Proportion of Patients Who Could Tolerate Daily Ingestion of 800 mg Peanut Protein Up to 26 weeks	Proportion Who Could Tolerate Maximum Dose 10-Fold Increase Compared with Baseline	Proportion of Participants who Could Reach Max Maintenance Dose of 5000 mg
AR101							
Bird 2017 ⁴¹	AR101	29	6-9 months	NR	NR	NR	NR
	Placebo	26	6-9 months	NR	NR	NR	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day	372	24 weeks	NR	NR	NR	NR
	placebo	124		NR	NR	NR	NR
PALISADE 2018 ¹² (Age 18-55)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	42	24 weeks	NR	NR	NR	NR
	placebo	14	24 weeks	NR	NR	NR	NR
Viaskin/DBV Technologies							
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	46.00%	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	25		48%	NR	NR	NR
	placebo	25		12%	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	56		NR	NR	NR	NR
	placebo	56		NR	NR	NR	NR
	Peanut Patch	238	12 months	NR	NR	NR	NR

Author, Year	Intervention	N	Timepoint	Proportion of Patient Who Could Tolerate 5044 mg Peanut Challenge or ≥10-fold Increase from Baseline	Proportion of Patients Who Could Tolerate Daily Ingestion of 800 mg Peanut Protein Up to 26 weeks	Proportion Who Could Tolerate Maximum Dose 10-Fold Increase Compared with Baseline	Proportion of Participants who Could Reach Max Maintenance Dose of 5000 mg
PEPITES, 2019 ⁸¹	Placebo Patch	118		NR	NR	NR	NR
Other OIT							
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	49	6 months	NR	84%	NR	NR
	placebo	50	6 months	NR	0%	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach MMD	NR	NR	NR	21%
	Observation	20	time to reach MMC	NR	NR	NR	NA

Table D6. Outcomes III

Author, Year	Intervention	N	Timepoint	Percentage Reaching an Individual Maintenance Dose	Median Dose of Peanut Protein Ingested at End of Study	Maximum Severity of Symptoms during Exit Challenge Moderate (%)	Maximum Severity of Symptoms During Exit Challenge Severe (%)	Peanut Specific IgE
AR101								
Bird 2017 ⁴¹	AR101	29	6-9 months	23/29 (79)	218.15 (5.895)	3 (13) mild	NR	NR
	Placebo	26	6-9 months	5/26 (19)	32.30 (5.674)	≥1	10 (38)	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	24 weeks	NR	NR	25%	5%	NR
	placebo	124		NR	NR	59%	11%	NR
PALISADE 2018 ¹² (Age 18-55)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	42	24 weeks	NR	NR	NR	NR	NR
	placebo	14		NR	NR	NR	NR	NR
Viaskin /DBV Technologies								
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	144mg	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	25		NR	144mg	NR	NR	NR
	placebo	25		NR	14 mg	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	244 mg	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	444 mg	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	56		NR	444 mg	NR	NR	NR
	placebo	56		NR	144 mg	NR	NR	NR
PEPITES, 2019 ⁸¹	Peanut Patch	238	12 months	62.6		NR	NR	

Author, Year	Intervention	N	Timepoint	Percentage Reaching an Individual Maintenance Dose	Median Dose of Peanut Protein Ingested at End of Study	Maximum Severity of Symptoms during Exit Challenge Moderate (%)	Maximum Severity of Symptoms During Exit Challenge Severe (%)	Peanut Specific IgE
	Placebo Patch	118		28	297 mg (44, 444) median cumulative reactive dose difference	NR	NR	
Other OIT								
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	49	6 months	NR	1400 mg (ag 6 months)	NR	NR	NR
	placebo	50	6 months	NR	5 mg (at 6 months)	NR	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach MMD	NR	NR	NR	NR	NR
	Observation	20	time to reach MMC	NR	NR	NR	NR	NR

Table D7. Safety I

Author, Year	N	Timepoint (Months)	ANY AE (%)	AE Mild (%)	AE Moderate (%)	AE Severe (%)
AR101						
Bird 2017 ⁴¹	29	6-9 months	28 (96.6)	96%	4%	NR
	26		22 (84.6)	94%	6%	NR
PALISADE 2018 ¹² (Age 4-17)	372	24 weeks	98.7%	34.7%	59.7%	4.3%
	124		95.2%	50.0%	44.4%	0.8%
PALISADE 2018 ¹² (Age 18-55)	--	--	--	--	--	--
Viaskin/DBV Technologies						
Jones, 2016 ⁴²	24	12 months	68%	68%	0	0
	24		80%	72%	4%	0
	25		24%	36%	0	0
Sampson, 2017 ⁴³	53	12 months	96.2%	NR	NR	3.8
	56		94.6%	NR	NR	17.9
	56		96.4%	NR	NR	14.3
	56		48.2%	NR	NR	7.1
PEPITES, 2019 ⁸¹	238	12 months	227 (95.4)	220 (92.4)	127 (53.4)	14 (5.9)
	118		105 (89)	97 (82.2)	53 (44.9)	2 (1.7)
Other OIT						
Anagnostou, 2014 ⁶⁰	39	6 months	68%	68%	0	0
	46		80%	72%	4%	0
Reier-Nilsen, 2018 ⁸²	57	time to reach max dose	time to reach max dose	98%	98.2%	38.6%
	20	NR	NR	n/a	NR	NR

Table D8. Safety II

Author, Year	Intervention	N	Timepoint (Months)	All-Cause Discontinuation, n (%)	AE Leading to Discontinuation, n (%)	Systemic Allergic Reaction (%)	Epinephrine Administered During Trial (%)	GI Symptom Related Withdrawal	Mild Treatment Emergent AE During Initial Escalation
AR101									
Bird 2017 ⁴¹	AR101	29	6-9 months	27 (93)	6 (NR)	26 (90) immune system	4 (screening); 2 (9) exit	66% (GI symptoms)	NR
	Placebo	26		12 (46)	0 (0)	10 (38) immune system	4 (screening), 11 (42) exit	27% (GI symptoms)	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	24 weeks	NR	11.6%	14.2%	14.0%	6.5%	45.7%
	placebo	124			2.4%	3.2%	6.5%	1.6%	26.8%
PALISADE 2018 ¹² (Age 18-55)	--	--	--	--	--	--	--	--	--
Viaskin/DBV Technologies									
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	13%	NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	24		NR	0%	NR	NR	NR	NR
	Placebo	25		NR	8%	NR	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	0%	2/53 (4%)	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	1.8%	0	NR	NR	NR

Author, Year	Intervention	N	Timepoint (Months)	All-Cause Discontinuation, n (%)	AE Leading to Discontinuation, n (%)	Systemic Allergic Reaction (%)	Epinephrine Administered During Trial (%)	GI Symptom Related Withdrawal	Mild Treatment Emergent AE During Initial Escalation
	Epicutaneous peanut patch 250 mcg	56		NR	0%	1/56 (2%)	NR	NR	NR
	placebo	56		NR	0	0	NR	NR	NR
PEPITES, 2019 ⁸¹	Peanut Patch	238	12 months	10.5%	4 (1.7)	NR	22 (9.2)	NR	NR
	Placebo Patch	118		9.3%	0 (0)	NR	4 (3.4)	NR	NR
Other OIT									
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	39	6 months	NR	13%	NR	NR	NR	NR
	placebo	46		NR	0%	NR		NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach max dose	24.5%	14/57 (25%)	6 (10.5%)	24.5%	NR	NR
	Observation	20		NR	NR	NR	NR	NR	NR

Table D9. Safety III

Author, Year	Intervention	N	Timepoint (Months)	Mild Treatment Related AE During Up-Dosing	Mild Treatment Related AE During Maintenance	Moderate Treatment Emergent AE During Initial Escalation	Moderate Treatment Related AE During Updosing
AR101							
Bird 2017 ⁴¹	AR101	29	6-9 months	NR	NR	NR	NR
	Placebo	26	6-9 months	NR	NR	NR	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	24 weeks	40.2%	51.9%	5.1%	53.8%
	placebo	124		56.1%	48/3%	2.4%	30.9%
PALISADE 2018 ¹² (Age 18-55)	--	--	--	--	--	--	--
Viaskin/DBV Technologies							
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	24		NR	NR	NR	NR
	Placebo	25		NR	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	56		NR	NR	NR	NR
	placebo	56		NR	NR	NR	NR
PEPITES, 2019 ⁸¹	Peanut Patch	238	12 months	NR	NR	NR	NR
	Placebo Patch	118		NR	NR	NR	NR

Author, Year	Intervention	N	Timepoint (Months)	Mild Treatment Related AE During Up-Dosing	Mild Treatment Related AE During Maintenance	Moderate Treatment Emergent AE During Initial Escalation	Moderate Treatment Related AE During Updosing
Other OIT							
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	39	6 months	NR	NR	NR	NR
	placebo	46		NR	NR	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach max dose	NR	NR	NR	NR
	Observation	20		NR	NR	NR	NR

Table D10. Safety IV

Author, Year	Intervention	N	Timepoint (Months)	Moderate Treatment Related AE During Maintenance	Treatment Emergent Severe AE During Initial Escalation	Treatment Related Severe AE During Up-Dosing	Treatment Related Severe AE During Up-Dosing
AR101							
Bird 2017 ⁴¹	AR101	29	6-9 months	NR	NR	NR	NR
	Placebo	26	6-9 months	NR	NR	NR	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	24 weeks	32.6%	0%	2.5%	2.6%
	placebo	124	24 weeks	31.4%	0%	0.8%	0%
PALISADE 2018 ¹² (Age 18-55)	--	--	--	--	--	--	--
Viaskin/DBV Technologies							
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	24		NR	NR	NR	NR
	Placebo	25		NR	NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	56		NR	NR	NR	NR
	placebo	56		NR	NR	NR	NR
PEPITES, 2019 ⁸¹	Peanut Patch	238	12 months	NR	NR	NR	NR
	Placebo	118		NR	NR	NR	NR

Author, Year	Intervention	N	Timepoint (Months)	Moderate Treatment Related AE During Maintenance	Treatment Emergent Severe AE During Initial Escalation	Treatment Related Severe AE During Up-Dosing	Treatment Related Severe AE During Up-Dosing
Other OIT							
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	39	6 months	NR	NR	NR	NR
	placebo	46		NR	NR	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach max dose	NR	NR	NR	NR
	Observation	20	--	NR	NR	NR	NR

Table D11. Safety V

Author, Year	Intervention	N	Timepoint (Months)	Treatment Related AE During Initial Day Escalation	Treatment Related AE During Build Up Doses	Treatment Related AE During Maintenance
AR101						
Bird 2017 ⁴¹	AR101	29	6-9 months	NR	NR	NR
	Placebo	26	6-9 months	NR	NR	NR
PALISADE 2018 ¹² (Age 4-17)	AR101 in escalating dose program to achieve 300 mg per day for 24 weeks	372	24 weeks	NR	NR	NR
	placebo	124		NR	NR	NR
PALISADE 2018 ¹² (Age 18-55)	--	--	--	NR	NR	NR
Viaskin/DBV Technologies						
Jones, 2016 ⁴²	Epicutaneous peanut patch 100 mcg	24	12 months	NR	NR	NR
	Epicutaneous peanut patch 250 mcg	24		NR	NR	NR
	Placebo	25		NR	NR	NR
Sampson, 2017 ⁴³	Epicutaneous peanut patch 50 mcg	53	12 months	NR	NR	NR
	Epicutaneous peanut patch 100 mcg	56		NR	NR	NR
	Epicutaneous peanut patch 250 mcg	56		NR	NR	NR
	placebo	56		NR	NR	NR
PEPITES, 2019 ⁸¹	Peanut Patch	238	12 months	NR	NR	NR
	Placebo Patch	118		NR	NR	NR
Other OIT						
Anagnostou, 2014 ⁶⁰	oral immunotherapy in up dosing phase to achieve 800 mg daily	39	6 months	NR	NR	NR
	placebo	46	6 months	NR	NR	NR
Reier-Nilsen, 2018 ⁸²	OIT with biweekly step up to goal of 5000 mg	57	time to reach max dose	NR	NR	NR
	Observation	20	--	NR	NR	NR

Appendix E. Comparative Value Supplemental Information

Table E1. Impact Inventory

Sector	Type of Impact (Add Additional Domains, as Relevant)	Included in This Analysis from... Perspective?	
		Health Care Sector	Societal
Health Outcomes	Longevity effects	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Health-related quality of life effects	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Adverse events	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Medical Costs	Paid by third-party payers	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	Paid by patients out-of-pocket	NA	<input checked="" type="checkbox"/>
	Future related medical costs	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	Future unrelated medical costs	<input type="checkbox"/>	<input type="checkbox"/>
Health-Related Costs	Patient time costs	NA	<input type="checkbox"/>
	Unpaid caregiver-time costs	NA	<input checked="" type="checkbox"/>
	Transportation costs	NA	<input type="checkbox"/>
Productivity	Labor market earnings lost	NA	<input checked="" type="checkbox"/>
	Cost of unpaid lost productivity due to illness	NA	<input checked="" type="checkbox"/>
	Cost of uncompensated household production	NA	<input type="checkbox"/>
Consumption	Future consumption unrelated to health	NA	<input type="checkbox"/>
Social Services	Cost of social services as part of intervention	NA	<input type="checkbox"/>
Legal/Criminal Justice	Number of crimes related to intervention	NA	<input type="checkbox"/>
	Cost of crimes related to intervention	NA	<input type="checkbox"/>
Education	Impact of intervention on educational achievement of population	NA	<input type="checkbox"/>
Housing	Cost of home improvements, remediation	NA	<input type="checkbox"/>
Environment	Production of toxic waste pollution by intervention	NA	<input type="checkbox"/>
Other	Other impacts (if relevant)	NA	<input type="checkbox"/>

NA: not applicable

Adapted from Sanders et al.⁸³

Table E2. Cost per QALY Gained for AR101 (Placeholder Cost) versus Avoidance Alone Over a Range of Time Horizons

Time Horizon	Treatment	Total Cost	QALYs	ICER (QALYs)
1 year	AR101	\$6,000	0.83	\$6,810,000
	Avoidance Alone	\$1,000	0.83	
	Incremental	\$5,000	0.00	
3 years	AR101	\$11,000	2.46	\$142,000
	Avoidance Alone	\$1,000	2.39	
	Incremental	\$10,000	0.07	
5 years	AR101	\$16,000	4.07	\$112,000
	Avoidance Alone	\$2,000	3.93	
	Incremental	\$15,000	0.13	
10 years	AR101	\$28,000	7.81	\$98,000
	Avoidance Alone	\$3,000	7.56	
	Incremental	\$25,000	0.26	
20 years	AR101	\$44,000	13.83	\$91,000
	Avoidance Alone	\$4,000	13.39	
	Incremental	\$40,000	0.44	
50 years	AR101	\$67,000	23.91	\$88,000
	Avoidance Alone	\$6,000	23.22	
	Incremental	\$61,000	0.69	

Table E3. Cost per QALY Gained for Viaskin Peanut (Placeholder Cost) versus Avoidance Alone Over a Range of Time Horizons

Time Horizon	Treatment	Total Cost	QALYs	ICER (QALYs)
1 year	Viaskin Peanut	\$7,000	0.83	\$25,410,000
	Avoidance Alone	\$1,000	0.83	
	Incremental	\$6,000	0.00	
3 years	Viaskin Peanut	\$12,000	2.43	\$429,000
	Avoidance Alone	\$1,000	2.40	
	Incremental	\$10,000	0.02	
5 years	Viaskin Peanut	\$16,000	4.00	\$315,000
	Avoidance Alone	\$2,000	3.95	
	Incremental	\$14,000	0.05	
10 years	Viaskin Peanut	\$25,000	7.68	\$257,000
	Avoidance Alone	\$3,000	7.60	
	Incremental	\$23,000	0.09	
20 years	Viaskin Peanut	\$39,000	13.61	\$231,000
	Avoidance Alone	\$4,000	13.46	
	Incremental	\$35,000	0.15	
50 years	Viaskin Peanut	\$58,000	23.56	\$218,000
	Avoidance Alone	\$6,000	23.32	
	Incremental	\$52,000	0.24	

Table E4. Cost per QALY Gained for AR101 (Placeholder Cost) versus Avoidance Alone Over a Range of Patient Starting Ages

Time Horizon	Treatment	Total Cost	QALYs	ICER (QALYs)
Age 1	AR101	\$73,000	27.58	\$90,000
	Avoidance Alone	\$6,000	26.80	
	Incremental	\$67,000	0.78	
Age 5	AR101	\$73,000	27.33	\$87,000
	Avoidance Alone	\$6,000	26.57	
	Incremental	\$66,000	0.76	
Age 7 (Base Case)	AR101	\$72,000	27.19	\$88,000
	Avoidance Alone	\$6,000	26.44	
	Incremental	\$66,000	0.75	
Age 12	AR101	\$71,000	26.74	\$89,000
	Avoidance Alone	\$6,000	26.01	
	Incremental	\$65,000	0.73	
Age 20	AR101	\$69,000	25.45	\$89,000
	Avoidance Alone	\$6,000	24.75	
	Incremental	\$63,000	0.70	
Age 25	AR101	\$67,000	24.55	\$89,000
	Avoidance Alone	\$6,000	23.86	
	Incremental	\$61,000	0.69	

Table E5. Cost per QALY Gained for Viaskin Peanut (Placeholder Cost) versus Avoidance Alone Over a Range of Patient Starting Ages

Time Horizon	Treatment	Total Cost	QALYs	ICER (QALYs)
Age 1	Viaskin Peanut	\$63,000	27.19	\$210,000
	Avoidance Alone	\$6,000	26.92	
	Incremental	\$57,000	0.27	
Age 5	Viaskin Peanut	\$62,000	26.95	\$214,000
	Avoidance Alone	\$6,000	26.68	
	Incremental	\$56,000	0.26	
Age 7 (Base Case)	Viaskin Peanut	\$62,000	26.81	\$216,000
	Avoidance Alone	\$6,000	26.55	
	Incremental	\$56,000	0.26	
Age 12	Viaskin Peanut	\$61,000	26.37	\$220,000
	Avoidance Alone	\$6,000	26.12	
	Incremental	\$55,000	0.25	
Age 20	Viaskin Peanut	\$59,000	25.10	\$220,000
	Avoidance Alone	\$6,000	24.86	
	Incremental	\$53,000	0.24	
Age 25	Viaskin Peanut	\$58,000	24.20	\$221,000
	Avoidance Alone	\$6,000	23.97	
	Incremental	\$52,000	0.24	

Table E6. Results of Probabilistic Sensitivity Analysis, AR101 (Placeholder Price) versus Avoidance Alone

AR101 Outcomes	PSA Mean	Credible Range	Avoidance Alone Outcomes	PSA Mean	Credible Range	Incremental Outcomes	PSA Mean	Credible Range
						ICER	\$96,419	(\$52,198 - \$194,932)
Total Costs	\$72,084	(\$56,300 - \$88,926)	Total Costs	\$6,285	(\$5,435 - \$7,140)	Incremental Costs	\$65,799	(\$50,040 - \$82,611)
Treatment	\$64,703	(\$48,959 - \$81,430)	Treatment	--	--	Treatment	\$64,703	(\$48,959 - \$81,430)
Healthcare	\$7,179	(\$6,120 - \$8,279)	Healthcare	\$5,997	(\$5,148 - \$6,848)	Healthcare	\$1,182	(\$857 - \$1,564)
Serious AEs	\$87	(\$42 - \$161)	Serious AEs	\$86	(\$59 - \$120)	Serious AEs	\$1	(\$-48 - \$76)
Epi Use	\$115	(\$79 - \$160)	Epi Use	\$202	(\$140 - \$276)	Epi Use	-\$87	(\$-139 - -\$45)
Total QALYs	27.20	(26.80 - 27.59)	Total QALYs	26.44	(25.98 - 26.84)	Incremental QALYs	0.77	(0.33 - 1.25)
On Treatment or Placebo	0.68	(0.66 - 0.70)	On Treatment or Placebo	0.78	(0.76 - 0.81)	On Treatment or Placebo	-0.10	(-0.11 - -0.09)
Untreated Peanut Sensitive	6.54	(4.62 - 8.71)	Untreated Peanut Sensitive	18.79	(17.61 - 19.93)	Untreated Peanut Sensitive	-12.25	(-14.19 - -10.16)
Peanut Desensitized	13.96	(11.63 - 16.26)	Peanut Desensitized	0.85	(0.27 - 1.72)	Peanut Desensitized	13.12	(10.89 - 15.25)
Peanut Tolerant	6.02	(5.08 - 7.00)	Peanut Tolerant	6.02	(5.08 - 7.00)	Peanut Tolerant	0.00	(0.00 - 0.03)
Epi Use & AEs	0.00	(0.00 - 0.00)	Epi Use & AEs	0.00	(-0.01 - 0.00)	Epi Use & AEs	0.00	(0.00 - 0.00)
Societal	0.00	(0.00 - 0.00)	Societal	0.00	(0.00 - 0.00)	Societal	0.00	(0.00 - 0.00)
Total Life Years	28.71	(28.69 - 28.85)	Total Life Years	28.69	(28.69 - 28.69)	Incremental Life Years	0.02	(0.00 - 0.15)

Figure E1. Results of Probabilistic Sensitivity Analysis: Cost-Effectiveness Acceptability Curve for AR101 (Placeholder Price) versus Avoidance Alone





Table E7. Results of Probabilistic Sensitivity Analysis, Viaskin Peanut (Placeholder Price) versus Avoidance Alone

Viaskin Peanut Outcomes	PSA Mean	Credible Range	Avoidance Alone Outcomes	PSA Mean	Credible Range	Incremental Outcomes	PSA Mean	Credible Range
						ICER	\$238,750	(\$125,594 - \$490,721)
Total Costs	\$60,659	(\$44,408 - \$80,950)	Total Costs	\$6,250	(\$5,405 - \$7,100)	Incremental Costs	\$54,409	(\$38,215 - \$74,613)
Treatment	\$54,463	(\$38,233 - \$74,679)	Treatment	--	--	Treatment	\$54,463	(\$38,233 - \$74,679)
Healthcare	\$5,986	(\$5,137 - \$6,838)	Healthcare	\$5,991	(\$5,142 - \$6,842)	Healthcare	-\$5	(-\$5 - -\$4)
Serious AEs	\$60	(\$40 - \$87)	Serious AEs	\$79	(\$54 - \$111)	Serious AEs	-\$18	(-\$30 - -\$10)
Epi Use	\$150	(\$103 - \$210)	Epi Use	\$181	(\$124 - \$249)	Epi Use	-\$30	(-\$56 - -\$11)
Total QALYs	26.80	(26.41 - 27.13)	Total QALYs	26.54	(26.11 - 26.91)	Incremental QALYs	0.26	(0.10 - 0.46)
On Treatment or Placebo	0.77	(0.75 - 0.79)	On Treatment or Placebo	0.78	(0.76 - 0.80)	On Treatment or Placebo	-0.01	(-0.01 - -0.01)
Untreated Peanut Sensitive	12.89	(10.64 - 14.95)	Untreated Peanut Sensitive	17.14	(15.67 - 18.49)	Untreated Peanut Sensitive	-4.25	(-6.03 - -2.64)
Peanut Desensitized	7.12	(5.09 - 9.42)	Peanut Desensitized	2.60	(1.53 - 3.94)	Peanut Desensitized	4.51	(2.81 - 6.43)
Peanut Tolerant	6.02	(5.08 - 7.00)	Peanut Tolerant	6.02	(5.08 - 7.00)	Peanut Tolerant	0.00	(0.00 - 0.00)
Epi Use & AEs	0.00	(-0.01 - 0.00)	Epi Use & AEs	0.00	(-0.01 - 0.00)	Epi Use & AEs	0.00	(0.00 - 0.00)
Societal	0.00	(0.00 - 0.00)	Societal	0.00	(0.00 - 0.00)	Societal	0.00	(0.00 - 0.00)
Total Life Years	28.69	(28.69 - 28.69)	Total Life Years	28.69	(28.69 - 28.69)	Incremental Life Years	0.00	(0.00 - 0.00)

Figure E2. Results of Probabilistic Sensitivity Analysis: Cost-Effectiveness Acceptability Curve for Viaskin Peanut (Placeholder Price) versus Avoidance Alone



Scenario Analysis: PALISADE Secondary Outcomes (for 300 mg, 1000 mg)

These two secondary outcome scenarios involved using alternative definitions for the health state transition probabilities. However, we did not assume any incremental quality of life benefit between people who passed food challenges at different levels. Therefore, the same utility value was used for the desensitized health state across both scenarios. We based this assumption on the quantitative risk reduction literature, which indicated minimal difference in relative risk beyond 300mg.

The scenario using the proportion of patients who tolerated an exposure to 300 mg of peanut protein results in slightly more people being classified as desensitized at one year. The impact of this scenario is that more patients continue treatment throughout the time horizon. Thus, this scenario results in slightly more incremental QALYs relative to the base case, and more treatment costs at each threshold price.

Table E8. PALISADE Secondary Outcome Scenario: 300 mg Using Placeholder Price¹²

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$73,000	\$81,000	27.30	28.69	\$91,000
Avoidance Alone	\$0	\$6,000	26.49	28.69	
Incremental	\$73,000	\$74,000	0.82	0.00	

The scenario using the proportion of patients who tolerated an exposure to 1000 mg of peanut protein results in fewer people being classified as desensitized at one year. The impact of this scenario is fewer patients being treated, so lower overall costs for AR101 and a 24% decrease in incremental QALYs relative to the base case at each threshold.

Table E9. PALISADE Secondary Outcome Scenario: 1000 mg Using Placeholder Price¹²

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$49,000	\$57,000	26.99	28.69	\$89,000
Avoidance Alone	\$0	\$6,000	26.42	28.69	
Incremental	\$49,000	\$50,000	0.57	0.00	

Scenario Analysis: Range of 50% Increase/Decrease in Rate of Epinephrine Use in Year 2+

We explored scenarios evaluating a range of increased and decreased rates of epinephrine use relative to the base case. These scenarios did not influence the model results in an appreciable

way. As expected, total costs decreased slightly in the scenarios with decreased epinephrine use and increased slightly in the scenarios with increased epinephrine use.

Table E10. 50% Decrease in Epinephrine Use in Years 2+: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$72,000	27.19	28.69	\$88,000
Avoidance Alone	\$0	\$6,000	26.44	28.69	
Incremental	\$65,000	\$66,000	0.75	0.00	

Table E11. 50% Decrease in Epinephrine Use in Years 2+: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$62,000	26.81	28.69	\$217,000
Avoidance Alone	\$0	\$6,000	26.55	28.69	
Incremental	\$56,000	\$56,000	0.26	0.00	

Table E12. 50% Increase in Epinephrine Use in Years 2+: AR101 versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
AR101	\$65,000	\$72,000	27.19	28.69	\$87,000
Avoidance Alone	\$0	\$6,000	26.44	28.69	
Incremental	\$65,000	\$66,000	0.75	0.00	

Table E13. 50% Increase in Epinephrine Use in Years 2+: Viaskin Peanut versus Avoidance Alone Using Placeholder Price

Treatment	Immunotherapy Cost	Total Cost	QALYs	Life Years	Incremental Cost per QALY
Viaskin Peanut	\$56,000	\$62,000	26.81	28.69	\$216,000
Avoidance Alone	\$0	\$6,000	26.55	28.69	
Incremental	\$56,000	\$56,000	0.26	0.00	

Appendix F. Public Comments

This section includes summaries of the public comments prepared for the CTAF Public Meeting on June 11, 2019. These summaries were prepared by those who delivered the public comments at the meeting and are presented in alphabetical order.

A video recording of all comments can be found [here](#), beginning at 1:32:05. Conflict of interest disclosures are included at the bottom of each statement for each speaker.

Charmayne Anderson, MPA, Allergy & Asthma Network

Director of Advocacy

Allergy & Asthma Network is a national nonprofit dedicated to ending needless death and suffering due to asthma, allergies, and related conditions. Since 1985, we have worked to build patient-centered, collaborative care teams throughout the United States to serve the 60+ million Americans living with these conditions, including the three to four million Americans living with peanut allergy.

Patients with severe life-threatening peanut allergies live in constant fear of accidental exposure. These are real people with families, hopes, dreams and fears. Allie is a 34-year-old with multiple food allergies including peanut and is hypervigilant at every meal so that she can avoid a life-threatening reaction; however, each year she averages at least two to three accidental exposures resulting in a reaction. Elijah was a three-year-old who died from a severe allergy to dairy due to an accidental exposure at his preschool. Karson is a 14-year-old living with a constant level of fear and anxiety that her next bite of pizza may be the one to land her in the ER, or that her friends may have to administer epinephrine simply to save her life.

ICER states that peanut allergy immunotherapy would result in a “small net benefit,” but patients would beg to differ. We implore ICER to reconsider its value framework. ICER’s process should capture not only the payer, but also the true societal perspective more effectively. Patients are depending on ICER to ensure this innovation actually reaches the community it can help the most.

<i>Allergy & Asthma Network has accepted contributions from DBV Technologies and Aimmune Therapeutics for unbranded disease education and awareness in 2018-2019.</i>
--

Todd Green, MD, DBV Technologies

Vice President of Medical Affairs

At DBV, we are committed to finding treatments that will help solve the urgent unmet medical need of those suffering from food allergies, including to peanut; our mission is to improve the lives of those patients and their caregivers.

DBV recognizes the importance of highlighting all innovations that potentially reduce peanut allergy care disparities. ICER acknowledges the distinct approach of Viaskin Peanut (VP) Epicutaneous Immunotherapy (EPIT), which leverages the unique immunologic properties of the skin. Through this approach, EPIT may offer patients effective treatment with low risk of significant adverse events.

DBV disagrees with ICER's basing its VP clinical rating on the recent Chu et al OIT review in Lancet which stated, "In patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo." Importantly, this review assesses OIT, whereas EPIT evidence is not considered. Moreover, the accompanying Lancet commentary states, "EPIT has a better safety profile than oral immunotherapy, which some patients might find more acceptable."

Further, ICER uses analogs and estimates of food allergy patient utility/disutility to inform its cost effectiveness model, with findings that should be interpreted with caution. The cost effectiveness of VP can only be meaningfully assessed after peanut allergy patient-reported quality of life data are available and analyzed with reliable approaches to calculate associated health state utility.

DBV believes this assessment's prematurity leads to unreliable estimates of cost-effectiveness, risking misinformed access and care decisions made on behalf of children with peanut allergy.

Dr. Todd Green is an employee of DBV Technologies.

Tessa Grosso

Patient Advocate

I am 16 and one of the first to go through OIT. It has been the most important, valuable, empowering experience in my life. I am here to make sure that your value assessment tools capture the perspective and values of a real person.

My food allergy caused isolation, depression, and anxiety for myself and everyone close to me. I was fortunate to live close to Stanford and to have a mom who searched tirelessly for a solution beyond avoidance.

I want to add a few points to your deliberations. 1) Desensitization is valuable. Kids like me don't want to eat a PBJ but we do want to sit with other kids at lunch. Something so simple is a privilege that you can only understand if you have walked in our shoes. 2) Controlled, anticipated use of epinephrine in a study is really different than an unexpected attack at school or with friends. As Dr. Gupta stated, families can be coached to understand this. 3) I can't comment on the health economic tools that you are applying, but I can say emphatically that the quality of life benefits are transformative. They are a substantial net benefit. I am the data and I know countless patients who would say the same. We stand ready to make our experiences and successes available to help others.

Undergoing therapy is a choice that should be available, accessible, and affordable for every single family. I want to implore you on behalf of all of the patients who aren't here to recognize the incredible value that these new therapies can deliver now—saving my life, giving me a new life—every child deserves this. We have fought to advance the first potential therapies for food allergy. Patients across the country are watching now. Your votes will profoundly influence access. Please include our voices.

<i>No conflicts of interest to disclose.</i>

Nurry Hong, Food Allergy Research & Education

Chief of Strategy and Innovation

Viaskin Peanut and AR101 represent the most significant breakthroughs to date for patients managing peanut allergy which is a life-altering disease that carries significant health, psychosocial and financial burden.

The only treatment for peanut allergy is avoidance – or a shot of life-saving epinephrine and trip to the emergency room when a severe reaction occurs. These are unacceptable standards of care. Food allergic patients deserve better and have been waiting years for FDA approval of therapies that will offer any level of protection from severe and potentially life-threatening food allergy reactions.

Recent peer-reviewed meta-analyses on oral immunotherapy show that desensitization is effective for many patients with peanut allergy. Both products under review by ICER have demonstrated the same. This is not in dispute. The food allergy community agrees that there is a need for better understanding of long-term outcomes including benefits and adverse reactions. However, absent perfect data, we implore payers to assess these therapies with a focus on understanding the patient experience, including the sacrifices that patients are willing to make for the potential benefit they will gain. The ability for patients to make an informed decision with their allergist based on patient preferences and realistic expectations of outcomes must be paramount to consider in this analysis.

It's difficult to overstate the significance of the breakthrough and value these therapies represent for the food allergy community: They provide treatment for peanut allergies where no treatment option exists. Patients with food allergies deserve options and access to life-changing therapies.

FARE has received general support grants or corporate sponsorship from each of DBV Technologies and Aimmune Therapeutics. These general support grants/sponsorships are charitable in nature and do not require FARE to perform any service for or on behalf of either DBV or Aimmune. At one time FARE was a shareholder of Aimmune, but those shares were sold in their entirety in 2016.

Kenneth Mendez, MBA, Asthma and Allergy Foundation of America (AAFA)

President and CEO

I'm here to provide comments on behalf of AAFA and the community we represent. I'm also here as a parent. Two of my sons have had severe allergies--my youngest, Theo, by two years old, visited the emergency room twice with anaphylaxis. He could not eat peanuts, beef, dairy, eggs, milk. My middle son Will has life-threatening allergies to peanuts and legumes.

I appreciate the opportunity to speak and thank ICER for their willingness to hear from patients. I'd like to focus on the CTAF vote.

As you consider your vote, please consider the following:

- Evaluation premature. The evidence report and discussions today acknowledge that the focus of this exercise is not price since the therapies have not yet been approved by the FDA. ICER's evaluation is premature and lacks enough data. However,
- High net health benefits. Positive net health benefits to patients and positive "contextual considerations" should be the focus of CTAF's vote. AAFA's research demonstrates the magnitude of the societal impacts and stories we've heard from patients in this room do the same. The "modified societal" analysis in ICER's economic model shows between a 30% to 70% improvement in value (88,000 to 27,000) and (216,000 to 155,000). This swing confirms that quality of life are significant benefits for families, caregivers, and patients with peanut allergies. In addition, ICER mentions the potential health benefits for underserved populations who are disproportionately impacted by peanut allergies.

AAFA receives greater than 25% of its funding to produce educational materials and for patient research through grants from pharmaceutical companies.

Kari Nadeau, MD, PhD, FAAAAI, Stanford University

Professor of Medicine and Pediatrics

The decision by ICER to downgrade peanut IT to a “D,” based primarily on the analysis by Chu et al entitled, “Oral immunotherapy (OIT) for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety,” should be reconsidered due to flaws in the analysis. The PACE study is not inclusive of all eligible studies – it does not include long-term peanut OIT studies and includes only a limited number of Quality-of-Life (QOL) studies. Additionally, adverse events were not defined the same. We have completed a three-year large NIH-funded randomized placebo-controlled study in peanut OIT where we found that the number of accidental ingestions decreased over time and increased overall safety. ICER reports that there are little quality data for peanut IT; however, major impact journals (NEJM, JAMA, Lancet) published high quality results in peanut IT. There are more than 13 published QOL studies (seven placebo-controlled), many of which show improvements in QoL with food IT.

The grading by ICER also contradicts the findings of a rigorous meta-analysis (e.g., Nurmatov et al, Allergy, 2017) and with EAACI guidelines (Pajno et al, Allergy, 2018). ICER’s decision should be in the context of IT with experienced medical staff in allergist’s offices who are trained to recognize and handle allergic symptoms, which are common, and which predictably occur within two hours of ingestion. Many patients and families feel strongly that peanut IT has greatly benefitted their QoL. ICERs grading is premature and based on a limited number of studies - it warrants re-evaluation.

Dr. Nadeau has participated in sponsored research for clinical studies from Aimmune Therapeutics, DBV Technologies, AnaptysBio, Astellas, Novartis, Regeneron, Adare, Sanofi, and Stallergenes-Greer. Dr. Nadeau serves as part of NIAID CoFAR, NIAID Immune Tolerance Network, and NHLBI Data and Safety Monitoring Board.

Stephen Tilles, MD, Aimmune Therapeutics*Senior Director of Medical Affairs*

Aimmune was born from the need of the food allergy community to deliver the first FDA-approved oral immunotherapy treatment for peanut allergy—an innovation long overdue for patients who currently must rely on avoidance. Avoiding peanuts in everyday life is not an easy prescription. Accidental exposures are inevitable, traumatic, and even fatal.

Aimmune’s AR101 has the potential to transform lives by helping peanut allergic children achieve clinically meaningful desensitization. In both PALISADE and ARTEMIS, part of the largest and only successful Phase 3 peanut allergy development program, patients experienced a 100-fold increase in median tolerated dose, equivalent of an increase from one-thirtieth of a peanut to three to four peanuts. The amount of protection against accidental exposures matters. The median quantity of peanuts that triggers allergic reactions in the real world is about half a peanut. Therefore, AR101 provides ample buffer for real-world accidental exposures.

Despite demonstrated safety and efficacy, ICER’s conservative base case assessment fails to capture the full societal benefit of AR101—something ICER itself acknowledges. From the outset, Aimmune has been concerned that ICER’s review of this nascent treatment area was premature. Recent data reinforces the clinical profile of AR101 and demonstrate improved safety and immunomodulation with continued longer-term daily treatment. It also illustrates improvements in quality of life experienced by patients undergoing treatment. We encourage all stakeholders, including ICER, to consider this report an early starting point—and not by any means a conclusion—of the true value AR101 will offer to patients, family, and society.

<i>Dr. Stephen Tilles is an employee of Aimmune.</i>

Appendix G. Conflict of Interest Disclosures

Tables G1 through G3 contain conflict of interest (COI) disclosures for all participants at the June 11, 2019 Public Meeting of CTAF.

Table G1. ICER Staff and Consultant COI Disclosures

Name	Organization	Disclosures
Pamela Bradt, MD, MPH	Institute for Clinical and Economic Review	*
Laura Cianciolo	Institute for Clinical and Economic Review	*
Sarah K. Emond, MPP	Institute for Clinical and Economic Review	*
Greg Guzauskas, MSPH, PhD	University of Washington	*
Ryan Hansen, PhD, PharmD	University of Washington	*
Serina Herron-Smith	Institute for Clinical and Economic Review	*
Steve Pearson, MD, MSc	Institute for Clinical and Economic Review	*
David Rind, MD, MSc	Institute for Clinical and Economic Review	*
Celia Segel, MPP	Institute for Clinical and Economic Review	*
Matt Seidner	Institute for Clinical and Economic Review	*
Jeffrey A. Tice, MD	University of California, San Francisco	*
Tia Tilson	Institute for Clinical and Economic Review	*

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

Table G2. Policy Roundtable COI Disclosures

Name	Organization	Disclosures
Todd Green, MD, FAAAA	DBV Technologies	Employee of DBV Technologies
Matthew Greenhawt, MD	University of Colorado School of Medicine, Children's Hospital Colorado	Paid consultant for Aimmune Therapeutics; served on advisory boards for Aimmune Therapeutics and DBV Technologies
Ruchi Gupta, MD, MPH	Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago	Received grants from Aimmune Therapeutics; served as consultant to Aimmune Therapeutics and DBV Technologies
Nurry Hong	Food Allergy Research & Education (FARE)	FARE received support from Aimmune Therapeutics and DBV Technologies
Caroline Moassessi	Patient Advocate	None disclosed
Stephen Tilles, MD	Aimmune Therapeutics	Employee of Aimmune Therapeutics
John S. Yao, MD, MPH, MBA, MPP, CPC, FACP	Regional Vice President and Chief Medical Officer, Anthem Blue Cross	Employee of Anthem Blue Cross

Table G3. CTAF Panel Member COI Disclosures

Name	Organization	Disclosures
Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA	University of California, San Francisco	*
Felicia Cohn, PhD	Kaiser Permanente, Orange County	*
Robert Collyar	Patient Advocate	*
Rena K. Fox, MD	University of California, San Francisco	*
Kimberly Gregory, MD, MPH	Cedars-Sinai Medical Center	*
Paul Heidenreich, MD, MS	Stanford University	*
Jeffrey Hoch, PhD	University of California, Davis	*
Jeffrey Klingman, MD	The Kaiser Permanente Medical Group	*
Neal Kohatsu, MD, MPH, FACPM	Kohatsu Consulting	*
Sei Lee, MD	University of California, San Francisco	*
Joy Melnikow, MD, MPH	University of California, Davis	*
Elizabeth J. Murphy, MD, DPhil	University of California, San Francisco	*
William Remak, BSc, MT, BPH	California Hepatitis C Task Force, Inc	*
Robert Rentschler, MD	Retired, Beaver Medical Group	*
Richard Seiden, JD	Patient Advocate; Retired, Foley & Lardner	*
Alexander Smith, MD, MPH	University of California, San Francisco	*

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.